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Background: Streptococcus pneumoniae is a significant human pathogen responsible for life-
threating diseases such as pneumonia, septicaemia and meningitis. Of the nearly 100 distinct 
pneumococcal serotypes, pneumococcal serotype 1 is described as one of main causes of 
invasive disease worldwide. One highly enigmatic feature of serotype 1 resides in its being 
rarely detected in human nasopharyngeal specimens.  
Aim: The aim of this project was to compare serotype 1 lineage A (ST306) and C (ST615) with 
respect to their immunological and virulence properties using both in vitro and in vivo tools, 
as well as their differential gene expression profile.  
Methods: A series of in vitro experiments were performed to assess the ability of serotype 1 
to adhere and invade epithelial cells, and to determine its ability to inhibit phagocytosis and 
gain insight into the mechanisms involved. In parallel, three in vivo standardized mouse models 
of pneumococcal infection were exploited to examine the virulence properties of ST306 and 
ST615 and their ability to colonise the nasopharyngeal tissue. Finally, RNA-seq analysis of in 
vitro cultures of ST306 and ST615 was carried out in an attempt to identify differential 
expression patterns.  
Results: ST615 serotype 1 was determined to be highly virulent, causing the death of 80-100% 
of infected mice by around 48h post-infection, while all mice infected with ST306 survived 
when using pneumococcal doses inductive of invasive pneumonia model. In a nasopharyngeal 
carriage mouse model, ST306 serotype 1 was shown to be able to establish colonisation 
persisting up to 28 day post-administration, although at a much lower density compared to 
ST615.  While ST615 was capable of establishing nasopharyngeal colonization, clearance 
occurred earlier at day 14 compared to ST306. RNA gene expression analysis focused on 
virulence factors and critical biological functions determined that ST615 serotype 1 presented 
a profile consistent with its weak colonisation and its invasive properties. The genes associated 
with capsule synthesis were not differentially expressed between ST615 and ST306 but that 
other virulence factors such as psp, pavA, ply and cpbD were differentially expressed.  
Conclusions: Although ST306 and ST615 possesse a unique and virulent capsule, ST306 was 
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1.1 General characteristics 
1.1.1 History of Streptococcus pneumoniae 
S. pneumoniae was first isolated over a hundred years ago by George Miller Sternberg [11] in 
the United States and by Louis Pasteur [12] in France. Pasteur isolated S. pneumoniae in the 
saliva of a patient with rabies, while Sternberg isolated the bacteria from his own saliva. A 
subsequent six years elapsed before Weichselbaum, in Vienna, resolved the disagreement 
between Carl Friedlander and Albert Fraenkel as to the importance of S. pneumoniae as a cause 
of bacterial pneumonia in humans [13]. In the 1880s, pneumococcus was confirmed as a cause 
of meningitis, endocarditis, arthritis, and otitis media, and experimental pneumococcal 
endocarditis was successfully modelled in the rabbit [14]. Between 1880 and 1910, advances 
were made towards the control of illness caused by pneumococcus; including the recognition 
by the Klemperers [15] that antiserum could offer a protective value against infection. 
Following this in 1900, the lytic effect of bile on pneumococcus was discovered and reported 
by Neufeld [16], which aided their identification. Neufeld and Haendel [17] succeeded in 
classifying pneumococcal type I and II by 1910. The quelling reaction, in which antibodies can 
bind to the bacterial capsule of S. pneumoniae, became an essential platform in serotherapy 
three decades later [19], allowing for different pneumococcal types to be visualised under a 
microscope, previously described by Neufeld in 1902 [18]. 
Serum therapy of type I and II pneumococcal pneumonia, developed at the Rockefeller Institute 
[20], led to treatment of those infected with a number of pneumococcal serotypes, with a case-
fatality rate reduction of approximately 20%. However, severe haemolytic reactions were 




pneumococcal capsular polysaccharide and type A blood group following treatment with horse 
antiserum. This led to rabbit antiserum replacing horse antiserum towards the end of the 1930s. 
Quinine, which had previously been used to treat experimental pneumococcal infection with 
little effect, led to the exploration of related compounds, including ethylhydrocupreine hydro-
chloride (optochin). Optochin showed significant efficacy in laboratory animals, however drug 
resistance soon began to arise [23, 24] in the form of optochin-resistant pneumococci from 
treated infected mice in 1912 [22]. Optochin was subsequently abandoned as a treatment for 
human pneumococcal infection for this reason, as well as in relation to apparent eye toxicity. 
Sulfonamides, while initially showing promise due to their ability to treat pneumococcus 
indiscriminately according to its capsular serotype, was over-shadowed in 1944 [25, 26] due to 
the drug penicillin showing extraordinary efficacy in the treatment of patients with both non-
bacteremic and bacteremic pneumococcal pneumonia, bringing about recovery and reducing 
case-fatality rate to 5 – 8%. The introduction of tetracyclines, chloramphenicol, and macrolides 
in the following decade gave further offers of protection, shifting a disease which has been 
previously feared to one which gave little cause for concern. 
In 1943, several laboratory findings reported the appearance of pneumococcal variants with 
increasing resistance to penicillin. Tillet [26], and Schmidt and Sessler [27] demonstrated 
resistance in isolations from mice, while Eriksen [28] demonstrated resistance in vitro, both 
following exposure of pneumococci to penicillin. However, these observations appeared to 
have little effect on clinical practice. 
In the early 1960s, reports of resistance to penicillin, as well as tetracyclines, chloramphenicol, 
macrolides, and cotrimoxazole, began to make more of an impact. Toward the end of the 1970s, 




multiple drug resistance occurred, and since then, the complications of infections caused by 
multiple drug-resistance pneumococci has become a progressively important issue. 
To date, vancomycin is currently the only antimicrobial agent that has yet to select drug 
resistant mutants in pneumococcal infection [40]. 
In South Africa in 1886, due to the high rate of recruit disease in the mining industry, in the 
form of lobar pneumonia, and related morbidity and mortality, Sir Almroth Wright, renowned 
for his work on typhoid vaccine, was recruited to conduct trials with a pneumococcal vaccine 
of an unknown serotype. The vaccine trial included 50,000 miners [30] and was initially 
concluded as efficacious, however, subsequent analysis of the data failed to support this. 
Following this, F. Spencer Lister, a colleague of Wrights’, continued with the trial and aimed 
to characterise the serotypes causing disease. He hypothesised that if one were to immunise 
50% of the individuals in a closed population, it would reduce spread of infection among the 
unimmunised [33]. However, issues with the structure of these trials with the whole killed 
pneumococci vaccine were disputed and therefore efficacy of immunisation could not be 
properly demonstrated [31, 32]. 
In 1927, mice were successfully immunised with homotypic capsular polysaccharide 
(Schiemann and Casper) [34], followed by reports of immunogenicity in humans in 1930 
(Francis and Tillett) [35]. In 1945, purified pneumococcal capsular polysaccharides proved to 
be effective in preventing infection with homotypic pneumococcal strains (MacLeod, Hodges, 
Heidelberger, and Bernhard) [36]. It also confirmed Lister's hypothesis that immunised 
individuals reduced the spread of pneumococcal disease in a closed population. The carriage 
of pneumococci also proved to be important. Immunisation did not appear to impact on the 




by around 50%. Recent studies of several polysaccharide vaccines have also confirmed this 
finding. 
Following this, two hexavalent pneumococcal polysaccharide vaccines were commercially 
produced, however with the introduction of highly effective penicillin and other agents, they 
were soon withdrawn from the market. Based on trials in South Africa showing dodecavalent 
vaccines had the ability to prevent both non-bacteremic and bacteremic pneumococcal 
pneumonia by approximately 80% [38], a tetradecavalent pneumococcal vaccine was licensed 
in South Africa in 1977. Other findings regarding the outcome of bacteremic pneumococcal 
infection treated with penicillin and identification of individuals at particular risk of mortality 
also had an impact on the re-emergence of vaccine trials for pneumococcus [37]. In 1983, the 
23-valent vaccine was introduced. Since only 18 serotypes out of the then known 90 
pneumococcal types have been shown to be responsible for the majority of bacteremic illnesses, 
the opinion was that the introduction of additional serotypes into the 23-valent vaccine showed 
little necessity. 
 
1.1.2 Streptococcus pneumoniae general characteristics 
Streptococcus pneumoniae (or pneumococcus) is a well-known commensal bacterium of the 
upper respiratory tract and can colonise the human nasopharynx asymptomatically. However, 
it is an opportunistic pathogen and is a major cause of disease in the susceptible host, including 
pneumonia, meningitis, bacteremia, otitis media and sinusitis [1, 2, 3].  S. pneumoniae is a 
Gram-positive bacterium with a thick cell wall, containing teichoic acid (C-polysaccharide), 
capable of producing toxin (pneumolysin). The organism is an encapsulated bacterium, an aero-




to spherical in shape, with a diameter ranging from 0.5-1.25 µm. Its usual appearance is in pairs 
(diplococcus) or forming short chains, shown in figure 1 [8, 472].  S. pneumoniae has a variety 
of surface antigens, including pneumococcal surface adhesin A (PsaA), pneumococcal choline-
binding protein A (PcpA), pneumococcal surface protein A (PspA), pneumococcal surface 
protein C (PspC), and pneumococcal autolysin A (LytA). It is a non-spore forming, non-motile, 
catalase negative, α-haemolytic bacterium. The ideal growth conditions include complex media 
with a source of catalase (i.e. from blood or serum), incubated at 37°C/5-10% CO2 [9]. S. 
pneumoniae is sensitive to ethyl hydrocupreine hydrochloride (optochin), an antibiotic used to 
differentiate pneumococcal from other streptococci. Observation of a growth inhibition halo 
around the optochin disk indicates detection and identification of S. pneumoniae [8]. The 
haemolytic properties on blood agar can also help classify S. pneumoniae and differentiate from 
others in the Streptococci family; the presence of α-haemolytic bacteria causes a chemical 
change in the haemoglobin of red blood cells, observed by a green pigment that forms a ring 










Figure 1. S. pneumoniae is a gram-positive bacterium. Its usual appearance is in pairs 
(diplococcus) or forming short chains. (SEM picture credit: Dr Manfred Rohde, 





1.1.3 Carriage of S. pneumoniae  
Carriage of S. pneumoniae is found at a higher rate in children compared to adults; the rate of 
colonisation increases from birth, peaking at the age of around 1 – 2 years old. Following this 
there is a decline which is age-related [150, 179].  
S. pneumoniae carriage typically lasts two weeks, with a duration of more than 30 weeks in 
some cases [180]. Carriage is also seasonal, peaking between January to March [181]. 
Bronchial pneumonia and lobar pneumonia are both caused by S. pneumoniae. During 
infection, the organism induces an immune response from the host, causing recruitment of 
white blood cells which migrate to the lungs. Pneumonia presents as the presence of white 
blood cells, proliferating bacteria and excessive fluid in this area [184]. A chest X-ray can 
detect pneumonia, and bacteraemia and septicaemia may occur in around 20 – 30% of cases 
[185]. The highest fatality rates among those infected with the organism are those presenting 
with S. pneumoniae meningitis (~40%), with symptoms of severe headache, photophobia, neck 
stiffness and fever, often with long-term consequences in survivors including mental 
retardation and motor deficiency [186, 187]. Otitis media is a common disease occurring with 
S. pneumoniae infection, presenting as inflammation of the middle ear, with limited mobility 
and enlarged tympanic membrane, often with recurrent episodes of infection, even despite 
successful antibiotic treatment. S. pneumoniae was found responsible for around 50% of otitis 
media cases [185]. Other relatively uncommon clinical illnesses known to be caused by S. 
pneumoniae include conjunctivitis, acute tracheobronchitis, endometritis, peritonitis, 
endocarditis, arthritis, and osteomyelitis [188].  
In children below the age of 2 years old, pneumococcal carriage was reported at 45% before 
the seven-valent polysaccharide conjugate vaccine was introduced in the UK. This was 





1.1.4 Transmission of S. pneumoniae 
Humans are the main host of S. pneumoniae due to its successful transmission, occurring 
through respiratory droplets from carriers of healthy individuals or those with pneumococcal 
disease [189, 190]. Risk factors for transmission of the organism include number of siblings 
and numerous visits to the doctor for other mild upper respiratory tract infections [190]. Day 
centres, military camps, and prisons where there are high numbers of individuals in a closed 
environment also have high rates of cases [192, 189]. Pneumococcus may be transmitted from 
children attending day centres, to their older siblings, demonstrated by similarities among 
isolates of genetic similarity [192]. Pneumococcus is first transmitted to the new host, with 
subsequent asymptomatic colonisation [180]. Following this, in some cases, the organism may 
move from the nasopharynx to other areas of the body, including the lungs where 
pneumococcus can successfully evade the host immune system defences and cause disease 
[189]. Since acquired pneumococcus is often asymptomatic, it proves difficult to identify the 
chain of transmission between individuals [197]. Other microflora of the nasopharynx may 
contribute to the development of disease by symbiosis, or hinder it by competing with the 
organism [198, 199]. Different serotypes of pneumococcus, such as serotypes 1, 4, 5 and 9A 
have high rates of related invasive disease, while serotypes 9N, 16F, 20 and 38 have relatively 
lower rates and have a shorter carriage duration [190]. Opaque and transparent colonies related 
to phase variation of pneumococcal variants demonstrate as an important factor in the 
progression of carriage to invasive disease [200, 201]. For example, the opaque form has been 
commonly isolated from patient samples, while the transparent form has adapted to 
colonisation of the nasopharynx due to phase variation to increase pneumococcal invasion into 




1.1.5 Invasive pneumococcal disease (IPD) 
 
Figure 2. Pathogenic route of S.pneumoniae infection [421] 
S. pneumoniae initially colonises the nasopharynx, spreading via the airways to the lower 
respiratory tract, leading to pneumonia, or to the sinuses or middle ear, resulting in medical 
morbidity [91, 408]. Invasive infections caused by S. pneumoniae amounts to approximately 
15-30 cases per 100,000 of the population per year in developed countries, with those above 
65 years of age with an estimated rate of more than 50 per 100,000, and those below the age of 
2 years estimated at more than 150 cases per 100,000 people [407, 410]. These figures are 
likely to be an underestimation, since they are based only on blood culture results so do not 
take into account cases diagnosed without a diagnostic blood culture [413]. Pneumococcal 
disease presents a worldwide public health problem, underlined by the progressively spreading 
antimicrobial drug resistance to widely used, essential therapies. Vaccination remains the only 
method to prevent disease caused by S. pneumoniae [412]. Individuals particularly at risk of 
IPD and other pneumococcal disease include children less than 2 years of age, the elderly, 
children between 2 to 5 years old, and the immunocompromised [377, 378]. S. pneumoniae is 




estimated 1.2 million children below the age of 5 years dying each year from pneumonia, 
approximately 10-30% of all deaths among this age group [405].  Of adults with pneumococcal 
bacteriaemia, 60-85% of cases were associated with pneumonia, 5-10% with meningitis, and 
5-10% with no focal signs of infection [407, 410, 411].  
 
1.1.6 Diagnosis of S. pneumoniae and laboratory typing schemes 
 
Since S. pneumoniae is present in humans as commensal flora, this has to be taken into 
consideration in any diagnostic approaches when identifying the organism [93]. Other 
streptococcus bacteria are also present in the nasopharynx, as well as other organisms such as 
Staphylococcus aureus, so distinguishing between species and other types of bacteria remains 
important [191]. Gram-negative rods and staphylococci are generally gentamicin-sensitive, 
whereas pneumococcal and other streptococcus species tend to be gentamicin resistant, 
therefore the isolation of pneumococcus via the use of gentamicin containing blood agar culture 
plates can be useful [193-196]. Other streptococcal species, such as S.mitis and S. oralis tend 
to be resistant to optochin and bile-insoluble, while S. pneumoniae is generally sensitive [191]. 
Whilst S. pseudopneumoniae is generally found to be bile insoluble, it is only optochin resistant 
in 5% CO2, but this is not the case if left in room air rather than left within an incubator [209, 
210]. S. pneumoniae can be identified by its morphology under a microscope, observing its 
Gram-positive stain, and its diplococcic shape and presentation. Colony morphology and 
phenotypic identification using α-haemolysis on blood agar can also be used, as well as testing 
for catalase negativity, optochin susceptibility, and bile solubility [191]. Identification can 
prove to be difficult for S. pneumoniae since some species of Streptococcus may be bile-




limited [220]. There are also some species that produce teichoic acid similar to that produced 
by S. pneumoniae. All of these techniques aid somewhat in the process of elimination however 
does not exclude all Streptococcus species, with some cases of pneumococcus still being 
misidentified. 
Figure 4. S. pneumoniae isolates expressing most capsule types make small round colonies 
similar to doughnuts on blood agar plate (A) but serotype 3 and 37 pneumococci develop 
characteristically large mucoid colonies (B) [406]. 
 
Figure 3. S.pneumoniae growth is inhibited around the paper disk containing optochin (A). The test tube 
containing S. pneumoniae shows a loss of turbidity in the presence of sodium deoxycholate (bile salts) 








1.1.7 Conventional methods for bacterial identification 
  
Early and accurate identification of pneumonia is of high importance due to a decreased 
mortality rate, particularly among the elderly when treated early with antibiotics, as well as the 
reduction of cost associated with excessive clinical investigations and inappropriate treatment, 
which may lead to complications [224, 225]. Pneumonia is generally diagnosed based on 
clinical symptoms and a chest X-ray. Symptoms related to pneumonia include cough or 
difficulty breathing, and tachypnea (rapid breathing) [226]. Diagnostic procedures for 
Community Acquired Pneumonia (CAP) typically include isolation of bacteria from sterile 
body fluid, followed by identification and confirmation that the bacteria present is S. 
pneumoniae – this is the gold standard. For identification of pneumococcus from body tissue, 
a lung biopsy or bronchoscopy to obtain lung tissue would be ideal [227]. An alternative would 
be to isolate the bacteria via transtracheal aspiration, which has been reported to obtain high 
yields of S. pneumoniae [228, 229]. However, these techniques are not always practical in a 
clinical setting, therefore the majority of identification for this bacteria is performed commonly 
with the more readily available bodily fluids, including peripheral sputum, blood samples, and 
pleural fluids. 
 
1.1.7.1 Sputum Gram stains and culture 
Typically, sputum Gram stains and culture are the first technique used for the identification of 
pneumonia if there is a high quality sample (less than 10 squamous epithelial cells, with more 
than 25 polymorphonuclear cells at a magnification of x100 under a light microscope). In this 




has demonstrated to be highly sensitive and specific in some cases [232], there are some 
limitations, including inadequate sample collection, particularly from children, and the 
treatment of antimicrobials before the collection of sputum, which may contribute to a low 
yield of bacteria [230, 232, 233]. Another issue is the false positives occurring from natural 
nasopharyngeal carriage of the bacteria. 
1.1.7.2 Blood and pleural fluid culture 
Since blood and pleural fluid cultures are generally collected from sterile tissues, this can 
provide a definitive, unambiguous platform for the diagnosis of pneumococcual disease. 
However, the rate of positive samples for the bacteria within the blood tends to be low, at less 
than 10% in total in patients with pneumococcus, which may present as false negatives [234-
237]. Possible causes of this may be patients presenting with non-bacteraemic pneumonia, 
autolysis of the bacteria during the stationary growth phase resulting in cell death, treatment 
with antimicrobials before samples are obtained, or inadequate sample collection, specifically 
insufficient blood volume [238]. Another issue with culturing bacteria includes the time it takes 
for bacterial growth and to a level required for identification, usually several days. Similar 
limitations occur with the collection of pleural fluid [238]. However, using real-time PCR for 
the detection of bacterial DNA in pleural fluids was a promised technique. 
 
1.1.7.3 Pneumococcal antigen detection methods 
Pneumococcal antigen detection method may be used to detect pneumococcus in a variety of 
tissue samples, including sputum, urine, breath, pleural fluids, and peripheral blood, by rapid 
detection of pneumococcus molecules [239-242]. An advantage of this technique is that the 




be used as a particularly important target since it can help in distinguishing pneumonia from 
carriage of the bacteria due to the observation that nasopharyngeal carriage tends to exhibit 
high levels of manganese, whereas these levels present at a comparatively lower level in the 
blood [243, 244]. 
 
1.1.7.4 Techoic acid (C-polysaccharide) detection 
Enzyme-linked immunosorbent assay (ELISA) and latex agglutination can be used to detect 
techoic acid and capsular polysaccharide antigens in sputum specimens, showing high 
sensitivity and specificity [239]. A recent addition to diagnostics is the Binax NOW S. 
pneumoniae assay which is a rapid immuno-chromatography test, introduced in 2003, proving 
useful as a point-of-care test to detect C-polysaccharide in urine samples. However, in children, 
specificity with this kit only amounted to around 50–60% due to the presence of high rates of 
nasopharyngeal carriage in children, subsequently producing high concentrations of techoic aid 
in the urine [245-165]. A high concentration of urine from children reduced the specificity of 
this kit further [246], and so is not recommended for the detection of pneumococcal pneumonia 
in this age group [250]. With the use of pleural fluid, on the other hand, sensitivity is much 
higher (71-96%) and specificity (71-100%) exceeds that of urine, therefore may prove to be 
useful in the diagnosis of pneumococcal empyema with the use of pleural fluid [251-256]. 
In adults, the Binax NOW® S. pneumoniae assay showed more promise, with sensitivity and 
specificity around 74-75% and 94-97%, respectively [93, 191, 193], increasing the rate of 
diagnosis of CAP by 11-23% above conventional techniques [93, 193]. The detection of 
bacteraemic S. pneumoniae was demonstrated to be more sensitive compared with non-




may be useful for optimising antimicrobial treatment in terms of distinguishing between 
bacteraemic and non-bacteraemic pneumococcal pneumoniae. The 2007 IDSA/ATS guidelines 
have recommended the use of the Binax NOW’ S. pneumoniae assay during intensive care 
admissions, failure of out-patient antimicrobial therapy, leukopenia, active alcohol abuse, 
asplenia, chronic severe liver disease, and pleural effusion [273]. An advantage of this kit is 
that previous antibiotic use before sampling has less of an impact than with conventional 
culture methods, however, false positives may arise in cases where there are low levels of C-
polysaccharide antigen present in the sample [193], or cross-reactivity with other bacterial 
species, asymptomatic nasopharyngeal colonisation of pneumococcus, and a history of 
previous pneumococcal infection showing the presence of antigens. Techoic acid may still be 
excreted in the urine for more than a month following pneumococcal infection in some cases 
[274, 193]. There are also concerns about recent vaccination presenting false positive with this 
kit [275]. In the UK, guidelines for the Management of CAP in Adults in 2009 stated that 
pneumococcal urine antigen tests should be performed for all patients with moderate or high 
severity CAP, [472]. 
 
1.1.7.5 Capsular polysaccharide detection 
ELISA for the detection of the pneumococcus capsule in the urine tends to be variable and 
dependent serotype and severity of infection. Other limitations include difficulty of testing 
procedure as well as being unable to detect some capsular serotypes [276]. The multiplexed 
immunoassay system based on the Luminex’ system using monoclonal assays has recently 
showed promise, using multiplexed serotype-specific urinary antigen detection (UAD) assays 
[278, 279]. This technique has shown high sensitivity (79-97%) and specificity (99-100%) in 




detection using this kit, including capsular serotype responsible for CAP, however it can only 
currently detect a limited number of serotypes (13-14 serotypes in total), and have not yet been 
introduced into a clinical setting [278, 281]. 
 
1.1.7.6 Antibody responses to pneumococcal infection 
Serological studies may be used to detect genetically diverse pneumococcal antigens, including 
pneumolysin, C-polysaccharide, capsular polysaccharides, and PsaA. PsaA is a highly 
immunogenic lipoprotein, which can be detected in the blood using IgG antibody, with a very 
high sensitivity and specificity of 85-89% and 83-98%, respectively, in pneumococcal 
pneumonia diagnosis in Kenyan adults [282, 283]. However, the sensitivity dropped to 42% 
when applied to detection in children [284], as well as having specificity concerns due to the 
fact that PsaA may also be found in the cell walls of other streptococcus species [285]. An 
advantage of using serological testing for pneumococcal pneumonia is that they are not affected 
by the use of antimicrobials before sampling and do not require the duration of culturing 
bacteria. However they can potentially be impacted by cross-reactivity to antibodies specific to 
colonised pneumococci, therefore are not used as a diagnostic tool, but more as an 
epidemiological surveillance tool [319, 320]. 
1.1.7.7 Biomarkers 
The concentration of biomarkers related to the response of infection, inflammation, and tissue 
injury can be used to distinguish between bacteraemic and non-bacteraemic infection [286]. 
Biomarker detection can also play a role in the optimisation of treatment or as a prediction of 
prognosis. As rapid detection tools, such biomarkers as C-reactive protein (CRP), procalcitonin 
and TREM-1, a receptor expressed on myeloid cells, may be detected as indications of 




components [287]. TREM-1 is capable of stimulating the secretion of numerous cytokines and 
chemokines of the immune system [288]. The serum soluble form of TREM-1 has been linked 
to the presence of bacteraemic CAP [288], whereas soluble TREM-1 present in 
bronchoalveolar lavage fluid has been associated with bacterial pneumonia [287]. During the 
pro-inflammatory response, particularly in response to bacterial pneumonia, procalcitonin is 
made by parafollicular cells of the thyroid and neuroendocrine cells of the lungs and intestines, 
whereas procalcitonin tends to be downregulated during viral pneumonia infection [289], 
therefore may be a useful biomarker to distinguish between the two. CRP and procalcitonin 
levels, together, have been demonstrated to be useful in identifying pneumococcal pneumonia 
in children with non-specific chest X-ray presentation [290, 291]. Procalcitonin showed a good 
correlation with positive PCR, serological testing, and chest X-ray’s in these patients [292], 
and also appear to correlate well with severity of infection. Elevated procalcitonin and CRP 
levels showed a strong association in patients presenting with pneumococcal CAP, with a 
sensitivity of 94.4% and 91.9% for procalcitonin and CRP, respectively [293]. These 
biomarkers may also be useful in distinguishing between bacterial and viral pneumonia in 
adults [294, 295, 296]. Biomarker detection has proved promising, however, they will require 
other detection methods used in conjunction to confirm pneumococcal pneumonia infection, 
specifically in distinguishing between bacterial and viral pneumonia. 
1.1.7.8 Nucleic acid amplification tests (NAAT) 
NAAT uses the polymerase chain reaction (PCR) to target and distinguish genetically diverse 
strains of pneumococcus pneumonia from the blood and respiratory tract. Detectable targets 
for S. pneumoniae include the pneumolysin gene (ply), autolysin gene (lytA), pneumococcal 




Using whole blood, S. pneumoniae DNA can be detected using PCR directed at the ply gene. 
Sensitivities have proved to be variable (35-100%) [210, 299-302] and is unable to distinguish 
S. pneumoniae from other streptococcus species due to the fact that some of these also contain 
the ply gene [303, 304]. In comparison to the low ply specificity, the lytA gene had higher 
specificity [303, 305, 306], but still presented an issue, in terms of not being able to distinguish 
between S. pneumoniae and S. mitus since lytA genes are not as variable between streptococcus 
strains compared with those between streptococcus species [305]. The Spn9802 PCR is highly 
specific for S. pneumoniae, but is unable to distinguish between S. pneumoniae and S. 
pseudopneumoniae [307]. In terms of quantitative viral loads by real-time PCR from whole 
blood, a high bacteraemic load has been linked with increased risk of mortality [308, 309], 
therefore may be used as a tool to predict severity of pneumococcal illness. 
Using respiratory tract specimens, ply PCR had a sensitivity of 68-100% [310-313], but 
specificity presented an issue, particularly in throat swaps between patients with pneumonia 
and those of the control group [311], suggesting the lack of specificity between pneumococcal 
pneumonia and nasopharyngeal colonisation. More notably, real-time PCR produced better 
specificity with Spn9802 PCR, showing sensitivity and specificity of 71% and 100%, 
respectively, for the detection of pneumococcal pneumonia in patients with more than 104 
copies/mL bacteria [307]. LytA PCR had sensitivity and specificity level of 82.2% and 92%, 
respectively, at bacteria levels exceeding 8x103 copies/ml in detecting pneumococcal 
pneumonia, and distinguishing from nasopharyngeal colonisation. Successful detection rates 








1.1.7.9 Multi-locus sequence typing (MLST) 
While pneumococcal serotype is important in determining invasiveness, it has become 
increasingly evident that genotype also plays an important role. Since multilocus sequence 
typing (MLST) has become available, allowing genotyping of bacterial species using house-
keeping genes, a database recognising over 3000 pneumococcal sequence types (ST’s) or 
clones has been established (http://pubmlst.org/spneumoniae/). 
MLST has recently been demonstrated as a useful tool to distinguish between different types 
of Streptococcus species [221-223]. The adapted form of this tool is named Multi-locus 
sequence analysis (MLSA) and is currently used as a research tool only, but has been 
demonstrated to be more reliable in distinguishing among Streptococcus species. MLST 
produces digital nucleotide sequences of approximately 500 base pair segments from seven 
pneumococcal house-keeping genes selected on the basis of their location within the genome 
and relative neutrality with regard to selective pressures. These results are portable between 
laboratories, and can be used in the molecular characterisation of Streptococcus species and S. 
pneumoniae, with the ability to compare isolates on a global scale. Serotype and sequence of 
pneumococcal can be analysed in conjunction, along with the monitoring of capsular switch 
and may provide useful information for the development of pneumococcal conjugate vaccines 
with regard to long-term efficacy [42]. 
1.1.7. 10 The advances of using whole genome sequencing to study the population 
biology of S. pneumoniae 
Whole-genome sequencing (WGS) provides us with a ‘top-down’ approach to associate 




antibiotic-resistance acquisition in pathogens [610]. An advantage of the increasing volume of 
sequence data available for bacteria is that it allows the testing of evolutionary hypotheses 
across the entire domain. Recent work by Hershberg and Petrov used bacterial WGS data to 
investigate the spectrum of mutation types. Surprisingly, this revealed that the spectrum varies 
very little with most biased towards C/G→T/A transitions. This was found universally, even 
for clades with particularly high GC contents, which suggests that in the absence of selection, 
bacterial genomes would approach an equilibrium GC content of 20–30%. Given the large 
variety of GC contents observed for bacteria (~20–80%), this observation suggests that 
mutational pressures alone are not responsible for the nucleotide composition of the majority 
of genomes and that selection probably plays an important role [611]. A sample of whole 
genome sequences makes it possible to adequately reconstruct the natural history of a lineage. 
The base substitutions used to construct the phylogeny have accumulated over about 40 years 
and occur, on average, once every 15 weeks. Recombinations happen at a rate approximately 
10 fold slower, but introduce a mean of 72 SNPs each. The responses to the different 
anthropogenic selection pressures acting on this variation are quite distinct. The apparently 
weak selection by aminoglycosides and chloramphenicol has led to the occasional deletion of 
loci encoding resistance to these antibiotics. By contrast, resistance to macrolide antibiotics has 
been acquired frequently throughout the phylogeny, with selection strong enough to drive 
supplementation or replacement of the resistance afforded by the mef efflux pump with the 
broader-range resistance provided by ermB-mediated target modification. The response to 
vaccine selection is different, involving the depletion of the resident population before it can 
respond to the selection pressure and thereby opening the niche to isolates that already 






1.1.8 Future diagnostic options for pneumococcal infection 
Future diagnostic options for the diagnosis of pneumococcus may include the detection of 
metabolites, including the analysis of urinary metabolites using nuclear magnetic resonance 
(NMR) [315], or a breath test to isolate bacteria and detect using mass spectrometry. Sensitivity 
and specificity to these testing methods are currently being investigated [318]. Matrix-assisted 
laser desorption ionisation time-of-flight mass spectrometry (MALDI-TOF MS) is currently 
being used in numerous clinical laboratories for the detection of bacteria, with advantages 
including ease-of-use, cost-effectiveness and rapid and high-throughput. However, specificity, 
again, presents an ongoing problem in distinguishing between S. pneumoniae and other species 
and strains of bacteria [316, 317]. Whole-genome shotgun (WGS) assembly of large and 
complex genomes was once a much-debated question [317]. The advent of next-generation 
sequencing and the comparative ease and speed with which WGS assemblies can be 
constructed for mammalian and many other genomes allowed sequencing projects to move 
beyond these concerns, accepting high quality draft genomes with nearly complete gene spaces 
[317]. 
1.2 Pneumococcal serotype 1  
1.2.1 Geographic distribution of serotype 1 pneumococcus disease 
Serotype 1 pneumococcus has a very low carriage rate and is uncommon with regard to nasal 
colonisation even in populations with a high prevalence of invasive disease (Figure 5), with the 




pneumococcal pneumonia in children, and 33% in adults, however serotype 1 was estimated to 
be responsible for only 2% of asymptomatic, colonised adults and children [321].  
 
Figure 4. Distribution of serotype-1 IPD worldwide 
Serotype 1 pneumococcus is generally associated with bacteraemia, empyema and peritonitis, 
with epidemics of meningitis arising in Africa. It more frequently affects young adults 
compared to other known serotypes and mortality and co-morbidity occurs at a low rate. 
Prisons, homeless shelters and closed environments of young adults in common with regard to 
outbreaks [322 – 325]. It has been demonstrated to be efficiently passed between close contacts 
to those infected, for example, healthcare workers working on pneumonia wards, and 
household contact, particularly with carriage of serotype 1 in homeless shelters [325, 360]. 
Colonisation tends to be short-lived, relative to other serotypes, while the probability of 
invasive resulting from serotype 1 infection appears to be very high, an explanation for this has 
yet to be uncovered [326]. Antibiotic resistance has rarely been reported for first-line 
antibiotics, such as penicillin, macrolides and quinolones, which is likely due to the shorter 
































duration of carriage of serotype 1, resulting in less time for recombination leading to genetic 
diversity, of which antibiotic resistance may be included, as well as reduced chance of selective 
pressure from antimicrobials [327-330]. It has been noted that there is limited geographical 
distribution of serotype 1 compared to other serotypes, again, likely due to the short duration 
of carriage, preventing the organism from spreading farther via international travel [331]. 
Serotype 1 pneumococcus is one of the most common serotypes found linked to invasive 
pneumococcal disease (IPD). In the last decade, an increase in serotype 1 pneumococcus 
causing IPD has been reported in Europe, in countries such as Portugal, Spain, France, 
Belgium, and the UK [442, 443, 444, 445, 446). Serotype 1 pneumococcus is one of the few 
serotypes that has been associated with IPD in small or closed communities [447, 448, 449, 
450, 451]. In some areas of the world, there has been a marked reduction of serotype 1 
bacteraemia reported, particularly between 1940 to 1955. For example, Boston City Hospital, 
USA [336], Danish national statistics [332], and to a lesser extent due to limited data; Glasgow, 
UK [337], have all reported a reduced incidence of serotype 1 pneumococcal disease over a 
period of decades.  Other reports from South America [338], Africa [339], and the Indian sub-
continent [340] have demonstrated a high prevalence of serotype 1 disease responsible for 
widespread epidemics, unfortunately historical data for these areas is not available. On the other 
hand, serotype 1 appears to be less prevalent in areas of South-East Asia [341]. Distribution of 
serotype 1 and arising epidemics appear to be seasonal; associated particularly with periods 
nearing the end of the dry season [339]. Serotype 1 IPD generally affects younger adults, which 
differs from what is usually seen in the general population affected by IPD [347]. Serotype 1 
IPD has also been shown to be common among neonates in Europe and North America [348, 
349]. A study across England and Wales demonstrated that from 256 cases of IPD in infants 
identified, 84/256 (33%) developed IPD in the first 48 hours of life. This was following the 




period demonstrated that of 513 children diagnosed with IPD, 36/513 (7%) of these were in 
infants younger than 90 days old, [476]. In a study of IPD isolates from Danish infants that 
were 0-90 days old from 1943-2013, serotypes 7F and 1 were the predominant serotypes found, 
accounting for 20% and 15%, respectively, of all the IPD cases, [476]. The high incidence of 
serotype 1 found in young adults may be attributed to a lack of other serotypes able to infect 
this age group, or the possibility that acquired immunity to serotype 1 IPD is age-independent 
[350].  
Serotype 1 has often been found responsible for the manifestation of empyema in patients. Over 
the past 15 years in the UK, the incidence of patients presenting with empyema has risen, with 
serotype 1 typically found to be the cause [351-355]. 
 
 
1.2.2 Contrast in the burden of pneumococcal disease in the industrialised vs. 
developing world 
Carriage rates of pneumococcus in children are notably higher in the developing world. For 
example, in the Gambia [179], carriage rates reach 80% rate in children less than 5 years of 
age, and 20% in adults, as reported in 1992 [369], with similarly high rates found throughout 
the developing world including Papua New Guinea [369], Zambia [372], Pakistan [373], The 
Philippines [375], and Bangladesh [370]. In contrast, the industrialisedworld appears to have 
lower rates of carriage overall. In Sweden, in 1992 [371], it was reported that the rate of carriage 
was 12% in infants aged 3 months, 30% aged 7 months, and 32% aged 12 – 18 months. In 
2005, the prevalence of carriage overall in the UK was estimated at 25%, with a carriage rate 
of 52% in children under 2 years of age, and 8% in adults [368]. In the Netherlands [374], 




and 44.5% at 14 months of age. There were an estimated 15 pneumococcal meningitis cases 
per 100,000 infants under 2 years of age in a UK wide study [376], and an estimated 45 cases 
of IPD per 100,000 reported in the elderly over 65 years of age in Scotland, prior to the 
introduction of the PCV-7 vaccine [377].  
In urban slums, a population estimated at around 1 billion people, and mostly situated in 
developing countries, are at particular risk of pneumococcal disease [43], as they do not benefit 
from current advances in treatment and prevention [44], particularly with regard to 
immunisation strategies. Conditions of poverty are associated with high rates of pneumococcal 
carriage and invasive disease, however with regard to transmission of S. pneumoniae, and the 
burden of IPD little is known from these communities. Epidemiological surveillance in 
Salvador - the third largest city in Brazil with a population of 2.8 million people, 60% of which 
live in slum settlements - reported that the annual incidence for pneumococcal meningitis was 
32 cases per 100,000 in children less than one year of age, and 8 cases per 100,000 in children 
less than 5 years of age [45]. More than 80% of meningitis cases reported in Salvador were 
found in individuals residing in slum settlements. Children less than 2 years of age were 
particularly susceptible to acquiring penicillin resistant strains, compared with those above 2 
years of age. Serotype 14 was found to be largely attributed as the cause to around 50% of all 
penicillin resistance meningitis cases [45, 46]. 
The surveillance network coordinated by the Pan American Health Organisation, together with 
the National Reference Laboratories of Argentina, Brazil, Chile, Colombia, Mexico and 
Uruguay have been monitoring pneumococcal serotype and antimicrobial resistance of S. 
pneumoniae causing IPD in children less than 6 years of age. Between 1993 and 1999, IPD 
serotypes had been isolated from patients, 44% of which were pneumonia cases, and 41% 




to be the common causes of IPD. These included serotypes 14, 6A/6B, 5, 1, 23F, 19F, 18C, 
19A, 9V, 7F, 3, 9N and 4. Penicillin resistance was detected in 29% of the isolates, 17.3% with 
intermediate resistance, and 11.3% with high level resistance. Resistance levels increased 
during this period of surveillance in Argentina, Colombia and Uruguay. Serotypes 14 and 23F 
accounted for 66.6% of resistance [47]. 
 
1.2.3 Serotype distribution of S. pneumoniae carriage isolates 
Currently, 46 serogroups and 94 known  serotypes of S. pneumoniae. The most recent serotypes 
identified were 6C [219], 6D [220] and 11E [221]. Pneumococcal vaccines generally target the 
capsular polysaccharides based on their high antigenicity. The diversity of virulence, including 
invasive disease, antibiotic resistance and outbreak potential differ between the different 
capsular serotypes. S. pneumoniae also has the ability to undergo transformation, and 
recombination of its genetic material can be exchanged among and between species. Minor 
changes to the capsule can have an effect on the pathogenicity and virulenceof these strains. 
There is also potential for the occurrence of capsular switch [222], producing clonal isolates, 
which express different polysaccharide capsule serotypes caused by recombination of 
heterologous DNA at the capsular locus. Changes in serotype prevalence among pneumococcal 
populations result from both serotype replacement and serotype (capsular) switching. There 
have been 36 independent capsular switching events identified to-date, which were found to be 
either the result of nucleotide substitution and/or deletion, or appeared to be due to 
recombination. Capsular switching has been found to occurr regularly prior to both PCV7 






1.2.4 Geographic distribution of the serotype-1 ST306 clone 
The clone ST306 was initially identified in Sweden in the 1990’s [452], and has subsequently 
been found in Canada, Denmark, France, Germany, Netherlands, Norway, Poland, Spain and 
in the USA. The clone has been consistently been associated with IPD [453]. Furthermore, an 
increase in this clonal group has been reported among healthy carriers following the 
introduction of the heptavalent conjugate vaccine in Portugal and Spain [454, 433]. The ST306 
clone is typically associated with non-lethal pneumonia with or without empyema. ST306 is 
the most prevalent serotype clone in Europe that is not associated with antibiotic resistance 
[470]. 
The ST306 serotype 1 clone has dramatically expanded worldwide during the last two decades 
and is now the source of >80% of cases of serotype 1 pneumococcus disease [342].  
In recent years, serotype 1 has emerged as a much more prominent serotype linked to invasive 
disease in Europe, first demonstrated in Sweden, where there had been >4-fold increase in the 
rate of pneumococcal bacteremia over a 10-year period, 1987-1997. A 10-fold increase of 
type 1 had occurred from 1992 through 1997 and of 20 type 1 isolates examined by MLST, 11 
represented the ST306 clone [342]. Other European countries, including England and Wales 
[343], Scotland [335], and Portugal [344], have reported the presence of the same clone to be 
linked to a high proportion of IPD cases. 
In late 2000 towards early 2001, an epidemic of serotype 1 in New Caledonia was reported, 
with considerable rise of incidence in the population of serotype 1, lasting a number of months 
exceeding 50 cases of IPD [333]. A smaller epidemic was noted in 2007 and both were 




Following the introduction of the PCV-7 vaccine into the childhood vaccination schedule in 
the UK 2006, considerable and significant changes in serotype and clonal distribution of 
pneumococcus was observed over time.  In Scotland, an increase in IPD caused by non-vaccine 
serotypes 1, 4 and 6 and a decrease in serotype 14, 19 and 23, which are included in PCV-7, 
was shown by comparing data of clonal and serotype changes in pneumococcal isolates causing 
IPD immediately prior to the introduction of PCV-7 between the period from April 2001 to 
April 2006. When sequence type data was analysed, a significant increase of 135.4% in the 
prevalence of the ST306 clone associated with serotype 1 was evident over the 5 year period, 
attributed to clonal expansion of this previously rare clone. The data suggested that PCV-10 
and PCV13 vaccines would offer significantly more protection from IPD compared to PCV7 
[432]. In Scotland where serotype 1 had previously been dominant, it was shown over time to 
be replaced by a single clone, ST306 [334, 335]. This type of clonal replacement is rare among 
the other serotypes, which usually consist of different clonal populations existing 
simultaneously.  
It has also been suggested that the emergence of ST306 clone in Scotland [356] was linked 
with the increased incidence of paediatric empyema in Aberdeen [351], occurring around the 
same time period. Paediatric empyema, with serotype 1 pneumococcus as the cause, continues 
to be reported repeatedly [357-359]. Among 3073 pneumococci isolates identified between 
2003 and 2007 in Scotland, ST306 was the second most frequently PMEN clone identified by 
a combination of serotype and MLST, amounting to 225 isolates. These were all found to be 
susceptible to penicillin and erythromycin, however continued surveillance for the emergence 
of antimicrobial and vaccine resistance is advised despite the current low levels of resistance 
found in Scotland, since the prevalence remains much higher in other European countries with 




After the introduction of the PCV7 vaccine in Spain, the incidence of IPD rates linked to PCV7 
serotypes have decreased in both children and adults, however there has been an increase of 
IPD due to serotypes not included in the PCV7 vaccine, counterbalancing the progress [425, 
428). When investigating the epidemiology of IPD in older people in Spain between 2007 and 
2009 before the PCV-13 vaccine had been introduced, data showed that from 335 samples 
collected from patients with IPD, 5.4% of these were serotype 1. 22 clonal groups were 
identified, including ST306 being one of the most common genotypes (n=17, 3.7%). The 
increase in serotype 1 between 2007 and 2009 has been attributed to the clonal expansion of 
the ST306 clone in most European countries [425]. 
When investigating the clonal structure and 21-year evolution of pneumococcus serotype 1 
isolates in northern Spain, an increase in the incidence of IPD from 1.8 per million inhabitants 
between 1987 to 1993 to 4.0 during the period of 1994 to 2000 was been reported. Between 
1987 and 1998 the predominant clone was ST228, with 61.5% (8/13 isolates) of those causing 
IPD. This decreased to 13.3% (10/75 isolates) after 1999 for this clone. ST306 appeared in 
1998. Following the introduction of the PCV7 vaccine in 2001, ST306 became the predominant 
sequence type (>80%). In northern Spain, between 1998 and 2007, ST306 was found to be the 
dominant strain for IPD, comprising 74.4% (58/78 isolates) [433].  
A high prevalence of serotype 1 pneumococcus in healthy adults with IPD was demonstrated 
in Barcelona, particularly with the ST306 clone, along with a high association of empyema 
occurring in serotype 1 patients [426]. In a prospective study during a 20 year period between 
1989 and 2008 in Barcelona, 56/347 isolates were identified as serotype 1 in patients <18 years 
of age, with 39 isolates (71%) of these being the ST306 clone [427]. The incidence of serotype 
1 was found to be significantly higher in older children than in children >2 years of age, as well 




In a study carried out on the outbreaks of serotype 1 pneumococcus in the South Pacific 
between the year 2000 and 2007, surveillance of the invasive pneumococcal disease outbreaks 
demonstrated that the most prevalent serotype was serotype 1 [431]. All 141 serotype 1 strains 
tested were susceptible to antimicrobials. The majority of serotype 1 isolates belonged to the 
ST306 clone and was the exclusive clone found across New Caledonia and responsible for the 
outbreaks in New Caledonia and French Polynesia based on serotype 1 data prior to the 
outbreaks carried out between 1999 and 2001 and the increased prevalence of ST306 serotype 
1 following the outbreaks. The ST306 clone remains an important serotype 1-associated 
sequence type in the South Pacific, able to cause pneumonia and septicaemia in healthy 
indigenous people [455]. 
Surveillance of pneumococcal serotype 1 carriage was carried out during an outbreak of 
serotype 1 IPD in Central Australia and serotype 1 ST306 was shown to be responsible for the 
65% increase in IPD during 2010 compared to the previous year [422]. This outbreak between 
2010 and 2012 consisted of 69 confirmed cases of ST306. The majority of cases (84%) were 
Indigenous, ranging from 3-61 years (mean age 18 years, median age 10 years). The serotype 
1 carriage reservoir in this region was investigated further and nasopharyngeal swabbing during 
the outbreak identified asymptomatic carriers of serotype 1 were highest in children below 10 
years of age living in remote communities. Serotype 1 is included in the 10-valent 
pneumococcal vaccine, PHiD-CV (Synflorix®), and participants that had been vaccinated with 
PHiD-CV showed no detection of serotype 1 carriage, while participants positive for serotype 
1 had either missing immunisation records or had received the PCV7 vaccine with a booster of 
PPV23. 
In Columbia, serotype 1 pneumococcus is one of the most prevalent invasive serotypes, with 




among children below 6 years old. A study of clonal distribution of 135 serotype 1 isolates 
recovered from patients with IPD in Columbia between 1994 and 2011 showed only two 
genetic lineages (types E and F). More than half (51%) of the isolates were recovered from 
children less than 6 years of age, with 58/69 (84%) found to be genetically related to ST306. 
The other 49% of all isolates were obtained from patients more than 6 years of age, in which 
95.4% were genetically related to the ST306 clone. Clinical diagnosis of these patients were 
typically pneumonia and meningitis. 14/135 isolates showed resistance to antimicrobials, with 
9 of these genetically related to the ST306 clone, specifically resistant to SXT, tetracycline or 
erythromycin [424]. 
It remains unclear whether these clonal changes observed are due to natural fluctuations in 
transformable pneumococcal species or are directly driven by vaccine pressure. Serotype 1 IPD 
was present the introduction of the conjugate vaccine, and there have been no correlations 
demonstrated between conjugate vaccination and changes in the national incidence of serotype 
1 IPD [330]. Interestingly, when Scotland introduced the 13-valent conjugate vaccine, 
expanded to the serotype 1 capsular antigen, this was followed by a reduction in the incidence 
of serotype 1 disease in this area. This suggests that previous rises in incidence of serotype 1 
in some areas was in fact due to its ability to cause epidemic disease, rather than human 
intervention [345, 346]. Surveillance of serotype replacement of vaccine types with non-
vaccine types is of high importance following vaccine introduction, particularly with serotype 
1 since it is commonly associated with outbreaks. This will be vital in responding to changes 
in the population of pneumococcus. Together with the increase in prevalence of serotype 1 
associated with the ST306 clone since the introduction of the PCV7 vaccine, and data suggests 
that outbreaks of this clone is nearing a pandemic. Fortunately, serotype 1 pneumococcus is 




low selective pressure.  Since carriage is needed for horizontal gene transfer, resistance to 
ST306 likely remains rare [423]. 
1.2.4.1 Epidemiology 
In the last decade, an increase incidence of serotypes 1 and 7F in invasive disease has been 
reported in some European countries such as Portugal, Spain, France and UK. In addition, while 
serotype 5 was increasingly detected in Spain. The few studies that investigated the genotype 
of these isolates found that most isolates were representatives or close relatives of PMEN 
clones typically associated with these serotypes, namely, Sweden1-28 (ST306), Sweden1-40 
(ST304), Colombia5-19 (ST289) and Netherlands7F-39 (ST191). These serotypes and 
associated clones are frequently isolated from patients during outbreaks [461]. 
In terms of carriage distribution, serotypes 1, 5 and 7F in disease, less is known about its 
epidemiology in carriage. This may be due to the fact that these serotypes are rarely carried. 
However, Almeida and her colleagues were able to detect serotype 1, 5 and 7F in carriage. 
These serotypes were able to transmit between children attending day-care centers, and are 
highly clonal [461]. 
Serotype 1 is highly invasive and causes sepsis and empyema in Europe and North America 
(lineage A), whereas it is the major meningitis-causing pathogen among the children above 5 
years old individuals in the African meningitis belt (a Sub Saharan region extending from 
Senegal to Ethiopia). Moreover, the region appears as specific features of infection, such as 
hyperendemicity, seasonal pattern and high lethality affecting all age groups (lineage B) [462].  
There is a strong relationship between site of infection and virulence factors. Both the serotype 




related strains. For example, carriage of Pilus-2 and psrp genes showed high association with 
pneumonia, whereas phtB was more prevalent in meningitis isolates [462].  
1.2.4.2 Pneumolysin variant of ST306 
 ply is an important gene and plays a role for progression a disease and induces inflammatory 
responses in the host lung. The pneumolysin amino acid sequence is thought to be highly 
conserved throughout all pneumococcal serotypes with little variance over time and geographic 
distance. A number of clinical isolates with mutations in their pneumolysin gene (ply) were 
identified by Jefferies et al [361,464]. 
The mutations in ply gene were predominantly in serotypes 1, 7, and 8. It has been reported 
that 2 isolates of serotypes 7 and 8 possess a threonine to isoleucine substitution at position 
172. Both alleles also contained a 2-aa deletion of valine 270 and lysine 271. The only T172I 
substitution affected the hemolytic activity of pneumolysin [465]. Recently, it has shown that 
serotype 1, sequence type (ST) 306 pneumococci produce a nonhemolytic pneumolysin [464]. 
Moreover, ST306 of serotype 1 has allele 5 that contains all the mutations reported for the 






Figure 5. Pneumolysin alleles dtermined by full sequencing of PLY genes from 22 isolates [464] 
 
Interestingly, despite of the fact that ST306 clone displays a non-cytolytic Ply variant that 
retains the ability to bind to cholesterol-containing membranes, ST306 cannot form pores. The 
absence of cytolytic activity in ST306 reduces the virulence compared to a sequencing type has 
the full cytolytic as D39 [466].  
With regard to immunity responses, in previous study it has been shown that strains expressing 
non-cytolytic Ply may have an advantage more than cytolytic strains as they do not activate the 
NLRP3 inflammasome and may be more resistance to clearance from the host [467]. The 
cytolytic activity of Ply enhances increased expression of genes encoding pro-inflammatory 
cytokines, such as GM-CSF and IL-23α, as well as IFNβ1. CSF2, while remained either 
unchanged or was weakly up-regulated in the strains expressing no or non-cytolytic Ply, but 
was significantly induced dependant on expression of cytolytic Ply [466]. 
A previous study was shown that the opportunity of detecting serotype 1 in carriage will 




young children 5 to 8 years of age from remote communities [468]. That study demonstrated 
the group of population would carry serotype 1 and they could potentially be driving the 
outbreak. However, the most outbreaks have occurred by serotype 1 ST306 was after the 
introduction of PCV7 and the increase in the prevalence of serotype 1 associated with the 
increased use PCV7 [469].   
1.2.4.3 Virulence factors specific to ST306 
Virulence genes carried by an extensive collection of invasive S. pneumoniae isolates from 
Europe and Africa were described in terms of their serotype and genotype distribution. The 
carriage of virulence genes inside the bacterial genome were assessed in African isolates 
collected between 2002 and 2007 [420]. Most of the studied virulence genes, including the ply 
allele 5, were found in the invasive Sp1 ST306 clone, circulating in Europe, but were absent 
on the Sp1 isolates which are genetically distinct from the French strain and are circulating in 
the African meningitis belt, where a higher level of serious patterns of infection appears to be 
more prevalent. These virulence genes circulating in different geographic regions, along with 
their encoded surface proteins which are now considered vaccine candidates, could therefore 
be important in future vaccine development and global efficacy for S. pneumoniae.  
Studies using animal models have suggested a link between the pneumococcal serine-rich 
repeat protein (PsrP), a pneumococcal virulence determinant able to mediate attachment to lung 
cells and thought to increase the ability of pneumococci to cause pneumonia, and the high 
prevalence in children with pneumonia with the ST306 clone, since PsrP was detected in all 
ST306 isolates studied (n=88), [428]. 
In a study in healthy children carriers and patients with invasive disease, the PspA clade 




clade 1 reported from adults with IPD from Australia, the UK and Japan [458, 459]. In contrast, 
there has been a high prevalence of PspA clade 2 isolated from IPD adults reported in Spain, 
Canada, Sweden, the USA and France [460, 458]. A number of studies have indicated that 
PspA family and clade distribution are independent of serotype, but PspA clade classification 
was related to genotype where all strains with the same ST have the same PspA clade, despite 
its origin or capsular type. This information will be important if a PspA-based vaccine were to 
be developed to combat IPD. A PspA-based vaccine inclusive of PspA family 1 and 2 
molecules would suggest a beneficial outcome. 
1.3 Virulence factors 
S. pneumoniae can produce a variety of virulence factors (Figure 7) linked to disease 
progression, although it is widely acknowledged that pneumococcal strains differ in their ability 
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SSURE (streptococcal surface repeats) domain. The SSURE 
domain consists of highly conserved repeats, each of ~150 
amino acid residues, whose number of repetitive units is 
variable and relies on the strain but does not correlate with 
the serotype [80, 81]. PavB has been demonstrated to 
interact via its SSURE domain with soluble fibronectin and 
plasminogen. In addition, PavB contributes as adhesin to 
nasopharyngeal colonization and airways infection [82] 
(Table 1 and Fig. 1). Similarly, utilizing genomic app-
roaches, some additional host-binding LPxTG-proteins were 
identified in S. pneumoniae. One of them is the highly con-
served LPxTG-protein PfbA, which was identified as a novel 
plasmin- and fibronectin-binding protein and is involved in 
fibronectin-dependent adhesion and anti-phagocytosis [83]. 
Another identified factor contributing to pneumococcal 
adherence and invasion of host cells is the pneumococcal 
collagen-like protein (PclA), which has a moderate dis-
tribution among pneumococci. The gene encoding PclA is 
located in a 9.6 kb genomic region of R6, which was dis-
covered after comparison of R6 with the TIGR4 genome. 
This R6-genomic region, referred to as R6-specific cluster 1 
[84], encodes a putative Mga-like regulatory protein  as  well  
 [85]. The pneumococcal serine-rich repeat protein (PsrP) 
was recently shown to mediate pneumococcal attachment to 
lung, but not to nasopharyngeal cells. Keratin 10 of lung 
cells was identified as PsrP receptor. PsrP is a highly 
conserved pathogenicity island-encoded adhesin with an 
extended serine-reach repeat (SRR2) domain for adherence, 
promoting in vitro and in biofilm pneumococcal aggregation 
(Table 1) [86-88]. Moreover, pneumococci produce two 
kinds of pilus: pilus-1 (PI-1) and pilus-2 (PI-2). Both 
pneumococcal pili are strong structures made of covalently 
attached subunits: the RlrA-regulated genes RrgA, RrgB and 
RrgC for PI-1; and the pilus-islet-two PitA and PitB for PI-2. 
All the pilus constituents are LPxTG-proteins, containing 
functional pilin motif, signal peptide and TM domain [89-
93]. The major pilin subunit forming the pilus backbone is 
RrgB for PI-1 and PitB for PI-2. RrgA and RrgC in PI-1, and 
PitA in PI-2 are considered as the correspondent ancillary 
pilus proteins. The PI-1 assembly is done by the sortase 
enzymes (SrtB, SrtC and SrtD) and the structure is stabilized 
by isopeptide bonds in RrgB and RrgC [94-96]. According to 
electron microscopic analysis of PI-1 in S. pneumoniae 
TIGR4, RrgC anchors the pilus to the cell wall, the pilus 
 
Fig. (1). Virulence factors displayed on the surface of pneumococci. The cell wall of pneumococci is decorated with virulence 
determinants belonging to different classes of surface-exposed molecules. Here, the LPxTG proteins PavB, PsrP, PfbA and the pilus-1 
subunits RrgA, RrgB and RrgC are depicted. Similarly, the choline-binding proteins PspA, PspC and LytA, and the lipoproteins PsaA, PiuA, 
PiaA, PpmA and SlrA are shown. In addition, the anchorless proteins PavA, Enolase and GAPDH, the cell wall components TAs, LTAs and 
PCho, and the cytosolic pneumolysin are also depicted.  






1.3.1 The capsule 
The polysaccharide capsule is known as one of the most important contributors to virulence of 
the pneumococcus, due to its anti-phagocytic activity [109]. Seventeen immunogenic proteins 
have been discovered on the polysaccharide capsule, thirteen of which are age-dependent. 
Antibodies attach to the pneumococcus cell wall, which then binds to complement. The capsule 
blocks interaction of the iC3b and the Fc of immunoglobulins on the bacterial cell surface with 
phagocytic cell surface receptors. A consequence of this is that the bacterium remains 
extracellular [110]. The capsule also plays an important role in colonisation, preventing the 
mucus of the host from removing the bacteria [111], as well as limiting autolysis and exposure 
to antimicrobial drugs [112]. In terms of pathogenicity, the polysaccharide envelope is 
currently the main area of focus since it is known as a major virulence factor.  
1.3.2 Pneumococcal surface protein (PspA) 
Pneumococcal surface protein A (PspA) is a choline binding protein that is present in the cell 
wall, exposed extracellularly on the cell surface [224, 225]. It is conserved across all 
Streptococcus pneumoniae strains [226], though its molecular weight varies between strains, 
with sizes ranging between 67-99 kDa. PspA has three structural domains; the N-terminal 
which is composed of repeated α-helices, which extend the cell wall and appear on the outside 
of the capsule, therefore highly immunogenic [227]. The outer domain of PspA is highly 
electronegative with anti-complement properties to avoid attachment of S. pneumoniae by the 
host complement system [228-230]. The role of PspA in complement inhibition is uncertain, 
and studies show conflicting data. While some studies demonstrate that PspA suppresses 




[231, 232], other studies demonstrate that PspA is able to interfere with complement C3 
activation on the cell surface of pneumococcus, thus protecting the bacteria from complement 
mediated phagocytosis [233, 234, 230]. 
PspA has been studied as a potential target in pneumococcal vaccines, since it is abundant 
across all serotypes and elicits a serotype independent antibody response [235, 227]. PspA can 
also confer cross-protection against strains regardless of capsular type [236, 237, 238]. 
Administrating PspA intranasally as a vaccine has showed a promising protective effect against 
secondary pneumonia as a consequence of influenza, with PspA-specific IgGs showing a 
fundamental role in protection against S. pneumoniae [239]. Immunisation with recombinant 
fusion proteins consisting of PspA fused with flagellin, administered intranasally was 
demonstrated to elicit a more effective protective mucosal immune response against S. 
pneumoniae infection in mice, compared to immunisation with PspA alone [240]. PspA has 
been suggested as a virulence factor, since the PspA-deficient mutants show reduced virulence 
in a sepsis mouse model [167]. 
1.3.3 Pneumolysin (PLY) 
 
Pneumolysin (PLY) is a key virulence factor of pneumococcus. It is a pore-forming toxin, 
which is a member of the family of cholesterol-dependent cytolysins. PLY is produced by the 
majority of clinical isolates of pneumococcus, hence its importance as a potential target for 
future vaccine formulations. CDCs also produced by over 20 species of Gram-positive bacteria, 
and therefore the most widely studied virulence factor for pneumococcus to date. PLY is 53-
kDa in size and is expressed during the late log phase of growth [113]. It can be released both 
during cell autolysis or independently of the major autolysin [114, 115]. PLY first binds to the 




which subsequently produces large pores of up to 30nm in diameter, which in turn causes potent 
induction of inflammation and tissue damage.  
Using knockdown experiments of the gene for PLY in animal models, a reduction in virulence 
of the bacterium was observed in both intranasal and systemic routes of pneumococcus 
infection [118]. When these mutants of pneumococcus were introduced into the mouse lung, 
much less inflammation was observed as a consequence of infection [119, 120]. Immune cell 
recruitment in response to infection was delayed and in comparison to wild-type pneumococcus 
infection there was a reduced number of immune cells [120].  Most notably was the delay and 
reduction in the neutrophil response, and the redistribution of T-lymphocytes and B-
lymphocytes found inside and surrounding the inflamed bronchioles. In the absence of PLY in 
these mutants, a reduction in the number of pneumococcus bacteria were found in the 
nasopharynx as a result of intranasal infection [122], however another study indicated PLY did 






Figure 7. Domain structure of pneumolysin and the likely changes upon membrane binding [435] 
 
At sublytic concentrations, PLY can also activate the classic complement pathway, even in the 
absence of specific antibody [117]. The pro-inflammatory response is induced and other 
reactive oxygen intermediates and mediators produced in response to low concentrations of 
PLY [124]. This is thought to be a result of the interaction between PLY and the 
lipopolysaccharide receptor, Toll-like receptor 4 (TLR4). A study found PLY was able to 
synergise with TLR agonists to enhance secretion of proinflammatory cytokines IL-12, IL-23, 
IL-6, IL-1b, IL-1a and TNF-a by dendritic cells (DC) and enhanced cytokines IL-17A and IFN-
c by splenocytes. IL-17A and IFN-Ƴ are known to be required for protective immunity to 
pneumococcal infection. PLY-induced DC maturation and cytokine secretion by DC and 
splenocytes was found to be TLR4-independent. When muce were intranasally infected with 




compared to infection with wild-type bacteria [125]. In the absence of TLR-4 in mice, 
macrophages did not prompt an inflammatory response to PLY; colonisation was more 
widespread and mice were more prone to pneumococcal sepsis [125]. Level of susceptibility 
was dependent on the presence or absence of PLY.  The PLY mutant, with undetectable 
cytotoxicity and no complement-activating properties, also known as PdT (Figure 8), showed 
PLY was still active, suggesting the TLR4 interaction was distinct from these actions [125]. 
Using a solid-phase assay, it was noted that PLY can physically interact with TLR4 [126]. Pore 
formation induced by PLY can also activate the NLRP3 inflammasome, which leads to the 
Caspase-1 activation, followed by processing and release of IL1β by the immune system. It has 
been suggested that pore formation may also be responsible for potassium efflux and lysosomal 
destabilisation, leading to detection by NLRP3 directly, or through intermediary factors 
resulting in inflammasome assembly and Caspase-1 activation. 
During pneumococcal disease, the role of PLY remains debated. In the chinchilla model, PLY 
did not stimulate any inflammatory response associated with otitis media [133]. In the rabbit 
model, a rapid inflammatory response was observed in the brain as a result of intra-cisternal 
injection; however PLY-deficient and wild-type pneumococcus were not compared to 
determine the contribution of the PLY toxin in this model [134]. In the mouse [135] and guinea 
pig model [136], PLY lacked of any inflammatory response in the brain. Specifically, CSF 
leukocytosis did not appear to be significantly affected by the lack of PLY and the PLN-A 
inoculum had no detectable hemolytic activity. No difference was observed between the PLY-
deficient mutant and wild-type pneumococcus. The PLY-deficient mutant has, however, been 
shown to reduce protein influx into the cerebrospinal fluid (CSF), accompanied by a reduction 
in structural damage to the cochlea of infected animals, and a decline in pneumococcus-




Pneumococcal meningitis has been found to emerge in the rabbit infection model [137], leading 
to brain damage, with levels of PLY released measuring approximately 20 ng/mL in the CSF 
[138]. In patients, these levels range from around 1 to 180 ng/mL for those suffering from 
pneumococcal meningitis. Levels of PLY toxin found in the CSF tends to be dependent on the 
type of antibiotic used. For instance, more PLY is released into the CSF when ceftriaxone is 
used to treat infection in rabbits compared to that of a non-bacteriolytic antibody such as 
rifampicin [138]. This suggests the importance of treatment decisions when treating 
pneumococcal meningitis and the consequences with regard to bacterial lysis in the release of 
PLY. 
Lytic activity and activation of complement are the major activities linked to PLY. PLY does 
not appear to play a role in the inflammation linked to meningitis [134-136], but appears to 
play a role in deafness associated with meningitis [135], along with bacteraemia [140] and 
pneumonia [118]. 
 
1.3.4 Pneumococcal autolysin A (LytA) and other choline-binding proteins 
LytA is an important autolysin which promotes lysis of pneumococcus. LytA is located in cell 
envelope and plays numerous roles in physiological cell function, particularly associated with 
cell wall growth [241]. The enzyme has been shown to release highly inflammatory cell wall 
degradation components, as well as PLY from the cytoplasm. The structure of LytA is consists 
of two domain proteins with an N-terminal N-acetylmuramoyl L-ala-nine amidase domain and 
a C-terminal choline binding domain. The choline binding domain facilities this enzyme to 
bind to phosphocholine residues present on the teichoic acids of the cell wall [242]. Cell wall 
linkage via the choline-binding domain is necessary for LytA activity since choline 




cleavage of the lactyl-amide bond that attaches the stem peptides and glycan strands of the 
peptidoglycan, leading to hydrolysis of the cell wall. LytA orthologs have recently been shown 
to be conserved through bacteria and in many bacteriophages [243-245].  
The role of LytA in vivo is still under debate. However, there are three suggestions, firstly, 
LytA may perform lysis in order to release other virulence factors of pneumococcus, including 
pneumolysin; secondly, LytA may be released to degrade neighbouring, non-competent 
pneumococcal cells in a fratricidal manner; and third, LytA may mediate lysis to release either 
proteins that may contribute to immune evasion, or cell wall components that might interact 
with the host immune response [246-248].  
Some studies have shown that mutations in the LytA gene of the S. pneumoniae chromosome 
result in greatly reduced virulence compared to the parent strain, demonstrated in a mouse 
intraperitoneal challenge [165]. Moreover, other studies involving LytA have demonstrated 
that this enzyme prompts a protective response in mice against pneumococcal infection when 
administrated directly into the lungs [250-252]. The protective property of LytA resulted in a 
greatly extended survival in mice challenged intranasally with autolysin, making LytA a 
potential component of novel anti-pneumococcal vaccines [253, 254]. Immunisation, with both 
autolysin and pneumolysin presented the same degree of protection compared with singular 
administration, corresponding with the idea that, at least in vivo, anti-autolysin antibodies exert 
their effects first by preventing the secretion of pneumolysin.  
LytB, LytC and CbpE aid in colonisation of the nasopharyngeal [161]. The pneumococcal cell 
wall consists of repeat domains with choline present, which interact with CBPs that attach to 




ten CBPs in the R6 strain and 15 in the TIGR4 strain [162, 163]. LytA, LytB, LytC and CbpE 
are hydrolytic enzymes present in the cell wall, contributing to virulence [164, 165]. 
1.3.5 Neuraminidase 
Several enzymes encoded by genes of pneumococci have neuraminidase activity. 
Neuraminidase has the ability to cleave N-acetylneuraminic acid from glycolipids, lipoproteins 
and oligosaccharides on the cell surface and in body fluids, causing damage to the host cells. 
This may also uncover binding sites that the bacteria can potentially attach to. Neuraminidase 
may therefore function in terms of strong adhesion and other processes [255]. Neuraminidase 
activity degrades sialic acid which subsequently aids spread of the organism up the Eustachian 
tube to the middle ear. Although neuraminidase possibly promotes colonisation as a result of 
its action on glycan, its main role in pathogenicity has yet to be identified [256]. 
There are two forms of pneumococcal neuraminidase enzymes, NanA and NanB. NanA is 108 
kDa and NanB 75 kDa in size [155, 258]. The sequence of NanA and NanB display slight 
homology. Both enzymes show propensity for degradation to smaller fragments during in vitro 
growth and purification, with some of these fragments maintain neuraminidase activity. There 
are differences between NanA and NanB [155, 258, 259]. Firstly, NanA activity is 
approximately 100 times greater than that of NanB; secondly, NanA contains a C-terminal 
sequence that has an LPXTGX motif, which is not present in NanB. This is thought elucidate 
potent covalent binding of NanA to peptidoglycan structures of pneumococci [258, 260]. 
It is still not clear why S. pneumoniae has two different neuraminidases. However, they are 
likely to specialise in different environments during exposure during infection and invasion of 
the host. Notably, the two enzymes elicit different activities at a different pH. NanA is found 




(NanA) has been demonstrated as a virulence factor, playing a role in biofilm production. It 
has also been found to contribute to colonisation and the development of otitis media when 
observing pneumococcus infection in the chinchilla model. However, NanA has not been found 
to play a role in deafness associated with meningitis. NanA activity has been shown to induce 
the release of sialic acid, which may prove to be of importance to signalling to control 
pneumococcal virulence. 
1.3.6 Pneumococcal surface antigen (PsaA) and other lipoproteins 
Pneumococcal surface antigen (PsaA), is part of an ABC transporter that transports manganese 
and zinc ions into the cytoplasm of the bacteria [261]. Manganese is necessary for normal 
bacterial growth, thus mutation in PsaA results in impairment of manganese transport, which 
affects the expression of other pneumococcal genes, including adhesins. Manganese is also 
important in bacterial ability to resist oxidative stress [154-156], resulting from the production 
of hydrogen peroxide during pneumococcal metabolism, as well as the output of the reactive 
oxygen species during the interaction between the host innate immune response and bacteria. 
When a mutation arises for PsaA, there is decreased adhesion to cells, followed by a decrease 
in virulence and an increase in sensitivity to oxidative stress, illustrating the disability of PsaA 
mutant strains of pneumococcal to invade and colonise [262]. 
PsaA has been identified as the substrate-binding lipoprotein, PsaB as the ATP-binding protein, 
and PsaC is the permease [153]. The lipoprotein peptidyl prolyl isomerases, SlrA and PpmA 
have demonstrated roles in virulence and colonisation [157, 158]. The lipoproteins Pia and Piu, 
known to be involved in iron uptake, are also shown to be virulence factors [159, 160].  




Pneumococcal surface protein C (PspC) is an adhesion protein, which binds to the polymeric 
immunoglobulin receptor, as well as the complement regulatory protein factor H, to provide 
protection from complement. PspC is the only molecule homologous to PspA, with a similarity 
in its structure and function [263]. It is a surface exposed protein linked to the bacterial cell 
wall through specific choline binding motifs [227] and has been characterised as one of the 
essential virulence factors of S. pneumoniae, with an important role in adherence, colonisation 
and immunogenicity of pneumococcus. In vitro binding to sialic acid and epithelial cell 
residues becomes impaired when infecting with PspC deficient mutants of serotype 2 and 3 and 
demonstrated decreased nasopharyngeal colonisation and virulence compared to the wild-type 
strain, in sepsis models [264, 265]. A high degree of genetic variability has been observed 
between strains for PspC and its contribution to pneumococcal virulence is strain-dependent, 
not only in lung infection but also during systemic infection [266, 267]. 
Moreover, PspC plays an important role in evading complement due to its ability to bind factor 
H (FH), a negative regulator of the alternative pathway, thus preventing immune activity 
against S. pneumoniae [268-270]. The separation of factor B from the alternative pathway C3 
convertase (C3bBb) decreases the C3b deposition on the surface of bacteria. Furthermore, 
factor H can perform as a co-factor in the degradation of C3b via factor I-dependent cleavage 
of C3b, bound to bacterial surface, to iC3b. Finally, the formation of C3 convertase on the 
surface of bacteria may be suppressed due to factor H binding to C3b, which can dislocate C3b 
from factor B and decay the C3 convertase C3bBb [271]. PspC also has ability to bind to the 
fluid phase complement inhibitor C4b-binding protein, which blocks the activation of the 
classical complement pathway [272]. 




IgA1 proteases are enzymes able to cleave human IgA1 [48], which predominates in mucosal 
tissues and secretions [49]. When cleavage occurs, pneumococcal bacteria producing IgA1 
become coated with antibody fragments lacking their Fc domains. This allows the bacteria to 
evade the host immune response, specifically avoiding the recognition by Fc receptors and 
complement which usually elicit an inflammatory response [50]. Cleavage also results in the 
organism retaining the Fab fragments on its surface, which aids pneumococcal bacteria in 
masking its capsular polysaccharide surface antigen. Cleavage of IgA1 protease to human IgA1 
also promotes adherence to epithelial cells, enhancing infection, by electrostatic interactions 
between positively charged Fab fragments coating the bacteria and the negatively charged host 
cell plasma membrane [51]. 
1.3.9 LPXRG-anchored surface proteins 
17 LPXTG-anchored proteins have been found, although the number may be variable between 
strains [141]. The LPXTG motif is typically found near the C-terminus of the protein, however 
it has also been observed near the N-terminus end in some pneumococcal proteins, thought to 
be involved in the surface location of proteases [142]. The C-terminus sequence is recognised 
by sortase enzymes, which recognise LPXTG and these attach to the cell surface via covalent 
linkage of peptidoglycan found in the cell wall. Hyaluronidase, neuraminidase, and serene 
protease PrtA are LPXTG proteins, and all present as virulence factors. Hyaluronidase is 
secreted by almost all clinical isolates (99%) [143], and is responsible for the breakdown of 
hyaluronic acid found in mammalian connective tissue and the extracellular matrix. It has been 
observed in other micro-organisms, that the degradation of this component can assist bacterial 
spread and colonisation [144]. Hyaluronidase may increase pulmonary inflammation in 
pneumococcal pneumonia by interacting with pro-inflammatory cytokines and chemokines 




binding to CD44 on host cells. The serine protease PrtA gene was found in all clinical isolates 
[146], and encodes a member of the subtilase family, with hyper-variable region across the 
central domain of the protein. The catalytic triad of this protein remained conserved. The exact 
role of PrtA has yet to be uncovered, however it has been demonstrated that PrtA gene 
expression is co-regulated with the virulence genes for pilus locus and PLY by the transcription 
factor pneumococcal surface antigen (Psa)R [147]. On the other hand, manganese or zinc has 
been shown to have opposing effects on the regulation of PrtA by PsaR [148]. When a Prt-A-
deficient mutant of D39 was attenuated and introduced into the murine infection model, 
vaccination provided protection from intra-peritoneal challenge close to that of antibody levels 
found in healthy control individuals and in patients with invasive disease [146].  
1.3.10 Pneumococcal virulence and adhesion 
Other virulence factors identified for pneumococcus include the pneumococcal adherence and 
virulence factor A (PavA) family, glyceraldehyde-3-phosphate dehydrogenase and enolase, 
which are two glycolytic enzymes, and the pneumococcal histidine triad protein (Pht) family. 
PavA binds to fibronectin and mediates attachment to endothelial cells, and mutants lacking 
this protein have been shown to be attenuated in sepsis and meningitis models [168, 169]. 
Glyceraldehyde-3-phosphate dehydrogenase and enolase enzymes bind to plasminogen [170, 
171], which aids in transmigration of the bacteria through the basement membrane [172]. The 
PhT family has been shown to offer protection against pneumococcus in vaccination models 
[173, 174], however, mutagenesis of all four proteins are required to attenuate pneumococcus 
[175]. PhtA, PhtB, PhtD, and PhtE are all members of this family of proteins, which all contain 
a conserved motif, HxxHHxH, believed to be of importance to the binding of zinc ions. 




reduce binding of complement to the bacterium by recruiting the complement regulator factor 
H [175]. 
 
1.3.11 Pneumococcal pilus 
Pili are found on the surface of some strains of pneumococci [149]. The rlr locus or pilus islet 
(PI-I) are the genes responsible for pilus production. They code for three structural proteins and 
three sortase enzymes, which play a role in the linkage of structural subunits. The pilus is a 
virulence factor in that it mediates binding of pneumococci to the cell surface (Figure 9), as 
well as stimulating the pro-inflammatory response in terms of inducing cytokine production 
[149]. Another pilus type aids adherence of pneumococci to epithelial cells [151]. Certain 
strains of pneumococci are able to express both types of pili [151]. 
 
 





1.3.12 Immune responses to the pneumococcus 
The induction of a pro-inflammatory response to pneumolysin and the stimulation of TNF, IL-
1, IL8 and IL6 production has been well documented in a number of different host cells [43-
47]. Pneumolysin has demonstrated its ability to induce nitric oxide which is an important 
component of antimicrobial immunity and contributes to tissue pathology, as well as induce 
the production of CXCL8 and IL-6 in cells of the upper airway. Macrophages are also produced 
by the upregulation of cox-2 gene expression via an IFNγ- dependent pathway. Other pathways 
that are thought to play a role against pneumolysin are the MAPK, NFκB and TLR-4 signaling 
pathways. Several pattern recognition receptors including Toll-like receptors 2 and 4 are also 
thought to play a role in mediating the inflammatory response to pneumococci [487]. 
 
Figure 9. (A) The host mechanisms use to battle pneumococcal colonising and infecting, (B) the main 





Pro-inflammatory cytokines IL-6, IL1β and the transforming growth factor-β are responsible 
for the development of the distinct set of T cells, Th17 [129-131]. Th17 cells produce IL-17 
cytokine which boosts neutrophil production and migration to areas of infection [128]. Mice 
that have been immunised by a variety of pneumococcal proteins have been shown to stimulate 
IL-17 production, however it is uncertain whether this result is primarily IL-17 production from 
the spleen or whether there were contributory pro-inflammatory cytokines involved [132]. IL-
17 has been shown to contribute to the immune response against pneumococcus colonisation, 
also dependent on the presence of PLY [127]. Inflammasome signaling is important for the 
promotion of IL-17A responses, which are thought to play an important role in resistance to 
both pneumococcal carriage and pneumonia, [487]. 
Pneumolysin has been shown to have complement activating activity and may play a role in 
induction of memory T cell responses, as well as its role in T cell recruitment and T cell 
cytokine production [487].  
1.4 Pneumococcal disease interventions 
1.4.1 Antimicrobial treatment of pneumococcal disease 
Increasing emergence of antimicrobial resistance is progressively hindering attempts at treating 
pneumococcal infections [84-86]. Treatment using β-lactam agents, such as ampicillin, with 
individuals presenting with CAP is generally not associated with poorer outcomes, but this is 
not the case with high-level macrolides resistance or fluoroquinolone resistance, in which 
treatment failure is likely to occur [84-86]. In the treatment of severe CAP, recommended 
therapy is a combination of β-lactam and macrolides agents, such as azithromycin, or 




has been demonstrated to show a more beneficial effect in bacteraemic pneumococcal CAP and 
in severe pneumococcal bacteraemia compared to monotherapy [53, 54].  
1.4.1.1 Adjuvant anti-inflammatory strategies in severe   pneumococcal disease 
The invasion of the host immune cells, particularly epithelial and endothelial cells [56], as well 
as erythrocytes [57], can protect the bacteria against β-lactam agents, though with more 
lipophilic agents such as macrolides, protection is to a lesser extent due to these agents being 
poorly taken up by eukaryotic cells [58]. Furthermore, β-lactams have been shown to cause 
disintegration of pneumococcal bacteria, followed by release of pro-inflammatory cell wall 
components including lipoteichoic acid and peptidyoglycan, as well as the cytotoxin 
pneumolysin, resulting in detrimental inflammatory responses [59]. Adjunctive anti-
inflammatory therapy, such as the use of macrolides in combination therapy, aims to optimise 
treatment by suppressing the production of pneumococcal adhesins, invasins, cytotoxins, and 
immunosubversins, while simultaneously limiting the potentially harmful host inflammatory 
response by acting as an anti-inflammatory [60]. Macrolides have the ability to inhibit the 
potentially harmful effect of neutrophil-mediated inflammation, which mobilise chemokines 
and cytokines interleukin-8 (IL8) and tumour necrosis factor (TNF) by epithelial cells, 
fibroblasts and smooth muscle cells in the airways, and lung macrophages [61, 62]. Macrolides 
are thought to interfere with the transcription process of genes encoding these pro-
inflammatory proteins 61-64]. Treatment with macrolides have been associated with reduced 
mortality in patients presenting with pneumonia and severe sepsis caused by macrolide-
resistant bacteria [65], pneumonia caused by pneumococcus resistant strains [66], and in acute 






Corticosteroids are broad spectrum anti-inflammatory agents, currently suggested as adjuvant 
treatment for individuals with penicillin-susceptible meningitis [68], due to higher survival rate, 
reduced duration of hospital stay, and less neurological and auditory complications in both 
adults and children [69-72]. However, it is known that neutrophils are relatively insensitive to 
corticosteroids as an anti-inflammatory [73], and recent reports show that high levels of the 
endogenous corticosteroid, cortisol, is predictive of severe disease and mortality in individuals 
with severe CAP [74]. Furthermore, recent studies have failed to confirm the benefit and 
efficacy of systematic administration with corticosteroids [75-76]. 
1.4.1.3 Statins 
Statins inhibit the enzyme 3-hydroxy-3-methylglutaryl co-enzyme A reductase and can act as 
therapeutic agents capable of controlling hypercholesterolemia and reduce the risk of 
cardiovascular disease and stroke. In addition to these functional properties, statins also possess 
anti-inflammatory properties and can be used to control harmful neutrophilic inflammation. 
Firstly, they appear able to interfere with G-protein receptor-mediated signalling mechanisms 
in immune and inflammatory cells [77], and secondly, they are able to induce the enzyme 
hemeoxygenase-1 which mediates the induction of anti-inflammatory proteins [78]. Statins 
have been shown to provide a significant survival advantage among individuals with bacterial 
CAP [79-80], as well as with individuals with pneumococcal disease [81]. Statins may also 
provide protection against acute cardiac complications triggered by pneumonia [79], along with 
potential interference with cytotoxic and pro-inflammatory processes of the cholesterol-





1.4.2 Pneumococcal vaccines 
Current pneumococcal vaccines consist of capsular polysaccharide antigens, or vaccines 
conjugated with proteins to boost the immunological response in order to match the response 
seen during natural infection with pneumococcus, termed protein-polysaccharide conjugate 
vaccines [152]. The most often used pneumococcal vaccines to date are the 7-, 10-, and 23-
valent vaccines [367]. It is thought that this is due to the emergence of infections caused by 
pneumococcal serotypes absent from the current vaccine spectrum [404]. Current research is 
focussed on evaluating potential adjuvants to polysaccharide or conjugate vaccines, or 
extending the range of coverage to more protein antigens common to all pneumococcal 
serotypes, forming novel vaccine candidates [364-366]. 
                
 
Figure 10. Coverage of serotypes for pneumococcall vaccines [407] 
 
1.4.2.1 Capsular polysaccharide vaccines 
In 1911, a crude, whole-cell vaccine was developed aimed at preventing pneumococcus [89]. 
Following this, pneumococcus became known to consist of different capsular serotypes, and so 




including two or four serotypes. Towards the end of the 1940s, two hexavalent vaccines were 
marketed, until highly effective antibiotics against pneumococcus became available a few years 
later. In 1964, it became obvious that vaccines were still a necessity, due to reports that the 
incidence of mortality due to pneumococcal bacteraemia remained very high despite the use of 
antibiotics [90]. In a large hospital in New York, it had been estimated during a longitudinal 
study over 10 years that approximately 25% of all patients with bacteraemia died, with around 
50% of these consisting of patients over 60 years of age. During 1977, after the revival of 
vaccine interest, a polysaccharide 14-valent vaccine, including 14 capsular serotypes became 
available for use in the USA. This vaccine was replaced in 1983 with the 23-valent vaccine, 
which includes purified capsular polysaccharide antigens for the following 23 serotypes (1, 2, 
3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 




Antigenic differences of the capsular polysaccharide remain the basis of pneumococcal 
vaccines [92]. These antigens are capable of eliciting specific antibody responses that can 
provoke opsonisation, phagocytosis and killing of the bacteria by phagocytic cells [91]. The T-
cell independent mechanism is primarily responsible for the induction of antibodies against 
pneumococcal polysaccharide antigens, thus, children below 2 years of age may respond poorly 
due to an under-developed immune system. This makes immunisation particularly important 
in this age group since they have little protection from numerous opportunistic bacterial 
infections in the first few years of life. In the elderly, antibody response is usually adequate 




They may also have lower functional activity, in terms of avidity, opsonisation and 
phagocytosis, induced by antibodies against the vaccine serotypes [99]. Despite these potential 
low responders, in general vaccination can induce a two-fold or greater increase in specific 




1.4.2.3 Pneumococcal 7-valent conjugated vaccine 
In 2000, the protein conjugate vaccine (PCV-7 Prevenar, Pfizer, previously Wyeth), was 
recommended for use in the USA by the Committee on Infectious Diseases. By 2008, 22 
countries had introduced PCV7 to their vaccination schedule. It included protection from 7 
different serotypes of the bacteria based on their polysaccharide capsular antigens – 4, 6B, 9V, 
14, 18C, 19F and 23F, which covers 80-95% of serotypes known to be responsible for invasive 
pneumococcal infection in the USA [161]. Conjugated to this is CRM197, which is a non-toxic 
diphtheria variant carrier protein which is highly immunogenic, able to elicit a strong T-cell 
dependent response, and therefore improve vaccine efficacy. Since this vaccine was introduced 
in the United States, data has reported that there has been a reduction by 94% in pneumococcal 
disease in children under the age of 5 years, confirming the effectiveness of this particular 
vaccine [162]. However, PCV7 does not include optimal protection for all serotypes included 
in the vaccine [176]. The most notable effectiveness in terms of serotypes protection was 
against serotypes 14, 9V and 23F, which showed the most significant reduction (more than 
three-fold) in occurrence after the 7-valent vaccine was introduced. Serotypes 18C and 6B 
showed a modest reduction of around 2-fold of cases, while serotype 19F showed little 




the frequency of infections, as did the strains resistant to antibiotics. There was promise in 
terms of resistance levels among the serotypes included in vaccine coverage, with a 1.5-fold 
decrease, however, those not included within the vaccine continued to double in frequency of 
resistance. Non-invasive serotypes also showed a rise in resistance to multiple (two or more) 




In 2010, the WHO announced the pre-qualification of the 10-valent pneumococcus vaccine 
(PCV10) [177] and some countries, such as Poland, saw an increase in the number of people 
being vaccinated, though unfortunately there was not a matched decrease in incidence of 
pneumococcal disease [178]. While PCV-7 is gradually being removed from the market, 
PCV10 and PCV13 are licensed for immunisation of infants and children from 6 weeks to 5 
years of age against IPD and acute otitis media caused by the vaccine serotypes of S. 
pneumoniae.  PCV13 is also licensed for the prevention of pneumococcal disease in adults >50 
years of age [478]. 
 
1.4.2.5 PHiD-CV and PCV13 
PHiD-CV (Synflorix®) and the conjugate 13-valent pneumococcus vaccine (PCV13, Prevenar 
13) are both currently available in the UK, with PCV13 replacing PCV7 in the UK 
immunisation program in April 2010, [478]. These aimed to widen the spectrum of coverage 
in terms of serotypes responsible for the increasing numbers of infection, but not previously 




two capsular polysaccharide types conjugated to either diphtheria (serotype 19F) or tetanus 
(serotype 18C) toxoid, and 8 other serotypes (1, 4, 5, 6B, 7F, 9V, 14 and 23F) conjugated to 
non-typable Haemophilus influenzae (NTHi) protein D [362]. NTHi protein D is thought to 
offer additional protection against acute otitis media (AOM) caused by H. influenza [362].  
PCV13 consists of 6 additional polysaccharide antigens alongside those 7 previously included 
in PCV7. Additional serotypes included in PCV13 were 1, 3, 5, 6A, 7F and 19A, combined 
with the diphtheria toxoid, CRM197 [363]. These additional serotypes were most often seen in 
Africa, Asia and Latin America and known to be responsible for 70% of invasive pneumococcal 
disease worldwide [177, 415]. This vaccine was also documented to be useful in vaccinating 
children infected with the human immunodeficiency virus (HIV), and offers some protection 
against pneumococcal infection [414]. PCV13 has now been introduced in over 40 countries; 
however there is lack of data to report the impact of PCV13 on the incidence of pneumococcal 
infection caused by the spectrum of serotypes included in this vaccine [177]. Serotype 22F is 
not included in either the PHiD-CV or PCV13 vaccine, which is of concern since the prevalence 
of 22F IPD has recently shown a dramatic increase in children less than two years of age in 
England and Wales [340], as well as ranking sixth in Scotland for causes of IPD in children 
less than 5 years of age. Currently, PCV13 appears to be the most effective vaccine against 
pneumococcus and has been introduced into numerous childhood immunisation programs 
worldwide. 
 
1.4.2.6 23-valent polysaccharide vaccine (PS) 
Polysaccharide 23-valent vaccine (PPV23) offers the highest coverage across the different 
pneumoccoccal serotypes; however, PPV23 presents weak immunogenicity in children, [480-




gained some ground [178]. The effectiveness of the 23-valent polysaccharide vaccine is 
uncertain in its capability to protect against pneumococcal pneumonia. However, in the 
protection against invasive pneumococcal disease, severe pneumonia and serotype-specific 
otitis media in children below 2 years of age [386], the vaccine has shown promising efficacy, 
is cost-effective and has demonstrated a protective effect in the immunocompetent population, 
including the elderly [417, 418], and in groups of immunocompromised individuals, such as 
those with HIV infection or infants with sickle cell disease, [485]. It may also be useful in 
limiting the spread of antibiotic-resistant pneumococci. The 23-valent polysaccharide vaccine 
is currently recommended to individuals aged 2 years or over who are at high risk of 
pneumococcal disease, and to all elderly individuals over 55-65 years of age. Following 
primary vaccination, a booster vaccination is recommended when 5 years have elapsed [416]. 
The 23-valent polysaccharide vaccine (PPV, Pneumovax®, Merck) has been marketed for 
almost 30 years, and is primarily used to protect adults at risk of pneumococcal disease, and 
the elderly. While this vaccine is not recommended in children below 2 years of age due to 
under-developed T-cell-independent immune responses in these individuals [380], conjugate 
vaccines have been introduced to improve the overall efficacy. The Joint Committee on 
Vaccination and Immunisation have reported the protective ability of the vaccine as largely 
unsuccessful in the elderly population in the UK, which is disappointing [336]. 
 
1.4.2.7 Vaccine coverage and serotype replacement 
When PCV7 was introduced into the UK routine childhood immunisation program by the 
Department of Health in 2006, it was predicted to reduce the incidence of pneumococcal 
disease and reduce pneumococcal antibiotic no-susceptibility [381-384]. However, 




cases among those aged 5 years and under (794 cases in 2005–2006, to 470 cases in 2007-
2008) [385]. This can be attributed to invasive pneumococcal disease caused by serotypes 
included in the PCV7 vaccine, which previously accounted for 70% of cases in those less than 
5 years of age during 2005 and 2006 and reduced to 24% in 2007-2008. This overall trend has 
also been demonstrated in Scotland [387]. Indirectly, herd immunity has also been a co-factor 
in the protection against serotypes-specific IPD since PCV7 immunisation. In the unvaccinated 
population, a reduction in IPD has also been noted in children over 5 years of age and in adults 
[385]. Herd immunity due to reduced exposure appears to correlate with number of doses given 
to the population [388]. Decreased carriage and transmission from vaccinated individuals 
improves cost-effectiveness and impact of vaccine efficacy [382, 389]. For PhiD-CV and 
PCV13, serotype coverage in England and Wales was 53% and 74% respectively for 2007-
2008. This showed a reduction in coverage compared to the previous years’ 2005-2006 which 
were 81% and 92% for PhiD-CV and PCV13, respectively, likely due to serotype replacement 
and disease replacement [382, 385]. Serotype replacement describes the shift in prevalent 
circulating serotypes present in the populating with the ability to cause disease due to 
vaccination [390]. Following the introduction of PCV7, this shift was observed in the USA and 
predicted to occur in the UK as well [391]. Serotype replacement has now documented across 
all age groups in the UK, with a reported increase in IPD cases caused by serotypes 7F, 19A 
and 22F [385]. In the post PCV7 period, an increased incidence of IPC caused by serotype 7F 
has also been reported in Portugal [392], and the same phenomenon was observed for 19A and 
22F IPD in the US [393]. The ST320 clone known to incur high antibiotic resistance was noted 
as particularly important in the rise of serotype 19A IPD in the USA [394, 395]. In contrast, 
the ST199 clone appeared predominantly responsible for the rise of serotype 19A IPD in the 
UK [396]. This suggests that intrinsic factors other than that of antibiotic resistance were 




conjuguate vaccines, has not offered cross-protection to serotype 19A [397]. This may be due 
to the fact that 19F presents the lowest immunogenicity out of all serotypes covered in the 
PCV7 vaccine [398]. Cross-reactive antibodies of 19F measured against 19A have also been 
shown to elicit a weak response, in vitro [399]. Following PCV7 introduction in the UK, other 
serotypes not comprised in the coverage of the vaccine have shown an increase, including 
serotype 6C [400, 401, 403], despite the presence of 6B antigen in the vaccine. Similarly, the 
inclusion of 6B polysaccharide in the vaccine formulation did not protect against serotype 6A 
either [402]. Serotype replacement has contributed to the shift in the pneumococcus niche more 
than originally predicted, likely due to vaccine pressure among the serotypes able to cause IPD, 
causing  a reduction in the protective efficacy of PCV7 [404]. Serotype replacement was also 
demonstrated in Scotland, with the example of serotype 7F reported to cause little disease 
incidence between 2005-2006, and now becoming the most common cause of IPD in children 
less than 5 years of age, responsible for 12% of cases [385], post PCV-7 introduction. In the 
UK, a highly significant increase in serotype 1 was reported prior to the introduction of routine 
PCV7 immunisation [360, 361]; demonstrating serotype dynamics are also prone to 
fluctuations [404]. Therefore, long-term epidemiological surveillance remains important in 
treatment responses to these changes.  
1.4.2.8 PCV-15 
PCV-15 is currently in pre-clinical trials. PCV-15 was produced in order to create a vaccine 
which covered a broader range of serotypes to allow for the changing epidemiology of 
pneumococcus, particularly regarding serotype 19A, which after the introduction of Prevnar 
into the infant vaccination schedule in the US and Europe, showed an increase in prevalence of 
disease in infants due to serotype replacement. Serotypes 22F and 33F are the next two most 




children and older adults [309, 437, 438, 439]. PCV-15 consists of the 13 original 
pnueumococcal polysaccharide serotypes included in the licensed PCV-13 vaccine, plus two 
additional serotypes (22F and 33F). These additional serotypes have been shown to account for 
approximately 10% of IPD cases in adults in the US in 2007, [309]. 
A study describing the development and pre-clinical evaluation of PCV-15, demonstrated that 
the antibody response to this vaccine was comparable to the antibody response in infant-rhesus 
monkeys to the PCV-7 vaccine of the 7 serotypes it has in common. PCV-15 was shown to 
induce strong immunological responses to all 15 polysaccharide components within the 
vaccine, including the 7 serotypes included in PCV-7 and the 8 new serotypes, however 
correlate of protection and sero-conversion in human infants has yet to be established. 
Immunisation with PCV-15 in infant rhesus monkeys did not show serotype interference of 
antibody responses between the 7 original serotypes and the additional oligosaccharide 
conjugates. In terms of functional antibody responses based on opsonophagocytosis activity to 
S. pneumoniae, PCV-15 demonstrated excellent responses to all 15 polysaccharide serotypes 
[440]. 
In 60 healthy adults immunised with the PCV-15 vaccination, PCV-15 was shown to have an 
acceptable saftey profile, although had a higher incidence of injection-site and systemic adverse 
effects, as well as some incidences of elevated body temperature and fever, when compared to 
recipients of PCV-7.  PCV-15 was able to induce both IgG and opsonic activity to all 15 
serotypes included within the vaccine [441].  
 




The immunogenicity of current polysaccharide antigens may be improved with the use of 
adjuvants capable of boosting the immune response [415]. Another potential technique is to 
convert polysaccharide antigens to T-cell dependent forms of protein-conjugation, further 
enhancing the immune response. In mice studies, interleukin-12 (IL-12) was found to give an 
enhanced response of IgG2a, which plays a role in mediating complement fixation and 
opsonisation, and IgG3, in treatment of pneumococcus when given in conjunction with the 
pneumococcal polysaccharide vaccine. IL-12 is was also demonstrated to have an important 
role on the basis of its ability to enhance cell-mediated immunity through the activation of T-
cells and natural killer (NK) cells, which suggested this cytokine could potentially be used as 
an adjuvant to boost the protective efficacy when treating humans with the pneumococcal 
vaccine. However, when tested in phase I/II randomised, double-blind vaccine studies, results 
demonstrated a disappointing IgG and antibody isotype response, and antibody avidity, in 
comparison to the placebo group given the 23-valent pneumococcal vaccine only, without 
recombinant human IL-12 (rh-IL-12). Furthermore, the co-administration of rhIL-12 and 23-
valent pneumococcal vaccine was associated with a high incidence of local and systemic side-
effects [420]. 
 
Surface protein A (PspA) is the most widely studied antigen common to all serotypes [100]. 
Being highly immunogenic, it has been demonstrated to induce antibodies protective against 
pneumococcal infections in mice [101-103], as well as being produced in human sera, both 
adult and children, in response to previous infection [104]. It is thought that PspA antibodies 
may play an important role in the protection against pneumococcal invasive infection due to 
the significantly reduced antibody level of PspA antibody in children aged 7-36 months with 
invasive pneumococcal infection, compared to other infections. Other targets for protein 




(psaA), choline-binding protein A (cbpA), and S. pneumoniae secretory immunoglobulin-A 
(IgA) binding protein (SpsA). These proteins have common functional characteristics, likely 
revolving around the process of bacterial adherence [105-107]. Pneumolysin [108] and 
neuraminidase [100] are two proteins playing an important role in the virulence of 
pneumococcus, so are also important targets for vaccination. Current vaccine efforts are largely 
focussed on the above mentioned pneumococcal proteins, as well as whole-cell vaccines, which 
may provide extended, serotype-independent protection. 
 
1.5 Pneumococcal genetic plasticity 
1.5.1 Recombination events 
  
Recombination is an important factor related to the evolution of S. pneumoniae compared to 
other factors responsible for genetic variation of the organism. For instance, the rate of 
recombination has been documented as 10 times higher than the rate of mutation [203], 
showing hundreds of recombination events in a single lineage of pneumococcus, with 74% of 
the genome being subjected to recombination in at least one isolate [204]. However, it has yet 
to be uncovered whether this rate is similar in all pneumococcal strains, or whether there are 
other driving factors such as geographical location. High rates of pneumococcal recombination 
may be a result of the presence of the high density of repeat elements in the genome that may 
contribute to the integration of foreign DNA into the genome and consequently lead to 
rearrangement of its structure [205]. S. pneumoniae has been reported to have the greatest 
density of repeats (1 every 500 bp) in comparison to 51 other prokaryotic genomes [206]. BOX, 
RUPS and Rho-independent Terminator-like Element (SPITE) have all been identified as 




termination of transcription [207]. S. pneumoniae consist of an open pan-genome, of an infinite 
size which means the organism can adapt rapidly to changes in its environment in the form of 
genetic evolution [208]. High rates of recombination in this organism mean distinct 
pneumococcal strains or clones may form, but these may be less stable in comparison to other 
bacteria [203, 208]. 
Genetic exchange of material between S. pneumoniae species in the form of recombination is 
commonly observed in streptococcus of the mitis group [211], including S. pneumoniae, S. 
mitis, S. oralis, S. infantis, S. sanguis, S. gordonii, S. pseudopneumoniae, S. cristatus, S. 
oligofermentans, S. parasanguinis, and S. peroris. Some of these organisms from the mitis 
group also colonise in the nasopharynx, making genetic exchange easier [212]. S. mitis and S. 
oralis have been documented to be donors of genetic information passed to S. pneumoniae 
resulting in evolution of mosaic penicillin-binding protein genes [213]. Pneumococcal isolates 
which had elements of hyper-recombination showed selective advantage, with a significantly 
higher rate of resistance for various antibiotics, including penicillin, erythromycin, tetracycline, 
chloramphenicol, and cefotaxime, compared the pneumococcus isolates that had no evidence 
of recombination. Defects in the mechanism of the DNA mismatch repair system are thought 
to play a role in hyper-recombination [214, 215, 216]. 
1.5.2 Genes expressed during infection and colonization 
In the last decades, Pasteur and Sternberg first described the pneumococcus, a number of 
virulence factors involved in invasive disease have been identified. Major virulence 
determinants such as capsular polysaccharide, pneumolysin, and choline-binding proteins have 
obviously established roles in pathogenesis [227]. Recently, massive identification of S. 




mutagenesis (STM), have used transposons and suicide vectors to pepper the chromosome of 
the bacteria with mutations and identify genes required for virulence [55]. 
Characterization of pneumococcal virulence determinants should ideally include analysis of 
gene expression during invasive disease. Confirmation of their expression in vivo would not 
only verify the contribution of these genes to pathogenesis but would also clarify their 
contribution to discrete forms of disease (e.g., genes expressed during pneumonia versus those 
in the blood during bacteremia). However, analysis of in vivo bacterial gene expression, much 
less at discrete sites, has been limited by the difficulties of isolating sufficient quantities of pure 
and intact bacterial RNA from infected host tissues [87]. To challenge the requirement for 
RNA, investigators have used differential fluorescence induction (DFI) to identify S. 
pneumoniae promoters that are induced during disease [87]. Pneumococcal genes play critical 
roles either with pneumonia and sepsis, or pneumonia and carriage, or sepsis and carriage. For 
example, comDE up-regulated during pneumonia and sepsis, while dwon-regulated during 
colonisation in nasopharynx [496,497, 498, 499]. A recent study was found a mutation in sodA 








Figure 11. Important genes expression during inftection by S.pneumoniae [607] 
 
Table 1. Important genes expression of pneumococcal during infection 
 
1.6 Aims and objectives 
1.6.1 Aims 
This study aimed to characterize the carriage, invasive and immunological properties of S. 
pneumoniae serotype 1 ST306 and ST615 clinical isolates using in vitro and in vivo models. 
Meanwhile, The ST306 was compared directly with ST615 by using RNA-seq.  
Infection Involved genes 
Nasopharyngeal carriage cbpD,ply, pspA, pspC, nanA, nanB, rlrA,lytA, sodA, cbpA, 
piaA, spxB, pcpA, pavA  
Pneumonia cbpA, cbpD, vanZ, adcR, cps4A, nanB, pavA, pspA, ply, 
zmpA, zmpC, eno, comDE, iga ,lytA, lytB   
Sepsis (blood circulation) malX, prtA, psaA, cps4A, nanB, zmpA, comDE 
Nasopharyngeal 
cbpD, ply, pspA, 
pspC, nanA, nanB, 
rlrA, lytA, sodA, 
cbpA, piaA, spxB, 
pcpA, pavA 
Pneumonia 
cbpA, cbpD, vanZ, 
adcR, cps4A, nanB, 
pavA, pspA, ply, 
zmpA, zmpC, eno, 
comDE, iga ,lytA, 
lytB   
Sepsis 







Host-pathogen interactions of S.pneumoniae were observed with a focus on cellular  immune 
responses; colonisation and invasive properties of naturally occurring ST-306 which exhibit 
low haemolytic activity were investigated; and novel key virulence genes were identified by 
comparing the expression profiles of S. pneumoniae in vitro. In this project, we merely focus 
on ST306 and ST615. 
 
Chapter 2 describes the materials and methods used in this study, including the characterisation 
of pneumococcal strains originating from Uruguay and Switzerland, ST615 and ST306, 
respectively. It also highlights the spontaneous mutations in pneumolysin found to be present 
in ST306 isolates, which resulted in attenuated bacteria. All of the procedures undertaken in 
this section have enabled us to illustrate the differences between sequence types and will assist 
in explaining the interaction between bacteria and their host cells in vitro and in vivo, including 
those involved in genetic expression of the bacterial genome identified in chapter three. 
Chapter 3 is focused on the in vitro results describing the differences in pneumolysin between 
predominate sequence types in Europe and South America. A haemolytic assay and PLY 
ELISA were used to measure the concentration of pneumolysin produced, followed by the use 
of Detroit and BEAS-2B cell lines to characterise adherence and invasion abilities of both 
sequences. To measure the host response, a complement deposition and opsonizing 
phagocytosis killing assay were performed. With regard to molecular and genetic techniques, 
RNA-Seq was used to compare gene expression during the growth phase of bacteria in normal 
media without any additional nutrients. This chapter is also focused on the in vivo 
methodology. It includes the study of the behaviour of both S. pneumoniae serotype 1 (ST306 




pneumococcal to cause pneumonia and bacteremia after intranasal infection for both the 
spontaneous mutation strain and non-mutant strain was observed, with mouse survival 
indicated in this particular experiment. A competition experiment was then carried out using 
ST306 and ST615 isolates by co-infecting mice with both strains to determine their interaction 
within the host. Finally, the most significant experiment included intranasally infecting mice 
with a mixture of the spontaneous strain (ST306) and pure pneumolysin.   
 
Chapter 4 is focused on transcriptome analysis of ST306 comparing to ST615. Analysis of 
certain genes differential RNA expression provides us with greater insights into biological 
pathways and molecular mechanisms. 
 





         



























2.1 Pneumococcal bacterial strains 
The pneumococcal isolates used in this project are listed in Table 2. All serotypes are clinical 
isolates, with the exception of laboratory strain D39 and its pneumolysin-deficient variant, 
PLN-A, which are laboratory-adapted strains [499]. Pneumococci ST306 and ST304 were 
kindly provided by our collaborator, Dr Lucy Hathaway, Institute for Infectious Diseases, 
University of Bern, Switzerland, while the strain belonging to ST615 was provided by Prof 
Francois Trottein, at the Pasteur Institute in Lille, France.   
Table 1. List of pneumococcal strains used in this project 
 
















































































Strains were confirmed optichin-sensitive (Oxoid limited, Hampshire, UK), alpha-hemolytic 
on 5% sheep blood agar, and soluble in 2% sodium desoxycholate.  
2.2 Culture media 
2.2.1 Blood agar 
  
For the preparation of blood agar base (BAB, Oxoid) plates, 39g of blood agar base was 
added to 1L of distilled water. The mixture was sterilised by autoclaving at 121ºC for 15 
minutes, then cooled down to 50ºC. Horse blood (HB, Oxoid), warmed to room temperature, 
was added to the media at a final concentration of 5% and flask was swirled to mix thoroughly. 
The blood agar was then poured into 100x15 mm sterile petri dishes under aseptic conditions, 
left until solidification, then plates were inverted and stored at 4ºC until use. 
2.2.2 Brain heart infusion broth (BHIB) 
To prepare BHIB (BHIB, Oxoid), 37g of BHI powder were added to 1L of distilled water. The 
pH of the broth was adjusted to 7.4 and autoclaved at 121ºC for 15 minutes. Media was poured 
into sterile plates, left until solidification, then plates were inverted and stored at 4ºC until use. 
 
2.3 Solutions 
2.3.1 Phosphate buffer saline (PBS) 
To prepare PBS, 10 tablets of phosphate buffer saline (PBS, Oxoid, Thermo Scientific) were 
dissolved in 1L of distilled water and autoclaved at 121°C for 15 minutes.  
 





The following chemicals were added to make up the lysis buffer: distilled water 1L, 1M Tris-HCl 
20ml (Tris-HCl, Sigma-Aldrich); 10% SDS 20ml (SDS, Sigma-Aldrich); 0.5M EDTA 40ml 
(Sigma-Aldrich). 
 
2.3.3 Freezing media for immune cell storage at -80°C 
The following ingredients were added to make up the freezing media: 90ml of fetal bovine serum 
(FBS, Sigma-Aldrich); and 10ml dimethyl sulfoxide, DMSO (Sigma-Aldrich). 
2.4 Bacterial growth and cultures 
2.4.1 Preparation of bacteria liquid stocks 
One streak of the respective Streptococcus pneumoniae isolates incubated overnight on a 5% 
blood agar plate was inoculated into 10mL of 20% FCS in BHI broth and further incubated for 
18 hours at 37°C under anaerobic conditions, and aliquots of 1ml were stored at -80°C until 
use.  
2.4.2 Bacterial growth curve 
Growth curves were established to compare the growth kinetics of different pneumococcal 
strains. For each strain, a single colony of S. pneumoniae was inoculated into 50ml of Brain 
Heart Infusion broth (BHIB), and grown at 37°C under anaerobic conditions to an absorbance 
value of 0.5-0.6 (OD500nm).  Growth was measured using a spectrophotometer (Thermo Helios, 
Fisher Scientific) to confirm attainment of the mid-logarithmic growth phase.  A 500µl derived 
from these cultures was further inoculated in 50ml of BHI overnight under the same growth 
conditions. Aliquots were chosen at each hour to perform viable counts. Results were recorded 





2.5 Determination of S. pneumoniae viable counts on blood agar plates 
The Miles-Misra technique [501] was used to enumerate the number of colony-forming units 
(CFU) per ml in stored aliquots of pneumococcal serotypes or mouse tissues. Pneumococcal 
liquid aliquots or freshly homogenized mouse tissues were serially diluted ten-fold in 
duplicate on a 96-well microplate, to a final dilution of 106. A 5% blood agar plate was divided 
into six sectors and 60μl of every dilution were spotted over each section. This process was 
repeated on a second plate to confirm results. P lates were incubated o v e rn i gh t  in a  
c an d l e  jar at 37ºC. The following day, the dilution sector containing the optimal numbers 
of colonies (between 20-200 colonies) was identified and viability calculated using the 
following formula: 
CFU per ml = mean number of colonies in section × Dilution × 1,000/60 
 
2.6 DNA extraction for MLST analysis 
Pneumococcal strains were grown on two blood-agar plates to high density. Cells were 
collected using a plastic loop and resuspended in 1ml of 50mM Tris-10mM EDTA pH 8 in an 
Eppendorf® tube. 20µl of 50mg/ml lysozyme was added to each tube and incubated at 37°C 
for 15mins on a shaker. 5µl of 20mg/ml proteinase K was added to each tube and incubated at 
37°C for 40mins on a shaker. 10µl of RNAse at a working concentration of 10µg/ml was added 
to each tube and incubated at room temperature for 2 minutes. 100µl of 10% SDS (100mg/ml) 
was added to each tube and incubated at 37°C for a maximum of 2 hours on a shaker until lysis 
was complete. Tubes were centrifuged for 5 minutes at 13,000 rpm and 900µl supernatant 
transferred to a new tube. 900µl of phenol/chloroform/isoamyl alcohol was added and mixed 
carefully, then centrifuged for 5 minutes at 13,000rpm. 800µl of supernatant was transferred to 




Tubes were centrifuged at 13,000rpm and 700µl supernatant was transferred to a fresh tube. 
700µl of chloroform was added and mixed carefully, followed by centrifugation for 5 minutes 
at 13,000rpm. 600µl of supernatant was transferred to a fresh tube and 1 ml of ice cold 100% 
ethanol added and mixed. Tubes were incubated at -20°C for 15 minutes, centrifuged for 5 
minutes at 13,500rpm at room temperature, followed by removal of supernatant. Pellets were 
allowed to try at room temperature, and then DNA was dissolved in 50µl of DEPC water. DNA 
was stored at -20°C until further use. 
2.7 PCR amplification for MLST analysis 
Seven house-keeping genes were used [501] to identify and confirm the sequence type of the 
pneumococcal isolates. 
• aroE (shikimate dehydrogenase) 
• gdh (glucose-6-phosphate dehydrogenase) 
• gki (glucose kinase) 
• recP (transketolase) 
• spi (signal peptidase I) 
• xpt (xanthine phosphoribosyltransferase) 
• ddl (D-alanine-D-alanine ligase) 
The primer pairs used for the PCR amplification of internal fragments of these genes are: 
aroE-up, 5'-GCC TTT GAG GCG ACA GC  
aroE-dn, 5'-TGC AGT TCA (G/A) AA ACA T(A/T)T TCT AA 
gdh-up, 5'-ATG GAC AAA CCA GC(G/A/T/C) AG(C/T) TT 
gdh-dn, 5'-GCT TGA GGT CCC AT(G/A) CT(G/A/T/C) CC 
gki-up, 5'-GGC ATT GGA ATG GGA TCA CC 




recP-up, 5'-GCC AAC TCA GGT CAT CCA GG 
recP-dn, 5'- TGC AAC CGT AGC ATT GTA AC 
spi-up, 5'-TTA TTC CTC CTG ATT CTG TC  
spi-dn, 5'-GTG ATT GGC CAG AAG CGG AA 
xpt-up, 5'-TTA TTA GAA GAG CGC ATC CT  
xpt-dn, 5'-AGA TCT GCC TCC TTA AAT AC 
ddl-up, 5'-TGC (C/T) CA AGT TCC TTA TGT GG  
ddl-dn, 5'-CAC TGG GT(G/A) AAA CC(A/T) GGC AT  
Master mix was prepared and contained 6µl 5X buffer, 0.5µl 40mM dNTPs, 0.5µl of each 
20µM primer, 0.25µl 5000U/ml NEB Phusion taq, 1µl DNA from bacterial strain, and 
dispensed at a volume of 21.25µl H2O, per tube. PCR conditions used were: 98°C for 30secs, 
98°C for 10 secs, 54°C for 30 secs, 72°C for 45 secs (35 cycles), and 72°C for 10 mins. PCRs 
were performed using a Techne Flexigene thermal cycler (Thermo Fisher, Loughborough, UK). 
2.8 Haemolytic assay 
  
The haemolytic activity of the different isolates was determined using a modified version of a 
method published by James C. Paton in 1983 [503]. The bacterial isolates were grown in BHI 
to a late exponential phase (OD500 < 1) and then lysed by treatment with 0.1% sodium 
deoxycholate. The total protein of the lysates was determined using the BCA Protein Assay Kit 
(Thermo Scientific, Loughborough, UK). Approximately 85μg of total protein was used for the 
determination of the haemolytic activity of each isolate by making serial dilutions of the lysates 
and incubating them with a 4% solution of sheep red blood cells (Oxoid). After a 30-minute 




of the supernatants was measured to determine the haemolytic activity. The results presented 
are representative of three independent experiments.  
2.9 Pneumolysin detection using ELISA 
A 96-well ELISA microplate (eBioscience, Cheshire, UK) was coated with 1µg/well of PLY 
domain 4 mouse antibody (IgG1) (Abcam) mixed with coating buffer (eBioscience, Cheshire, 
UK) and left overnight at 4oC. Wells were washed with 200µl 1X PBS, 0.05% Tween/PBS 
wash buffer (eBioscience, Cheshire, UK), then blocked with 200µl/well 20% FBS in PBS, 
incubated at 37ºC for 4 hours. Wells were washed and 100µl per well of sample and standards 
were added. The plate was incubated for 1 hour at 37°C (or overnight at 4°C). Wells were 
washed (as above) and 1µg PLY polyclonal antibody (Abcam, Cambridge) in 100µl blocking 
buffer was added to each well, and then incubated at 37°C for 30 minutes. Wells were washed, 
then anti-rabbit IgG alkaline phosphatase was added at a 1:5,000 dilution in blocking buffer, 
and left to incubate at 37ºC for 30 minutes. Wells were washed and then colour reagent pPNPP 
(50µl/well) was added and left to incubate for 30 min in the dark. 100µl/well of 1M NaOH was 
added to stop the reaction, then absorbance read on an automated plate reader using a BMG 












2.10 Tissue culture 
The cell lines used for this study were the human bronchial-epithelial cells BEAS-2B (ATCC® 
CRL-9609™), the human nasopharyngeal epithelial cells Detroit-562 (ATCC® CCL-138™) and 
the promyelocytic leukaemia human cell line HL-60 (ATCC® CCL-240™). 
  
The BEAS-2B is an adherent cell line that was maintained in Dulbecco’s Modified Eagle’s Medium 
(DMEM) supplemented with 5% inactivated Foetal Calf Serum (FCS) and 1% Penicillin-
Streptomycin solution. The flasks were kept in horizontal 75cm2 flasks at 37°C and 5% CO2 until 
confluent. Once confluent, approximately every 2-3 days, the cells were split into a new flask after 
being detached using 5ml of 1xTripsin/EDTA. The Detroit-562 is also an adherent cell line and 
was maintained in Minimum Essential Medium Eagle (MEM) supplemented with 10% FCS and 
1% Penicillin-Streptomycin solution. This cell line was kept under the same conditions as the 
BEAS-2B and the cells were split after incubation with 5ml 1xTrispin to induce the detachment of 
the cells from the flask.  
The HL-60 cell line was maintained in suspension in RPMI-1640 Phenol Red free media 
(Invitrogen, Thermo Scientific, Loughborough, UK) supplemented with 20% FCS. The cells were 
kept in vertical 75cm2 flasks at 37°C and 5% CO2, and were fed every other day. This cell line was 
used for opsonophagocytic killing assays, for which the cells had to be differentiated into 
polymorphonuclear lymphocytes (neutrophils) by incubating 2x105cells/ml in 100ml with 750μl of 
dimethylformamide (DMF) for 4 days. For the opsonophagocytic killing assay, the viability of the 
cells after differentiation needed to be above 90%, which was determined with trypan blue. 
  
2.11 Adhesion and invasion assays  
Adhesion and invasion assays were performed using the lung epithelial cells BEAS-2B and the 




A density of 105 cells per well were seeded into 24-well plates and grown in their respective 
media (DMEM for BEAS-2B, and MEM for Detroit-562) in the presence of FCS and 
antibiotics. The cells were grown at 37°C and 5%CO2 until confluent, approximately 48h after 
seeding. Frozen stocks of known concentration of bacteria were used. The bacteria were 
washed and re-suspended in the respective media supplemented with FCS but without 
antibiotics to a final concentration of a ratio 1:10 (cell: bacteria) . Following 3 washes with 
PBS (Oxoid), one ml of bacterial suspension was added to the cell monolayer. The 24-well 
plates were then incubated for 2 hours at 37°C and 5% CO2. For each independent experiment, 
two 24-well plates were used at a time, one of them to assess the adherence of the bacteria to 
the surface of the cells, the other one to assess the invasion of the bacteria into the cells.  
 
Following 2 hours of incubation, both plates were washed 5 times with PBS to remove the 
excess of bacteria that did not adhere or invade the cells. To determine the invasion ratios 
bacteria, 1ml of media supplemented with FCS and 5ul of penicillin was added to each well 
and incubated at 37°C and 5%CO2 for a further 2 hours. To assess adhesion ratios, 100μl of 
1xTripsin/EDTA were added to each well and the plate was incubated for 10 minutes at 37°C 
and 5% CO2. Once the cells were detached they were lysed by incubating them for 10 minutes 
in 1ml of 0.05% Triton X-100 media with FCS. Finally, the viable bacterial number was 
determined using the Miles and Misra method [501].  
 
After the 2 hour-period of incubation with penicillin, cells were washed 3 times with PBS to 
remove penicillin. Cells were then detached and lysed in order to assess invasive bacteria by 
using viable bacterial numbers were determined using the Miles and Misra method [501]. The 
number of adhered bacteria was determined by subtracting the number of invading bacteria 




These experiments were performed in triplicate on three independent days and appropriate 
controls were used. 
2.12 Capsule thickness  
The bacterial capsule thickness was determined using a modified version of the FITC-dextran 
exclusion method originally published by Gates in 2004 [504]. This method consists in 
measuring the zone of exclusion of FITC-dextran which correlates with capsule size.  
Briefly, a single colony from an overnight culture in 5% BAB plates was incubated for 
approximately 8-12 hours at 37°C in 10ml of BHI to mid-log phase. The bacteria were then 
sub-cultured to again, a mid-log phase. Finally, 2µl of 200kDa FITC-dextran (Thermo 
Scientific) was added to 10µl of the culture and pipetted onto a microscope slide. The slides 
were observed using a Nikon Eclipse 80i fluorescence microscope (Nikon, Kingston Upon 
Thames, UK). At least 100 individual bacteria were analysed for each sample using the ImageJ 
software. These experiments were kindly done by Mansoor, a PhD student in the lab.  
2.13 Complement deposition assay 
A volume of 5 ml of bacterial stock solution at 1x105CFU/ml in BHI was prepared and 
incubated at 37°C for 15 minutes. 100µl suspension was removed at 0.5 OD500nm (viable count 
determined using the Miles and Misra technique). The suspension was centrifuged at 3,359 x 
g for 10 minutes then supernatant removed and pellet resuspended in 5ml PBS. Suspension was 
distributed evenly across 5 x 1.5ml Eppendorf tubes. Tubes 1-3 contained 1) Bacteria, 2) 
Bacteria and Thiazol Orange, and 3) Bacteria, plus human sera from healthy donors, mouse 
anti-human C3 and anti-mouse conjugated to APC fluorochrome (abcam, Cambridge, UK), 
tubes 4) and 5) contained bacteria, complement and anti-mouse APC conjugate.  Tubes were 




100µl of 20% human serum in PBS with1% gelatin veronal buffer. Tubes were incubated at 
37°C/5% CO2 for 30 minutes, washed with 900µl PBS per tube and centrifuged at 17,000 x g 
for 3 minutes. Supernatants were removed, and pellet from tube 3 was reconstituted in 100µl 
of mouse anti-human C3 (1:300 dilution), while pellets in tubes 1 and 2 were reconstituted in 
PBS only. Tubes were incubated at 37 °C/5% CO2 for 30 minutes, washed with 900µl PBS per 
tube and centrifuged at 17,000 x g for 3 minutes. Supernatants were removed and tube 3 pellet 
reconstituted in 100µl of anti-mouse APC, while tube 1 and 2 pellets resuspended in 100µl 
PBS. Tubes were incubated at 4 °C in the absence of light for 30 minutes, washed with 900µl 
PBS per tube and centrifuged at 17,000 x g for 3 minutes. Supernatants were removed, pellets 
washed with 100µl PBS and centrifuged at 17,000 x g for 3 minutes. Supernatants were 
removed and pellets resuspended in 500µl PBS, followed by the addition of 5µl Thiazol Orange 
at a 1:1,000 (0.5ul/ml) dilution to tubes 2 and 3. The tubes were briefly vortexed and incubated 
for 5 minutes at room temperature, then stored at 4°C in the absence of light until acquisition 
on a flow cytometer (BD Accuri™ C6, BD Biosciences). Once the samples acquired, the mean 
fluorescence intensity (MFI) was calculated to quantify C3 deposition. 
 
2.14 Opsonophagocytosis killing assay (OPKA) 
Differentiated HL-60 cells were used in an opsonophagocytic assay at an effector: target cell 
ratio of 40:1. The volume required for 4 x 105 cells/well per 100 wells in a microtitre plate were 
harvested by centrifugation at 160 x g for 10 minutes at room temperature, the supernatant was 
discarded removing any residual medium. The pellet was resuspended in Hanks’ buffer without 
Calcium and without Magnesium (Life Technologies), using 5ml for every 50ml of centrifuged 
cell culture. Resuspended cells were kept at 37°C/5% CO2 for 10 minutes until use in the 




serially diluted (2-fold) in 10ml of opsonophagocytosis buffer (20% of FBS in DPBS) for a 
total of 8 dilutions, from 1:8 to 1:1,024. 40µl of IVig was added in duplicate to the first row of 
a round-bottomed microtitre plate (Costar, Cambridge).  Bacterial suspensions diluted from 
frozen stocks, were added at 1x105 CFU per well in 10µl opsonophagocytosis buffer consisting 
of 4ml Hanks’ buffer with Ca++ and Mg++ (Life Technologies) and 0.1% gelatin. The assay 
plate was incubated at 37°C/5% CO2 for 15 minutes. Following incubation, sterile baby rabbit 
serum, (Sigma-Aldrich) was thawed and 5µl/well of this complement source was added to the 
plate. Harvested differentiated HL-60 cells were washed as described above, and the pellet 
gently resuspended in opsonophagocytosis buffer. 4 x 105 cells in a 40µl volume were added 
to each well immediately after the addition of complement. The assay plate was incubated at 
37°C for 45 minutes with horizontal shaking (220 rpm) to promote the phagocytic process. 
Using a multichannel pipette, 10µl from each well was plated onto solid medium prepared from 
5% horse blood and 4% agar. Aliquots were allowed to air dry, and culture plates were 
incubated overnight at 37°C/5% CO2. Viable colony counts were performed after 
approximately 18 hours incubation period.  Complement control wells included all test reagents 
except IVIg. A viable count of the initial number of bacteria added per well at time zero (T0) 
was included in each run. The difference of complement control counts and number of bacteria 
counts should not be more than 60%  .The purpose of that experiment was to determine the 
resistant and sensitive strain against phagocytosis. 
 
2.15 Purification of rPLY 
Full-length recombinant PLY (rPLY) was prepared as described previously [505]. Briefly, the 
ply gene was cloned into the pQE-31 vector (Qiagen, Manchester, UK), and the recombinant 




which contains lacI and kanamycin resistance genes. rPLY was produced in E. coli cells as a 
six-His-tagged protein by incubation of the transformants with 2 mM isopropyl-β-D-
thiogalactopyranoside at 25°C for 6 h. The E. coli cells were then harvested by centrifugation, 
incubated with lysis buffer (50 mM NaH2PO4, 300 mM NaCl, 20 mM imidazole, 1 mg/ml 
lysozyme, 200 U DNase I, pH 8.0), and disrupted by vortexing with 0.1-mm zirconia-silica 
beads (Bio-Spec Products, UK). rPLY was then purified from the soluble fraction by use of a 
nickel-nitrilotriacetic acid column (Qiagen) under native conditions according to the 
manufacturer's instructions. Contaminating LPS was extensively removed using a Detoxi-Gel 
endotoxin-removing gel (Thermo fisher, Loughborough, UK). The purity was analyzed by 
Coomassie brilliant blue staining and immunoblotting using an anti-His-tag monoclonal 
antibody (penta-His antibody; Qiagen) after sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE).  
To inhibit its cytolytic activity, rPLY was treated with 20 μg/ml of cholesterol for 30 min on 
ice. Heat-treated PLY and LPS were prepared by heating the aqueous stock suspensions, in 
50% glycerol-water (vol/vol) for PLY and in PBS for LPS, in a boiling water bath for 60 min. 
This experiment was kindly done by Hesham, a PhD student in the lab. 
2.16 Mouse models 
2.16.1 Models of Intranasal infection 
 
2.16.1.1 Invasive pneumonia model 
Bacteria were grown until desirable optical density and used to perform these experiments. 
Female MF1 mice (Charles River Laboratories) at 6-8 weeks of age were challenged with 
50µl, containing 1×106
  
pneumococci, via the intranasal route. Mice were divided into two 




assayed using the f o l l o w i n g  pain scoring scale: 1) normal, 2) hunched, 3) stary and 
piloerected, 4) lethargic, 5) moribund and 6) dead, as d e s c r i b e d  by Morton [506]. The 
scoring sheet used can be found in Appendix 1.
 
 
Bacterial CFU counts were determined in the inoculum. each group (ST306 and ST615) 5 mice 
from were humanely euthanised at time zero (i.e, approximately 5 minutes post-infection), and 
their lungs and nasopharynx were collected, homogenised and processed for viable counts 
(Miles and Misra) and flow cytometry analysis.  
 
The following time points were targeted:  
0 hour: 50ul/mouse S. pneumoniae intranasally administration  
 0 hour post-challenge: Schedule 1 n=5 mice per sequence type 
 6 hour post-challenge: Schedule 1 n=10 mice per sequence type 
12 hour post-challenge: Schedule 1 n=10 mice per sequence type 
24 hour post-challenge: Schedule 1 n=10 mice per sequence type 
48 hour post-challenge: Schedule 1 n=10 mice per sequence type 
 
2.16.1.2 Nasopharyngeal carriage model 
 
Frozen stocks of bacteria grown to exponential phase were freshly thawed to run these 
experiments. Female MF1 mice (Charles River) at 6-8 weeks of age were intranasally 
challenged with 10µl pneumococci at a final concentration of 1 × 105
 
(CFU/10µl). Mice 
were divided into two groups: ST306 (n=65) and ST615 (n=65). 
 




group; ST306 and ST615, were humanely euthanised at time zero and their nasal mucosa, 
lymph nodes, lungs and nasopharynx collected, homogenised and processed for either viable 
counts on BAB plates, or flow cytometry analysis. Whole blood was collected by cardiac 
puncture. Animals will be anaesthetised with a mixture of O2 and isofluorane, and infected 
intranasally with 105 CFU S. pneumoniae/mouse in a volume of 10μl. Mice were closely 
monitored for the visual development of clinical signs of disease, as described previously [506]. 
Mice Nasopharynx and lungs were removed at predefined timepoints (as detailed below). 
Whole blood samples were collected by cardiac puncture into sterile heparinized tubes.  
 
The following time points were targeted: 
Day 0: 10ul/mouse S. pneumoniae intranasally administration to all n=130 mice.  
Day 0 post-challenge: Schedule 1 n=10 mice, 5 mice per sequence type.  
Day 1 post-challenge: Schedule 1 n=20 mice, 10 mice per sequence type.  
Day 3 post-challenge: Schedule 1 n=20 mice, 10 mice per sequence type. 
Day 7 post-challenge: Schedule 1 n=20 mice, 10 mice per sequence type. 
Day 14 post-challenge: Schedule 1 n=20 mice, 10 mice per sequence type.   
Day 21 post-challenge: Schedule 1 n=20 mice, 10 mice per sequence type.   
Day 28 post-challenge: Schedule 1 n=20 mice, 10 mice per sequence type. 
2.16.2 Pneumococcal sepsis model  
Frozen stocks of bacteria were freshly thawed to run these experiments. Female MF1 mice 
(Chiral river) were challenged intravenously with 50µl pneumococci containing 1x106
 
CFU. 
Mice were divided into 2 groups (n=6) and received either ST306 or ST615 pneumococci.  
Bacterial viable counts were determined in the inoculum and in postmortem samples, 




experiment were subjected to pain scoring at regular interval and at the most critical points to 
monitor the severity of the symptoms over time. 
Tail bleeding was performed, at 6, 12, 24 and 48 hours after infection. Blood samples were 
collected in 0.5 ml eppendorf tubes containing 1µl heparin to prevent clotting, and viable 
counts were determined.  
2.15.3 Mouse survival experiment 
This experiment was carried out to determine and compare the in vivo virulence of ST306 vs. 
ST615 isolate. The procedure used in this experiment is similar to that used in the intranasal 
model of infection in section 2.16.1.1. However, in this procedure mice were carefully 
monitored throughout the infection period and blood was collected from mouse tails in 0.5ml 
heparinised eppendorf tubes. Female MF1 mice (Charles River Laboratories) were challenged 
with 50µl pneumococci via the intranasal route in a final concentration of 1x106
 
CFU. Mice 
were divided into two groups: ST306 and ST615 mice. In total, 10 mice received 50µl of 
ST306 pneumococci intranasally, while another 10 mice received 50µl of bacteria ST615 
pneumococci. Mice were monitored and scored using the pain scoring system (1-5) discussed 
above up to 7 days.  
2.16.4 Induction of streptomycin resistant pneumococci 
Colonies of ST615 pneumococci were exposed to increasing concentrations of streptomycin in 
BHI broth until they became growth resistant to a concentration of 40 μg/ml of streptomycin. 
This experiment was performed in order to differentiate viable counts of ST306 and ST615 on 























Figure 12. Schematic diagram of experimental animal models. MF1 female mice were infected as 
described in the Materials and Methods section. Infected mice were sacrificed at mentioned days and 
nasopharyngeals, lungs and blood were collected to assess the levels of pneumococcal infection and 
characterise immune cells. 
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2.16.5. Pneumococcal ST306-ST615 co-infection model 
Female MF1 mice (Charles River Laboratories) at 6-8 weeks of age were challenged with 
10µl of a mixture 1:1 of ST306:ST615 pneumococci, at a final concentration of 2x105
 
CFU, 
via the intranasal route. Five mice per group from ST306- and ST615-challenged mice, were 
humanely euthanised at time zero and their lungs and nasopharynx collected, homogenised 
and processed for viable counts. Blood was collected by cardiac puncture.  
On days 1. 3 and 7, 10 mice from each group; ST306 and ST615, were humanely euthanised. 
Mice from each group; ST306 and ST615, were humanely euthanised and their lungs and 
nasopharynx collected using the same procedure. 
 
2.16.6. Pulse experiment using purified pneumolysin and ST306  
Female MF1 mice (Charles River Laboratories) at 6-8 weeks of age were anaesthetised with 
a mixture of O2 and isofluorane and challenged with 50µl of ST306 pneumococci (106
 
CFU 
per mouse) mixed with 100ng of LPS-free recombinant pneumolysin, via the intranasal route.
 
Five mice were humanely euthanised at time zero, and their lungs and nasopharynx collected, 
homogenised and processed for viable counts (Miles and Misra) and flow cytometry analysis. 
Mice were then closely monitored for the visual development of clinical signs of disease, as 
described previously [506]. Any animal judged to have reached 2+ lethargic (minimal 
movement in the absence of application of finger pressure) was humanely euthanized. Mice 
were monitored up to 48 hours post-infection, at which point the experiment will end. 
Nasopharynx, lungs, blood and brain tissues, and whole blood samples were collected for 
further analysis. 
  




0 hour: 50ul S. pneumoniae + Ply pulse intranasal administration  
 0 hour post-challenge: Schedule 1 n=5 mice per sequence type 
 6 hour post-challenge: Schedule 1 n=10 mice per sequence type 
12 hour post-challenge: Schedule 1 n=10 mice per sequence type 
24 hour post-challenge: Schedule 1 n=10 mice per sequence type 
48 hour post-challenge: Schedule 1 n=10 mice per sequence type 
 
2.17 Flow cytometry analysis 
 
FACS staining was performed with multiple antibodies, using the BD FACScalibur machine 
and data analysed using the BD CellQuest Pro software. 
 
2.17.1 Staining Buffer 
 
FACS staining was performed using PBS supplemented with 3% foetal-calf serum (FCS) or 
PBS containing 1% bovine serum albumin (BSA).  All buffers were filter sterilised before use.   
 
2.17.2 Preparation of single cell suspension 
 
 Lung tissues were placed into a clean 10 cm dish/petri dish and cut into fine pieces using 
disposable scalpel blades. Tissues were transferred into 1.5 ml eppendorf containing 500 l 
PBS supplemented with collagenase then incubated at 37C for 30 minutes, to digest the 




Tissues were placed into a cell strainer placed onto open top 50 ml Falcon tubes and pushed 
through the cell strainer using a plunger from 2 ml or 5 ml disposable syringes.  Any remaining 
cells attached to the cell strainers were pushed through by flushing with 10 ml PBS using a 10 
ml pipette.  Cell strainers were discarded and cap was placed back on the Falcon tube, then 
centrifuged at 300g for 5 minutes at 4C. The supernatant was decanted and cell pellet 
reconstituted in 5 ml of erythrocyte lysis solution (ACK lysing buffer, Invitrogen), diluted as 
recommended by the manufacturers.  The tube was further incubated at room temperature for 
5 minutes then quenched with 5ml PBS.  Following centrifugation at 300g for 5 minutes at 
4C, supernatant was discarded. Cell pellet was resuspended in 3% FCS for staining at a 
concentration of no more than 107cells/ml, at an approximately equal cell densities between 
samples.  
Lungs were resuspended in 5 ml and 100 l of the resuspended cells used for each individual 
stain; lung or cervical lymph nodes were resuspended in 750 l, using 100 l per stain; 
mediastinal lymph nodes or nasal mucosa were resuspended in 500 l, using 100 l per stain.  
2.17.3 Cell staining procedure 
All staining was performed on ice and samples covered with foil during the incubation periods 
to protect the fluorochromes from light. Appropriate isotype controls were used for each 
staining.  For example, if a rat anti-mouse CD3-PE of IgG2a isotype was used, then a Rat 
IgG2a-PE isotype control was included.  In addition, an unstained sample from every tissue 
was included in the FACS analysis to aid with the gating strategy.  
Staining was performed in 1.5ml eppendorfs or on round-bottomed 96-well plates.  Cells were 
transferred to tubes or plates and centrifuged at 300g for 5 minutes at 4C.  Supernatant was 
removed by pipette or decanting. Cells were resuspended in 50 l PBS 1% BSA or PBS 3% 




suspension was incubated for 20 minutes on ice then centrifuged at 300g for 5 minutes at 4C. 
Pellet was resuspended in 50l  PBS 3% FCS supplemented with antibodies at pre-optimised 
concentrations (see Table 3), then incubated for 30 mins on ice. 200 l PBS 1% BSA or PBS 
3% FCS was added to the stained cells and centrifuged at 300g for 5 minutes at 4C.  
Supernatant was removed and pellet washed. Each sample was resuspended in 300 l PBS 1% 
BSA or PBS 3% FCS and transferred to FACS tubes. Samples were acquired using a BD FACS 
Calibur (BD Biosciences) and Cell Proquest software. 
 
Table 2. Panel A &B showing the antibodies were used in flow cytometry 
2.18 RNA extraction protocol 
 Growth curves of NCTC7465 strain (ST615) and B915 strain (ST306) of serotype 1 were performed 
by inoculating 250ml of BHI with 2.5x106 bacteria and incubating them at 37ºC in a water bath. Samples 
were taken every hour to determine the optical density (OD500). This experiment was done in triplicates 
and plotted to determine the five phases of growth: early exponential phase (EEP), mid-exponential 
phase (MEP), late exponential phase (LEP), early stationary phase (ESP) and late stationary phase 
(LSP).  
Panel A Panel B 
APC - CD45 (Leukocyte surface marker) 
Clone I3/2.3 
FITC – CD45 (Leukocyte surface marker) 
30-F11 
PE – FoxP3 (T regulatory cells) 
Clone FJK-16S 
APC – F4/80 (Macrophages) 
Clone BM8 
PE/Cy7 - CD4 (T cells) 
Clone GK1.5 
PE/Cy7 – Gr1 (Neutrophils) 
RB6-8C5 
FITC – CD3 (T cells) 
Clone 17A2 





Ribonucleic acid (RNA) from each growth phase was stabilised by incubating the bacteria with 
a solution of 5% phenol (Invitrogen) and 95% ethanol for a minimum of 30 minutes in ice. 
Following stabilisation, the RNA was extracted using a phase separation method using 
TRIzol® (Invitrogen) [507]. Briefly, the cells were centrifuged and re-suspended in TRIzol® 
to allow bacterial lysis. The lysed bacteria were mixed with chloroform to separate the RNA 
from DNA, lipids and proteins. Once the aqueous phase was collected (RNA), the sample was 
washed and the RNA was precipitated using ethanol. Finally, the RNA was re-suspended in 
DNase/RNase free distilled water (Invitrogen). The RNA extraction was done in an RNase-free 
area and using RNase-free materials to avoid RNA degradation.  
The quantity of RNA was determined using the Qubit® Fluorometer (Thermo Scientific). A 
2100 Bioanalyzer (Agilent Technologies, Stanta Clara, USA) was used to assess the quality of 
the RNA. Once confirmed that the RNA was not degraded the samples were sent to Vertis 
Biotechnologie AG (Freising, Germany) for Illumina NextSeq 500 sequencing (Illumina).  
 2.19 RNAseq transcriptomic analysis 
The raw sequencing data were prepared by Vertis Biotechnologie AG in FastQ format. Chrispin 
Chaguza, PhD student, annotated the genomes. Assembly of the sequence reads was performed 
using Velvet and SPADes assembly programs. The resulting contigs of the genomes were then 
ordered by ABACAS and annotated using a combination of the RATT and PROKKA 
prokaryotic annotation pipelines. Orthologous genes between the NCTC7465 strain (GenBank 
assembly Accession number: GCA_001457635.1) and the B915 strain (Genebank Accession 
number: FQ312039) were identified using CD-HIT. The mapping of the RNA-Seq reads 
against the annotated genomes to infer transcripts was done by Dr. Karsten Hokamp at Trinity 




transcriptome was done in collaboration with Prof. Jay Hinton (Institute of Infection Biology, 
University of Liverpool) using the GeneSpring 7.3 software (Agilent Technologies). 
2.20 Details of mapping and RNA-seq reads 
RNA-seq was performed by Vertis Biotechnologie AG, followed by annotation that done by 
Chrispin Chaguza, and RNA-seq was mapped against annotated genomes to infer transcriptome 
by Dr. Karsten Hokamp at Trinit, College Dublin, as previously described. Expression analysis 
of the transcriptome was performed in collaboration with Professor Jay Hinton, University of 
Liverpool using the GeneSpring 7.3 software (Agilent Technologies). 
2.21 Statistical analysis 
All data from this experiment was analysed with Student t-test and ANOVA with a significant 
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Recent epidemiological studies have reported the clonal expansion of pneumococcal isolates 
expressing Ply with either low or non- hemolytic activity, in particular those associated with 
serotype 1, 7F, and 8, which, coincidentally, are also described among the most invasive 
pneumococcal strains [415]. As such, the reduced hemolytic activity of Ply in pneumococcal 
isolates readily capable of causing invasive pneumococcal disease (IPD) has questioned the 
importance and contribution of Ply to the pathogenesis of pneumococcal disease [413]. 
Interestingly, Ply possesses a number of immunomodulatory properties that perform 
independently of the toxin’s cytolytic activity. These properties include antibody-independent 
activation of the classical complement pathway [414], Toll-like receptor 4 (TLR4) [414],-
dependent and -independent activation of the NLRP3 inflammasome [414]. However, it 
remains unclear whether the noncytolytic properties of Ply are sufficient or essential for IPD 




IPD. Furthermore, it is not clear whether pneumococcal strains presenting low hemolytic 
activity will escape from vaccine formulations which include Ply-specific antigens [415]. 
 
Epidemiological data related to pneumococcal serotype 1 are still scarce, though, several 
reports showed an increased prevalence of invasive pneumococcal disease (IPD) caused by 
serotype 1, in Scotland [416], Sweden and Denmark [417] as well as throughout Europe, South 
America, Africa and Asia [418]. On the other hand, simultaneously diseases caused by serotype 
1 tend to show a decreased prevalence in North America and Egypt [418]. Pneumococcal 
serotype 1 is classically associated with clinical features such as complicated pneumonia, 
pulmonary empyema and peritonitis. It has been directly linked to mortality, irrespective of 
factors such as age, environment, and co-infection. Along with serotypes 5 and 7, serotype 1 is 
also associated with a higher ratio of hospitalisation versus ambulatory care compared with 
pneumococcal infections from other serotypes [415]. 
 
There are ten mouse strains were used for pneumococcal research which showed their 
susceptibility for different model of infections such as pneumonia, otitis media and sepsis,  
these  strains are   MF1,   BALB/C,  DBA/2, CBA/Ca,  AKR,  C57BL/6,  NIH, FVB/n, 
CSH/He and C3H/HeJ [613]. MF1 strain was used for these experiments as this strain is 
susceptible for all model of pneumococcal infection; survival rate of this strain is around 48 
hours and quite cheaper than other strains [613].Multiple infection mouse in vivo models were 
utilized in our study: an intranasal model of invasive pneumonia,  an  i n t r av en o u s  model 





The overall aim of this project was to compare the key microbial, immunological and invasive 
properties of pneumococci serotype 1 ST306 and ST615 which has fully active pneumolysin 
using both in vitro and in vivo experimental approaches. 
3.2 Multilocus sequence typing (MLST)  
 
MLST for the 12 serotype 1 isolates revealed that 10 of these isolates were ST306 and 1 was 
ST304, and there was also 1 ST615. 
 
 
3.3 Bacterial Growth Curve 
The different isolates were grown in order to monitor the growth kinetics specific to each 
sequence type, and compare them to the well characterised laboratory serotype 2 strain D39. 
Bacteria were grown in 20% BHI-serum for around 19h and growth measured throughout at 
500nm every 30 minutes (Thermo Helios, Fisher Scientific). As observed in Figure 8, all the 
isolates followed the same pattern of growth: at first, a lag phase reflecting the time required to 
adapt to a new growth environment, followed by a replication and growth phase commonly 
described as the exponential phase [328]. The final bacterial growth phase, also known as the 
stationary phase, reflects the exhaustion of available nutrients, or the increased accumulation 
of waste products and toxic metabolites that are detrimental to bacterial growth. During the 
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Figure 13. Growth profiles of strains (A) D39, (B) ST306 and (C) ST615 in BHI media without serum 
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Figure 14. Growth profiles of strains (A) D39, (B) ST306 and (C) ST615 in BHI media without serum 
by using bacterial counts  
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Growth curve analyses showed a pattern typical of bacterial growth for all three strains ST128, 
ST306 and ST615. Variations were observed between isolates from serotype 1 at the lag phase 
with ST615 growing faster than ST306, while ST128 (D39) was similar to ST306. Data 
collected during these growth phases illustrate the generation time which is the average time 
between two consecutive generations in the lineages of a population. Generation time, defined 
as time (minutes or hours)/ logB-logA, was equal to 20 min for ST128, 18 min for ST615 and 
36 min for ST306. The growth of all isolates steadily increased between 6 and 8 hours onward 
and reached exponential phase after 7-9 hours post incubation.  
The stationary phase started earlier 10 hours after inoculation in ST615 compared to ST128 
and ST306, which suggested that cells underwent reductive cell division and became more 
resistant to osmotic and acid stress. Thus, the count remained stationary due to balance between 
multiplication and death rate. On other hand, ST128 and ST306 did not reach the stationary 
phase as rapidly because the generation time was longer.  
3.4 Determination of the haemolytic activity of serotype 1 and 2 isolates 
The haemolytic activity of pneumococcal lysates was determined using a previously described 
haemolytic assay [503]. The haemolytic activity of pneumolysin produced by ST306, ST304 
and ST615 isolates was compared to that produced by D39 and PLN-A, control isolates [73]. 
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Figure 15. Haemolytic assay and Pneumolysin ELISA quantification. (A) Serial dilution was carried 
out (n=3 per strain) from bacterial stock solutions, different sequence types of serotype 1 isolates 
displayed as mean OD540 ± SEM of the bacterial lysates after incubation with a 4% red blood cell 
solution B) Quantification of PLY content in pneumococcal strains as determined by ELISA. Error bars 
denote standard deviation (C) Percentage hemolysis (n=3 per strain) for the strains of interest. 
Percentage was determined by comparison to purified pneumolysin 0.75mg/ml as a positive control and 
PBS as a negative control.  ***, p<0.005, **, p<0.05. D39, PLY-deficient (PLN-A) of D39, ST304, 
ST306 and ST615 were used in these experiments. 
 
 
3.4 Concentration of total PLY content in different strains of S. pneumoniae and in vitro 
haemolytic activity 
Hemolysis assays were performed to characterise the PLY hemolytic activity in a selected 
sequencing type (615, 304 and 306). PLY hemolytic activity relies on the toxin’s ability to lyse 
RBCs. In Figure 16A, pneumococci D39 reached max OD540 = 1.1 when being compared to 
other strains. Moreover, NCTC7465 which belongs to ST615 remained able to lyse higher than 
0.5 unit OD540 of red blood cells. However, all strains of ST306 (designated BIL777, 202, 308, 
204, BIL450, 879, 628, 455, 201) and one strain of ST304 (designated 106) were able to lyse 




In Figure 16, panel B, strains D39 and NCTC7465 - a serotype-1 pneumococcal isolate with 
sequence type 615 – were found to contain a significantly higher PLY content than any other 
strains tested (p<0.05) This coincides with the observation that the total content of pneumolysin 
(85ng/ml +/-…) in this strain was also the highest. Strains D39 and NCTC7465 were not 
significantly different in their total PLY content. The serotype 1 pneumococcal strain B915 
which belongs to the group of sequence type ST306 had a significantly smaller PLY content 
(12ng/ml +/- …) compared to the other tested strains (p<0.05).   
In Figure 16, panel C are presented the percentage hemolysis of a selected panel of 
pneumococcal cell lysates. PLN-A, a serotype 2 pneumolysin deficient strain [249], was 
included in the assay as a negative control. The strains tested included D39 strain belonging to 
serotype 2, and three other strains designated 106, FT and B915, all belonging to pneumococcal 
serotype 1. Percentage hemolysis was determined relatively to recombinant pneumolysin 75 
ng/ml as a positive control (100% hemolysis) and PBS as a negative control (0% hemolysis). 
Strains were considered to have low PLY activity if hemolysis was < 50% and high PLY 
activity if hemolysis was >80%, relative to the 100% lysis control. D39 and sequence type 615 
were designated high PLY activity strains with 80.5% and 67% hemolysis, respectively (Figure 
4A). Sequence types ST304 and ST306 were designated low PLY activity strains with 15.4% 
and 8.2 % hemolysis, respectively.   
3.5 Adhesion and invasion assays 
It is commonly accepted that, in order to cause infections, pneumococci must first colonise 
their host. Bacterial pathogens express various molecules able to enhance attachment to host 
cells [511]. These adhesins establish stable interactions between the host cell surface receptors 
or soluble proteins. Adhesion is a fundamental first step prior to invasion and/or secretion of 




including T-cells and specific antibody [512]. Bacterial adhesion on host cells and their 
invasion therefore play important roles to determine pneumococcal pathogenesis [511]. In this 
study, human nasopharyngeal epithelial cells (Detroit-562) and human broncho-alveolar 
epithelial cells (BEAS-2B) were used and infected with serotype 1 (ST304, ST306 and ST615) 
as well as D39, a serotype 2 laboratory strain.   
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Figure 16. Adherence of different strains of S. pneumoniae to (A) Detroit 562 epithelial cell monolayers 
(B) BEAS-2B human bronchial epithelial cells. To determine pneumococcal adherence, cell 




were determined as a percentage of the initial CFU count. The results are represented as mean +/- 
standard deviation (n=3). **p<0.001, *p<0.01 
 
3.5 Adherence of different strains of S. pneumoniae to Detroit 562 epithelial cell 
monolayers and human bronchial epithelial cell (BEAS-2B) 
Previous studies suggested [511, 512, 168] that PLY toxin contributes to nasopharyngeal 
colonisation, arguing that PLY-deficient strains have reduced adherence to respiratory 
epithelial cells in vitro compared to PLY-expressing strains. Level of adherence of 
pneumococcal cells to epithelial cells in vitro may be used to determine whether haemolitically 
active pneumolysin is a requisite for successful nasopharyngeal colonization, and whether this 
might be a contributing factor to the invasive potential of S. pneumoniae [511]. Moreover, PhtD 
and PcpA play also important roles in colonisation in a murine model [512]. It was shown that 
mutation in pavA gene reduced level of adhesion to immobilised human fibronectin as PavA 
mediates adhesion of pneumococci to fibronectin [168].     
In Figure 17 are shown the results obtained upon incubation of various pneumococcal isolates 
with nasopharyngeal Detroit 562 cells at 30, 60 and 120 minutes post-infection with 
pneumococci. Interestingly, D39 strain (serotype 2) adhered at a higher percentage than 
serotype 1 strains within half an hour of incubation. This is in line with a previous study 
showing that D39 displayed low level 0.03% of adherence to human bronchial epithelial cells 
(BEAS-2B) and the CFU was 6x103 CFU/well after 30 min of incubation [512].  On the other 
hand, all serotype 1 strains required a longer incubation to adhere to epithelial cells and CFU 
were only detectable at 60 min post-infection. Strains belonging to ST306 adhered evidently at 
a higher level than strains belonging to ST615 and ST304.  After two hours of incubation, there 




In relation to the adhesion ratios to BEAS, strains D39 and NCTC7465 were able to adhere and 
the CFU were approximately 5x102 CFU/ml, while other strains of serotype 1 were not detected 
on blood agar plates. However, the ability of both strains D39 and NCTC7465 to adhere to 
bronchoepithelial BEAS was lower compared to the adhesion levels observed in Detroit 562. 
Our findings are in the line with a previous study showing that pneumococci were found to be 
much lower adherence to pharyngeal cells comparing to other streptococcus species in vitro 
and vivo [513].  
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Figure 17. Invasion ratio of different strains of S. pneumoniae in Detroit 562 epithelial cell monolayers 
(A) and BEAS (B). Extracellular non-adherent bacteria were removed by treatment with penicillin and 
gentamicin post-infection. After 2 hours of incubation, the cell monolayer was then washed extensively, 
and the number of intracellular bacteria was determined as a percentage of the initial inoculum. The 
results are represented as mean +/- standard deviation (n=3). 
 
3.6 Invasion potential of different strains of S. pneumoniae in Detroit 562 epithelial cell 
monolayers  
The mechanism of pneumococcal invasion of the respiratory epithelium provides insight into 
the understanding of pneumococcal pathogenesis. It has previously been reported that invasion 
of epithelial cells requires specific cell-type and virulent strains [417]. Detroit 562 cells are 
readily invaded in vitro by pneumococci, and therefore provide a useful model to study the 
invasive potential of pneumococci. Studies have reported that encapsulated strains of 
pneumococci adhere to and invade cells less efficiently than un-encapsulated strains, while 
others have shown other virulence factors, such as CbpA are important for efficient 
colonisation of the nasopharynx [329]. The following experiments investigate the ability of 
pneumococcal strains to invade to epithelial cells and we discuss how this relates to their 
invasive potential.  
In figure 18 are represented the percentage of pneumococcal cells found upon lysis of Detroit 
cells at 2 hours post infection. ST615 was the only serotype 1 isolate showing the ability to 
invade Detroit 562 epithelial cells with approximately 0.003% as a percentage of the initial 
inoculum, while D39 in the serotype 2 group invaded the Detroit cells with approximately 
0.002%. No viable counts of ST306 and ST304 were found suggesting that these two particular 
sequence types are less invasive. No invasion was observed on BEAS from any strains 





3.7 Complement deposition  
Complement is an important part of the innate immunity that acts as a first line of defense 
against foreign and altered host cells. The activation of the host complement system results in 
the binding of complement protein C3 on the surface of the pneumococcus resulting in 
recruitment of phagocytes and engulfment of the pathogen [243]. A small amount of 
complement deposition would thus suggest that the pathogen in question is more likely to evade 
immune phagocytosis.   
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Figure 18. Deposition of rabbit complement C3 on the surface of pneumococcal isolates. C3 deposition 
is expressed as the median intensity of fluorescence (MIF). The error bars indicate the standard 








3.7 Deposition of complement C3 on the surface pneumococcal isolates 
PLY plays an important role in preventing complement activation and contributing to the 
spread of bacteria to other cells and tissues. PLY, itself, independently of PLY antibody, can 
activate the classical complement pathway, leading to depletion of complement in the host and 
reduced opsonic activity, and induce an inflammatory response, aiding the survival and spread 
of pneumococcal bacteria [517]. This assay was used to assess the propensity of pneumococci 
(serotype 1 vs. serotype 2) to bind to complement.  
Our results indicate that the complement binding percentage was dependent on the strain and 
not on the serotype. The three sequencing types (ST306, ST304 and ST615) belonging to the 
serotypes 1 group had almost the same MFI. D39 showed significant binding to C3, whereas 
ST306, ST304 and ST615 had lower C3 binding activity. Overall, the C3-binding activity on 
the bacterial surface of all strains of serotype 1 was lower than those in serotype 2.  
3.8 Opsonophagocytic killing assay (OPKA) 
To understand the ability of the serotype 1 isolates to evade phagocytosis, an 
opsonophagocytosis killing assay (OPKA) was performed in which the bacteria were opsonised 
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Figure 19. Opsonophagocytic killing of pneumococcal isolates. Each strain was tested with 1:4, 1:8 and 
1:16 dilution of IVig antibodies. Results are represented as the percentage of killing different strains in 
different dilution. The error bars indicate the standard deviation on three independent experiments. *, 
p< 0.05 (one-way ANOVA) 
  
3.8 Opsonophagocytic killing of serotype 1 vs. serotype 2 pneumococci 
Host protection against pneumococcal disease is mainly mediated by phagocytosis [519]. An 
opsonophagocytic assay measures the resistance of pneumococci to phagocytosis, using 
differentiated HL-60 cells as effector cells. Intravenous immunoglobulin (IVig) was serially 
diluted (two-fold) in opsonophagocytosis buffer for a total of 8 dilutions, from 1:8 to 1:1,024.  
 Among the serotype 1 isolates, ST306 showed higher killing percentage at 1:4 dilution of IVIg 
anticapsular antibodies compared to ST304 and ST615 strains belonging to ST304 and ST615, 
respectively (P < 0.05, one-way ANOVA with post-hoc Tukey's test). However, there were 
differences between the sequence types of serotype 1, some sequence types more resistant to 
opsonophagocytic killing than others and was statistically non-significant (one-way ANOVA). 
Moreover, a previous study showed that there was an increase in killing titer when the strain 
presented a null mutation on pspC. Even the incubation time had an effect on the killing titer 




3.9 Colonisation properties of S. pneumoniae serotype 1 in a nasopharyngeal carriage 
mouse model 
S. pneumoniae is a common commensal of the nasopharynx of healthy individuals, While 
particular capsular types, such as serotype 1, are rarely detected during nasopharyngeal carriage 
1, serotype 1 is also one of the main causes of pneumococcal invasive disease in Europe and 
North America and is ranked among the top five most prevalent pneumococcal serotypes in a 
number of countries [521,331, 522]. 
ST615 and ST306 serotype 1 strains ST304 and D39 were excluded because the results of 
ST304 were similar to ST306 and D39 was a control strain) were assessed  in a carriage mouse 
model in which mice were intranasally infected with 105 bacteria per mouse. The infection was 
performed in a total volume of 10μl, mimicking pneumococcal transmission in the 
nasopharyngeal tissue without translocation to the lungs. For each strain, three mice were culled 
straight after infection (day 0) and ten mice were culled at each time-point on days 1, 3, 7, 14, 
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Figure 20. Two groups of mice were infected by either ST306 or ST615. On day 0, mice were 
challenged intranasally with 10ul of sterile PBS per mouse, containing 1x105 CFU. This figure shows 
the bacterial density in nasopharyngeal tissue of mice. Data are represented as mean +/- standard 
deviation, n=10 mice per group. 
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Figure 21. Bacterial density in lung tissues. Mice were challenged intranasally with 10ul of sterile PBS 
containing 1x105 CFU of either ST306 or ST615. This figure shows the absence of detectable amount 
off pneumococci in the lungs. Data are represented as mean+/- SD, n= 10 mice per group. 
 




3.10 Capsule thickness of pneumococci isolated from nasopharyngeal mouse tissue  
The polysaccharide capsule is a major virulence factor of S. pneumoniae, which provides 
protection against opsonophagocytosis by the host immune system. The thickness of the 
capsule can vary between isolates and at different stages of infection. An increase in the capsule 
thickness results to an increased protection against the host immune system, while a reduction 
in the capsule thickness allows pneumococcus to adhere to epithelial and endothelial host cells 
[111, 515]. Measuring the capsule thickness may assist to determine the relative ability of the 
isolate to adhere, colonise and invade the host. The capsule thickness of serotype 1 isolates was 
determined using a FITC-dextran exclusion method [504].  
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Figure 22. Capsule thickness of ST306 and ST615 of serotype 1 isolates from nasopharynx of infected 
mice during a carriage experiment. Results are shown as the mean area ± SEM (n=100 bacteria) 
 
The FITC-dextran exclusion method requires the total surface area of the bacterium to be 




of different isolates. The principle of this method is the premise that pneumococci are generally 
uniform in their size, thus any size differences observed using this method are attributable to 
differences in capsule thickness. This method is mianly used to measure the size of individual 
pneumococci not found forming chains.This study suggests that there is maybe a small increase 
in capsule thickness but there is no difference. These finding are contradictory with a previous 
study which was showing that a reduction in the capsule thickness is associated with increased 
adhesion to (specific type of host cells) [522]. This study does not demonstrate any change in 
capsule thickness between day 0 and day 28, this could be a main reason why serotype 1 is not 
detected in colonisation, serotype 1 faces difficulty to adapt to the nasopharyngeal niche or 
does not have the regulatory machinery to change its capsule thickness.    
 
3.11 Competition experiment ST306 vs. ST615 in a nasopharyngeal carriage mouse 
model 
In order to mimic a scenario whereby pneumococcal strains are simultaneously carried in the 
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Figure 23. Female MF1 mice were co-infected with ST306 and ST615 at a dose of 2.106 CFU/mouse 
in 10ul of sterile PBS on day 0. Data are represented as mean +/- SD, n= 10 mice per group 
 
 
Pneumococcal serotype 1 ST306 and ST615 were administered intranasally as described in 
materials and methods (section 2.16). For each sequence type, ten mice  were euthanised at 
pre-determined time points (days 1, 3, 7, 14, 21, 28 for both isolates) and their lungs and 
nasopharynx collected, homogenised and processed for viable plate counts and flow 
cytometric analysis.  
 
 This experiment was performed over a 28-day experimental period (Fig. 21). There was no 
statistically significant difference in the nasopharyngeal bacterial density of mice challenged 
with ST306- or ST615- at day 0 or day 1 (24 hours) post-infection. However, the bacterial 
density of ST615 was significantly higher than ST306 on days 3 and 7 (p<0.001, p<0.01, 
respectively). Interestingly, the scenario was inverted between days 14 and 28. The difference 
was highly significant on days 14 and 21 (p<0.0003 and p<0.003, respectively), while on day 
28, no significant difference was detected between the two sequence types. Interestingly, the 




pneumococcal viable counts reached approximately 1x101 CFU/ml in both cases (Fig. 22). It 
is highly unlikely that bacteremia contributed to the increased bacterial density since no viable 
counts were detected in the bloodstream of these mice. Blood was monitored for bacteremia 
at 0, 1, 3, 7, 14, 21 and 28 days after nasal application and no bacteria were detected in the 
blood. 
In a competition experiment, we sought to determine whether the haemolytic activity of ST615 
could complement ST306 in its ability to colonise the nasopharyngeal niche. In brief, MF1 
female mice were infected with both sequence types at a total dose of 1x105 CFU per mouse in 
10ul.  
The results in Figure 24 failed to show any competitive advantage between ST306 and ST615 
when the mice were infected simultaneously with both sequence types. On day 1, the numbers 
of bacteria in nasopharynx for ST306 and ST615 were similar at approximately 1x102 CFU/mg 
tissue. However, ST615 bacterial density was slightly higher than ST306 and the differences 
were at 0.7 and 1 log at day 3 and 7, respectively. The reduction in ST615 pneumococcal load 
was noticeable and reached approximately 3x102 CFU/mg at day 14, while ST306 
pneumococcus increased again and reached a density similar to day 1, with viable counts of 
8x102 CFU/mg.  
 
The tendency of ST306 to establish a lengthier colonization period compared to ST615 – 
observed in Figure 23 - was not affected. Overall, the results do not suggest that any 
competition occurred between the two sequence types towards colonising the nasopharyngeal 
niche. It has previously been shown [525] the ability of pneumococcus to compete with each 
other for colonization highly depends on the type of capsular polysaccharide expressed by 
pneumococci and only to a lesser degree on strain or host genetic backgrounds. Moreover, it 




in vivo it depends on the capsule sturcture [526].This study has demonstrated that competitive 
relationship between different serotypes during host colonisation could affect the order of 
serotype distribution of nasopharyngeal carriage [526].  
3.12 Mouse survival experiment 
This survival experiment with serial sacrifice is designed to investigate the effect of introducing 
pneumococci, on mice in terms of the time course of pathological states. Two groups, infected 
with ST306 or ST615, are maintained under similar laboratory conditions and observed daily. 
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Figure 24. Virulence comparative study using a mouse model of invasive pneumonia.Kaplan-Meier 
survival chart monitoring the number of mice succumbing to disease at different time points. At the 
experimental endpoint, all mice (100%) challenged with ST306 mice survived as opposed to 5% 
































S T 3 0 6
S T 6 1 5*









Figure 25. Viable counts (CFU/ml) in peripheral blood after intranasal infection of female MF1 mice 
with ST306 compared to ST615 pneumococci at time of death (TOD). Data are represented 
represented as mean+/- SD (n= 10 mice per group). Each mouse is represented by a dot. 
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Figure 26. Viable counts (CFU/mg) in lungs after intranasal infection of mice with ST306 compared 
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Figure 27. Pain score in ST306 and ST615 mice. Pain scores were assigned as follows: -1 ( H  
&S + ) :  hunched and starry coat +, 2 (H &S++): hunched and starry coat ++, 3 (L+) :  
lethargic +, 4 (L++): lethargic ++ and 5 (M): moribund (data presented are mean of 10 mice 
per group). Data are represented as mean+/- SD. Area under curve for ST615=89.7% and 





Mice were challenged with serotype 1 pneumococci ST306 or ST615, as described in the 
methods section (2.16). At the time of death (TOD), bacterial viable counts were determined  
for ST306 and ST615-challenged mice.  
Using a pneumonia challenge mouse model, results showed that the survival of ST306-
challenged mice was 100% whereas only 5% of ST615-challenged mice survived, as shown in 
Figure 25. This suggests that ST615 serotype 1 is significantly more virulent than ST306. In 
terms of inducing disease symptoms, ST306-challenged mice looked healthy and alert. There 
was a highly significant difference (area under curve value at 48 and 52 hours, was 89.7% for 
ST615 and 52% for ST306 p<0.001) between ST306 and ST615. The group of ST615-
challenged mice started showing symptoms after 38 hours and onward (Figure 28).  
 
A significant difference was determined in the viable counts found in the blood of mice 
challenged with ST306 vs. ST615 (Figure 26). While no bacteria were detected on blood plates 
in mice challenged with ST306 - except for one mouse presenting a viable count of 1x105 
CFU/ml - the number of pneumococci in the group of mice infected with ST615 reached a 
count of 1x108 CFU/ml at the time of death (student-t-test*p<0.05). Interestingly, ST306 
pneumococci were found in the lungs at approximately 2x104 CFU/ml which was significantly 
less than the pneumococcal density found in mice challenged with ST615 (student-t-
test**p<0.01) (Figure 27). This suggests that ST306 is not able to replicate and survive in the 






3.13 Comparative studies of ST306 vs. ST615 serotype 1 in invasive pneumonia mouse 
model 
Pneumococcal serotype 1 ST306 and ST615 were administrated intranasally, as described in 
materials and methods (section 2.16). In brief, female MF1 mice (Charles River) were 
challenged with 50 µl pneumococci via the intranasal route at a final concentration of 1 × 
10
6 
CFU/ml. The mice were divided into two groups and infected with ST306 or ST615. 
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Figure 28. Serotype 1 (ST306 vs ST615) viable counts (CFU/mg) in nasopharyngeal tissue at 0, 6, 
12, 24 and 48 hours post-pneumococcal infection. Mice were challenged intranasally with 50µl of 
sterile PBS containing 1x106 CFU of either ST306 or ST615. Data are represented as mean+/- SD, n= 
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Figure 29. Serotype 1 (ST306 vs ST615) CFU counts in blood at 0, 6, 12, 24 and 48 hours post 
pneumococcal infection. Mice were challenged intranasally with 50 ul of sterile PBS containing 1x106 
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Figure 30. Serotype 1 (ST306 vs ST615) CFU counts in lungs at 0, 6, 12, 24 and 48 hours post 
pneumococcal infection. Mice were challenged intranasally with 50 ul of sterile PBS containing 1x106 






On day 0, for each sequence type (ST306 vs ST615), mice (n=10 per group) were humanely 




nasopharynx collected, homogenised and processed for viable counts on blood agar plates 
and flow cytometry analysis.  
Pneumococcal viable count results showed significant differences between all lung and blood 
samples collected from ST306 vs. ST615 challenged mice at 24 and 48 hours post-infection. 
The viable counts obtained in the nasopharyngeal tissue were not significantly different 
although ST615-infected mice presented half to 1 log10 difference after 24 and 48 hours, 
respectively, compared to the ST306-infected mice. 
The major differences in bacterial viable counts were observed at 24 and 48 hours in lungs 
and nasopharyngeal tissue in ST306-challenged mice. The lungs of ST615 challenged mice 
presented higher viable counts than those of ST306-challenged mice, a difference of the order 
of 4 to 5 log10 at 24 and 48 hours, respectively. The higher pneumococcal viable counts 







3.14 Pneumococcal serotype 1 in intranasal model of invasive pneumonia (high dose) 
Briefly, female MF1 mice (Charles River) were challenged with 50µl pneumococci via 
intranasal administration at a final concentration of 1 × 10
7 
CFU/ml in 50µl.  
All mice were observed regularly to monitor kinetics of disease progression over time. At 0, 
24 and 48 hours post-challenge, ST306- and ST615-challenged mice were culled, and their 
lungs and nasopharynx collected. Whole blood was collected by cardiac puncture in all mice. 
Tissue samples were then homogenised and spotted on blood agar plate for colony-forming 
unit counts.  
 



























Figure 31. Serotype 1 ST306 CFU counts in lungs at 24 and 48 hours post pneumococcal infection. 
Mice were challenged intranasally with 50ul of sterile PBS containing 1x107 CFU of ST306. Data are 



































Figure 32. Viable counts in the peripheral blood of ST306-challenged mice at 24 and 48 hours post 
pneumococcal infection. Mice were challenged intranasally with 50ul of sterile PBS containing 1x107 
CFU of ST306. Data are represented as mean+/- SD, n= 10 mice per group 
 
 



























Figure 33. Viable counts in the nasophrynx of ST306-challenged mice at 24 and 48 hours post 
pneumococcal infection. Mice were challenged intranasally with 50ul of sterile PBS containing 1x107 
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Figure 34. High-dose model -Viable counts in the blood of ST306 vs ST615 -challenged mice at 24 
hours post pneumococcal infection. Mice were challenged intranasally with 50ul of sterile PBS 
containing 1x107 CFU of either ST306 or ST615. Data are represented as mean+/- SD, n= 10 mice 
per group. (t-test, ** p<0.009) 
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Figure 35. High dose model - Viable counts in the lung of ST306 vs ST615 -challenged mice at 24 
hours post pneumococcal infection. Mice were challenged intranasally with 50ul of sterile PBS 
containing 1x107 CFU of either ST306 or ST615. Data are represented as mean+/- SD, n= 10 mice 






























S T 3 0 6
S T 6 1 5








Figure 36. High-dose model -Viable counts in the nasopharynx of ST306 vs ST615 -challenged mice 
at 24 hours post pneumococcal infection. Mice were challenged intranasally with 50ul of sterile PBS 





This experiment was performed in order to determine whether ST306 pneumococci could 
transit from the lung tissue into the blood when administered at a dose one log higher than 
that used in our standard pneumonia model, i.e. 107 CFU rather than 106 CFU per mouse. 
Results show that groups of mice challenged with ST615 caused infiltration of pneumococci 
into the lung tissues and blood stream at approximately 48 hours. Disease symptoms were 
obvious and pain score reached a level 4 (i.e., lethargic ++). On the other hand, none of the 
ST306-challenged mice presented any disease symptoms and viable counts were significant 
lower (**,p<0.009) compared to ST615 challenged mice in peripheral blood as well as in the 
lung tissues at 24 and 48 hours post-infection (**,p<0.007).  
        
In contrast to ST306 pneumococci, the use of a high dose of ST615 altered the survival time 
of mice to less than 48 hours compared to 53 hours upon administration of 106CFU per 
mouse. Interestingly, pneumococcal viable counts measured in the nasopharynx were similar 




lungs at 24 hours post-infection was 1x105CFU/mg and coincide with the time the mice 
started to exhibit disease symptoms (starry and hunched). Nine out of ten mice presented 
pneumococci in blood at 24 hours, and reached as high as 1x107 CFU/ml in the blood 
explaining the short survival time in these mice. 
 
Pneumococcal counts in the nasopharynx of ST306-challenged mice showed no significant 
difference between 24 and 48 post-infection and the viable counts were approximately equal 
to 1x104 at both time points. Interestingly, no bacteria were detected in the lungs for 9 out of 
10 mice and one mouse only presented 1x102 CFU/mg at 24 hours post-infection. Similarly, 
at 48 post-infection, 9/10 mice challenged with ST306 failed to show any pneumococci in 
their lungs, except for one mouse with a viable count of 102 CFU/mg. No bacteria were found 
in the blood at 24 hours, while two mice started to develop bacteremia with CFU counts 
reaching approximately 3x104 cfu/ml. The challenge of mice with a dose of 1x107 CFU per 
mouse (compared to our standard 1x106 CFU per mouse) failed to promote the ability of 
ST306 to reach the peripheral circulation. It is likely that using such a high dose may have 
alerted the immune system and triggered a more efficient elimination of bacteria in the lungs, 
resulting in rapid clearance 
 
3.15 Virulence of pneumococcal serotype 1 in sepsis and invasive pneumonia models 
A sepsis mouse model of infection was set up as described in the section materials and 
methods (section 2.16). In brief, a fresh liquid stock of ST306 and ST615 pneumococci was 
used to perform this experiment. Twelve MF1 female mice (Charles river) were intravenously 








in 50µl. The mice were divided into two groups: six mice in ST306-
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Figure 37. Comparative virulence study in a mouse model of invasive pneumonia. Kaplan-
Meier survival chart monitoring the number of mice succumbing to disease at different time 
points. At the experimental endpoint, data refer to 6 mice challenged with ST306 
pneumococci and 6 mice challenged with ST615 pneumococci. At 100 hours, the survival 
rate of ST615-challenged mice was only ~30%, while the survival rate was 100% in ST306 






Figure 38. Serotype 1 (ST306) CFU  counts in  blood  at 1,  6,  24  and  48  hours  post pneumococcal 
infection. Mice were challenged intravenously with 50 ul of sterile PBS containing 1x106 CFU of 
ST306 pneumococci. Data are represented as mean+/- SD, n= 10 mice per group 
 






































Figure 39. Serotype 1  (ST615)  viable counts in  blood  at 1,  6,  24  and  48  hours  post-pneumococcal 
infection. Mice were challenged intravenously with 50µl of sterile PBS containing 1x106 CFU of 
ST615 pneumococci. Data are represented as mean+/- SD, n= 10 mice per group 
 
 
At 1hour p o s t - i n f e c t i o n , pneumococcal viable counts in the blood of both ST306 
mice and ST615 mice were similar. ST306 pneumococcal viable counts were stable until 
24 hours and a reduction in pneumococcal density was observed at 48 hours post-challenge 
(Figure 39). At 48 hours, ST615 bacterial load was higher than ST306 with more than five 
log10 difference between ST615- and ST306-challenged mice. The major reduction in 
pneumococcal viability was determined at 48 hours post-challenge, the viability of ST306 
pneumococci mouse dropped to 50 CFU/ml. We previously described that mice infected 









3.16 Mouse challenge with ST306 pneumococci supplemented with pure pneumolysin   
in mouse model of invasive pneumonia 
Female MF1 mice were challenged with 1 0 6 C F U  S T 3 0 6  p n e u m o c o c c i  i n  50µl 
supplemented with 100ng LPS-free recombinant pneumolysin via intranasal administration, 
as described in materials and methods (section 2.16). The mice were divided into two groups; 
ST306 and ST306 supplemented with LPS-free recombinant pneumolysin mice. The number 
of tested mice in each time point was 10 mice for each sequencing types.  
Pneumococcal viable counts reached a peak at 12 hours in the lungs, while it peaked in the 
blood at 48 hours.  A gradual increase in the number of pneumococci occurred in the lung until 
12 hours post-challenge then slightly decreased, while a gradual increase in pneumococcal load 
was observed in the blood and peaked at 48 hours; however, there was a decline at 72 hours 
post-infection. 
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Figure 40. Pulse pneumolysin experiment with ST306-challenged mice: Serotype 1 ST306 was mixed 
with purified pneumolysin (100ng/mouse) and administered intranasally at 106 CFU per mouse in 50µl. 
Viable counts w e r e  d e t e r m i n e d  in lungs at 0,  6, 12,  24, 48  and  72  hours  post 
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Figure 41. Supplementation experiment: Serotype 1 (ST306) was mixed with purified 
pneumolysin(100ng/mouse) and administered intranasally at 106 CFU per mouse in 50µl comparing to 
ST306 only. Viable counts in blood at 0, 6, 12,  24, 48  and  72  hours  post pneumococcal infection. 


























S T 3 0 6
S T 3 0 6  m i x e d  w i t h  P L Y












Figure 42. Supplementation experiment: Serotype 1 (ST306) was mixed with purified 
pneumolysin(100ng/mouse) and administered intranasally at 106 CFU per mouse in 50µl comparing to ST306 
only. Viable counts in lungs at 0, 6, 12,  24, 48  and  72  hours  post pneumococcal infection. Data are 





In Figures 42 and 43 are shown the viable counts of mice challenged with ST306 vs. ST306 
mixed with recombinant pneumolysin in blood and lungs, respectively, at various time points. 
In the lungs, a statistically significant difference was found in bacterial viable counts at time 
zero, 6, 12 and 24 hours between the two groups of mice, while in the blood, a significant 
difference in bacterial viable counts was only determined at 12 hours. 
 
These results suggest that the supplementation of a low haemylotic strain (ST306) with highly 
haemolitically active pneumolysin enhanced the ability of pneumococci to infiltrate lung and 
blood cmpartments. These effects were also translated by a more rapid disease progression 
(Figures 42 and 43).  
 
 
3.17 Analysis of Immunity 
3.17.1 Lung immune cellular profiling during invasive infection with serotype 1 
The cellular profile of the lung of 10 MF1 mice infected with the ST306 and ST615 isolates 
were determined at different stages of infection using flow cytometry. The number of (A) T 
regulatory cells, (B) neutrophils and (C) macrophages present in the lung of up to ten mice per 













                               
























S T 3 0 6




















































S T 3 0 6






























                                   
























S T 3 0 6

























S T 6 1 5
C
 
Figure 43. Cellular profiling in the lung of MF1 mice during an invasive infection caused by ST306 and 
ST615 at times +15mins, 6h, 12h and 24h post-infection shown as mean ± SEM (n=10) 
 
 
The CD45 marker was used to gate leukocytes, thereby excluding non-immune cells such as 
endothelial and epithelial cells. The number of T regulatory cells (CD4+/FoxP3+) was found 
not to vary throughout the duration of the experiment (Figure 43 A) and no difference was 
observed between ST306 and ST615. The number of T regulatory cells in the whole lung was 
approximately 5x102 cells at 6h post-infection. The number of macrophages (F4/80+) and 
neutrophils (Gr1+cells) were stable at a 5x103 macrophages and 105 neutrophils per lung 
throughout the duration of the experiment (Figure 44, panels B and C). There were no 
significant differences observed in the recruitment of T regulatory cells, neutrophils or 
macrophages between ST306 and ST615 at all time points.    
  
3.17.2 Cytokine analysis of the lung during invasive infection by ST306 and ST615 
serotype 1 
Cytokine levels in the lungs of MF1 mice infected with ST306 and ST615 serotype 1 were 




used for cellular profiling (Figure 44). A selection of cytokines involved in host immune 
responses against bacterial infection was analysed: IL-1β, IL-6, INF-γ and TNF-α. The 
changes in cytokine levels during infection are shown in Figure 45: 
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Figure 44. Cytokines analysis of the lung of MF1 mice during an invasive infection caused by ST306 
and ST615 at times +15mins, 6h, 12h and 24h post-infection shown as mean ± SEM (n=10). **P-
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As observed in Figure 45, panel A the levels of IL-β were 250pg/ml throughout most of the 
infection, except 24h post-infection for ST615, when there was a significant increase to 
300pg/ml comparing to ST306 (*P-value<0.0001). While the levels of IL-6 were found to 
fluctuate throughout the monitoring period for both sequencing types, the levels of IL-6 were 
higher in the lung tissue of mice infected with ST615 compared to ST306. IL-6 is classically 
secreted by macrophages and T lymphocytes, but since our results failed to show any 
recruitment of these cell types, other cellular sources, such as epithelial cells, might be 
responsible for the observed increase. Interestingly, however, the increase of IL-6 levels 
observed in the lungs of mice infected with ST615 at 24h post-infection coincides with no 
increased number of neutrophils which was also observed in the lung at 24h post-infection.  
The levels of TNF-α were virtually null or below detection levels, throughout most of the 
infection, except at 24h post-infection, when the concentrations were found to increase in both 
groups of mice (Figure 45, D). TNF-α is a cytokine mainly produced by macrophages, it is 
involved in cellular apoptosis and immune regulation and is an indication of inflammation.  
Hence the increase observed in the concentrations of TNF-α at 24h post infection might reflect 
the inflammatory response present in the lung when the bacterial numbers are also at their peak 
titers of 104 CFU/mg of lung (Figure 31).     
There were no detectable changes in the levels of INF-γ throughout the course of infection 








3.17.3 Cervical Lymph nodes during carriage infection 
The cervical lymph nodes analysed in this study were anterior superficial, which are situated 
in the cervical area of mice. As with the nasal associated lymphoid tissue, these cervical lymph 
nodes are the draining lymph nodes for the nasopharyngeal tissue [528, 529]. 
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Figure 45. Immune cells phenotypic of (A) B cells, (B) T regulatory cells, (C) neutrophils and (D) 
macrophages in the cervical lymph nodes during nasopharyngeal carriage with ST306 and ST615 of 
serotype 1 in MF1 mice at days 0, 1, 3, 7 and 14 post-infection. Three mice were used for the day 0 
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As observed in Figure 46 B, the number of T regulatory cells was approximately 5x102 mg/ 
CLN tissue and this number remained constant throughout the observation period. The number 
of neutrophils and macrophages was different in this tissue, with the neutrophils ranging 
between 8x103 and 104 mg/ CLN tissue and the macrophages ranging between 103 and 104 
(Figures 46 C and 46 D). The number of macrophages and neutrophils in the cervical lymph 
nodes was stable throughout mice and time-points regardless to sequencing types. The 
clearance of ST615 pneumococci occurred at day 7 post-infection due to the migration of those 
neutrophils to the site of infection, the nasopharynx.  
3.17.4 Cytokine production during nasopharyngeal carriage  
Cytokines are small secreted proteins released by specific host cells in order to interact and 
communicate between each other allowing the recruitment and activation of other immune 
cells. Regulatory cytokines such as IL-10 and TGF-β1, were previously shown to be necessary 
in maintenance of carriage, while others i.e., IL-17 and IL-1β were documented for their role 
in pneumococcal clearance during invasive disease [467, 530].   
 The cytokines studied in the context of nasopharyngeal carriage were IL-6, IL-10, INF-γ, IL1β, 
MIP-2, TNF-α and active TGF-β1 based on their key roles in inflammation, protective 
immunity and regulation. In our carriage model, IL-6, INF-γ and TNF-α were found to be 
below detection level in the nasopharynx of mice at all stages of infection with both ST306 and 
ST615 (Figure 47 A, 47 C and 47 F). The nasopharyngeal concentration of IL-10 ranged 
between 250 and 300pg/ml throughout the duration of carriage, with no significant differences 
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Figure 46. Cytokines analysis of (A) IL-6, (B) IL-10, (C) INF-γ, (D) IL-1β, (E) MIP-2, (F) TNF-α and 
(G) active TGF-β1 in the nasopharynx of mice infected with ST306 and ST615 during the 
nasopharyngeal carriage experiment at days 0, 1, 3, 7 and 14 post-infection. Three mice were used for 
the day 0 control, and five mice were used for the rest of the timepoints. *P-value<0.05 when analysed 
using a one-way ANOVA 
 
As observed in Figures 47 D, 47 E and 47 G the cytokines analysed (IL-1β , MIP-2 and active 
TGF-β1) starting at low concentrations at time 0 and either gradually increasing throughout the 
carriage period to reach its peak on day 14 post-infection (active TGF-β1) or increasing only 
on day 14 post-infection (IL-1β and MIP-2). 
Our group has previously shown, using strain D39 (serotype 2), that, production of TGF-β1 in 
nasopharyngeal tissue resulted in an elevated concentration of TGF-β1 and recruitment of T 
regulatory cells which allow carriage to be maintained [467]. Similarly, we found here that the 
gradual increase, in active TGF-β1 observed in mice carrying ST306 and ST615 occurred 
concomittantly with an increased pneumococcal density in the nasopharynx. 
 In the same study that using a D39 strain of serotype 2 it was shown that mice carrying the 




carriage [467], while in this study the levels of IL-10 were constant throughout the 
experimental time. IL-10 is a suppressive cytokine that has anti-inflammatory properties and 
can be a marker for immunomodulation and tolerance during carriage. Therefore, no variation 
in the levels of IL-10 in the nasopharynx of mice carrying serotype 1 may maintain the 
colonisation for ST306.   
3.18 Conclusion 
Results presented in Figure 16B showed that strains D39 and ST615 release a significantly 
larger quantity of PLY compared to strains ST304  and ST306. Interestingly, while strain 
ST304 has almost a two-fold greater of PLY quantity (24.6 ng/ml), compared to B915 (12 
ng/ml), percentage hemolysis between the two strains (Figure 16, C) is less than two-fold 
different. A previous study suggested that the quantity of PLY does not necessarily determine 
the relative hemolytic activity or lysing ability of a given strain, while presence of mutation in 
domain 4 residues of PLY resulted in a decrease in hemolytic activity and a reduced affinity 
for sLeX [530]. The lack of lysing ability of strains ST306 and ST304 observed in (Figure 16, 
C) suggest that PLY may have critical functions other than that based on its haemolytic activity. 
Full active pneumolysin is responsible for short duration of colonisation that was obvious in 
mice infected with ST615. Moreover, PLY is a necessary factor to develop and accelerate 
diseases.    
The study of PLY toxin as a pneumococcal virulence factor has gained importance in the 
investigation of serotype-independent vaccines to reduce distribution of pneumonia. Previous 
epidemiological studies [319, 329] have shown various isolates able to express Ply, have low 
or undetectable hemolytic activity, particularly in serotypes 1, 7F, and 8 strains. While these 
isolates are capable of causing invasive pneumococcal disease (IPD), it has been suggested that 




with regard to its hemolytic activity [521, 532].  It is unclear whether reduced hemolytic 
activity of PLY in strains diminishes its role in IPD. A study has recently shown that non-
hemolytic PLY induced a greater pro-inflammatory cytokine response by dendritic cells [532]. 
Further investigation will be required to determine whether strains with reduced hemolytic 
ability enable the escape from pneumococcal vaccines with incorporated PLY-specific 
antigens, or will remain vulnerable to PLY-specific immunization [532].  
Previous authors reported [532] that while a reduced hemolytic activity of PLY led to a 
marginal reduction in virulence, this could also represent a growth advantage in blood during 
the early stages of infection. This might explain why highly invasive pneumococcal sequence 
types have expanded despite their apparent lack of PLY haemolytic activity.  
 Adhesion assays in the presence of Detroit cells showed that D39 (serotype 2) had the highest 
percentage of adhesion among the tested strains, while ST306 adhered at a higher rate than 
ST615 or ST304 (Figure 17). All four S. pneumoniae strains tested were able to bind to lung 
epithelial cells in vitro. Causing invasive disease depends primarily on the ability of 
pneumococcus to adhere. It was suggested, that capsule expression is essential for successful 
colonization of the upper airways [149]. It was also suggested, the present of pili-like on the 
cell surface of pneumococcus is another important factor to assist the adherence and 
transmission [149]. 
Next, we determined that invasion potential was strain specific, with D39 (serotype 2) and 
ST615 (serotype 1) showing a good ability to invade epithelial cells, while ST306 and ST304 
(serotype 1) failed to show any detectable invasive potential (Figure 18). While strain D39 also 
had quicker adherence kinetic - which may suggest a link with its invasive potential -  this was 
not the case for ST306, which showed higher adherence, but no invasive potential in vitro. 




relatively low adherence, which may suggest that the adherence ability of strains does not 
directly influence their invasive potential.  
On the basis of these results, the polysaccharide capsule of pneumococcus serotype 1 sequence 
type  inhibit C3b binding, compared to serotype 2 D39, aiding bacterial spread and invasive 
disease [534].  However, ST615, ST304 and ST306 all had similarly low C3b binding 
compared to serotype 2 D39, indicating that Ply and its haemolytic activity does not impact on 
the invasive and adhesion properties of pneumococci. Similarly, the results obtained during the 
adhesion and invasion assays do not associate with the C3b binding ability of pneumococci.     
A mouse model of nasopharyngeal carriage was used in this chapter to illustrate the patterns of 
nasopharyngeal carriage by serotype 1. The European (ST306) and South America (ST615) 
strains were used in the in vivo nasopharyngeal carriage model to assess the duration and 
density of carriage of serotype 1, and compare their carriage patterns. However, the two strains 
followed a different pattern during carriage, the carriage strain ST306 was carried for longer 
period (Figure 21) suggesting that during colonization, pneumococci serotype 1 may develop 
a mechanism which allows them to adapt to their new environment and establish colonization.  
The different behavour in colonisaton may be attributed to evolutionary genetic changes that 
are influenced by the environment e.g., through single point mutations (SNPs) which may be 
acquired through random mutations. 
These changes can be affected by up-regulation or down-regulation of the expression of critical 
biological functions or specific virulence genes and is under control tightly regulated networks. 
Future experiments focused on virulence genes, are required, in order to illustrate whether these 
mutations exist and whether are permanent or transient.  
In the context of a co-infection experiment whereby both ST306 and ST615 were 




carriage of each sequence types was not affected . In other words, the introduction of two 
sequence types from the same serotype in the nasopharynx of mice did not result to any 
competition, likely, due to both sequence types sharing the same capsular type.  
Overall, we determined that ST306, which express a haemolitically deficient pneumolysin, was 
able to colonise for a longer period of time than ST615 - which has a fully functional 
pneumolysin – but these key differences were not reflected in their immunomodulatory 
properties. 
An in vivo model of invasive pneumococcal pneumonia was used to study the pathogenicity of 
ST615 and ST306. Initially, these isolates from Europe and South America, respectively, were 
used to assess possible differences in virulence. A significant difference in bacterial viable 
count in blood was observed in the mice infected with ST615 compared to ST306. Mice 
infected with ST615 developed septicaemia resulting in death of the animals, while the mice 
infected with ST306 survived, and the mice were healthy and alert.  
Flow cytometry analysis was performed to determine the immune cellular profile at different 
timepoints upon administratin of mice with ST306 or ST615, and cytokines were assayed in 
order to understand the host immune responses to those sequencing types. The cellular profiling 
of the lung showed no changes during the timecourse of infection and no differences between 
ST306 and ST615. Cytokines analysis for IL-1β showed that there was a significant difference 
between ST306 and ST615. 
Additionally, no differences were observed in immune cells between ST306 and ST615 when 
a model of pneumococcal carriage was studied. However, active TGF-β1 significantly 




In a high dose 107 administration experiment,  ST306 pneumococci were found not able to 
translocate into the lungs and blood despite the significant dose increase. It remains unclear 
whether pneumolysin is the only factor involved in these differences observed, and whether 
others virulence factors have played a role. Interestingly, combining pneumolysin with ST306 
followed by intranasal administration led to an enhanced translocation of pneumococci to lungs 
and blood. 
In conclusion, the difference between two sequence types of the same serotype may be due to 
a differential gene expression patterns rather than the sole expression of haemolitically active 
pneumolysin. For a future study, researchers should focus on large-scale of virulence factors 
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A number of studies have investigated the pneumococcal genome and its influence on virulence 
[536, 537, 538], however while genomic variability between serotypes has been the main focus, 
there is still the question of how changes in gene expression contribute to pathogenicity 
particularly when pneumococci translocate from one tissue niche to another [472]. 
Transcriptomics can be used to compare closely related bacterial species and subtypes. 
Traditionally, transcriptomics analysis focuses on virulence and metabolic genes and their 
levels of expression in strains sharing the same virulence and metabolic genes [537, 538, 540]. 
Currently, little is known about the gene expression of serotype 1, particularly those of the 
ST306 isolate. The purpose of this study was to compare the transcriptional profiles of two 
pneumococcal serotype 1 strains B915 (ST306) and NCTC7465 (ST615) to identify 
differences in the level of expression of known virulence factors.  
Most gene expression analyses have largely consisted of real-time PCR assays or DNA 
microarrays. However, Sirbu et al. and Hurd have shown that there are significant limitations 
associated with microarray technology, particularly since they require the synthesis of specific 
DNA probes complementary of known genes, with the potential for cross-hybridisation 
between similar sequences, and background noise interference [541, 542]. RNA-Seq is a 
recently developed approach to transcriptome profiling that uses deep-sequencing 
technologies, and allows determination of gene expression levels [541]. A notable advantage 
of RNA-seq is that it allows for the investigation of non-annotated genes, and is more sensitive 




transcripts at lower levels with the absence of background noise [541, 542]. In this project, 
RNA-seq was used in order to determine differences in gene expression levels between 
serotype 1 strains ST615 and ST306 during five key stages of in vitro growth.  
4.2 Gene Expression During Bacterial Growth Phases 
Successful infection, survival and persistence in the mammalian host by intracellular pathogens 
requires rapid adjustment to changing environmental conditions during the passage through the 
nasopharynx and penetrating into host target cells [463]. Numerous virulence genes, their 
products, and their coordinated expression, play a key role in allowing the bacteria to invade 
and colonise host cells by adapting between the extracellular and intracellular phases of 
infection, to overcome antimicrobial and physical barriers to infections, and to manipulate and 
modify the actions of host cells [478]. For example, certain bacterial gene products may play a 
major role in mediating environmental signals involved in the regulation of both the 
extracellular and intracellular virulence gene products for adaptation to altered growth 
conditions [543]. Other gene products may play a role in the response to stress and nutrient 
limitations, such as amino acid starvation, acidic pH, intracellular proliferation in cells such as 
macrophages during aerobic, late log phase growth conditions, or dependence on the invasive 
gene expression under oxygen limited conditions [472].  
In the past, gene expression profiling has become an important tool for the investigation of 
bacterial adaptation to infection in host tissue niches. investigation of bacterial adaptation to 
host tissue niches. The investigation of gene expression in response to certain stressors in vitro, 
besides animal models, have been useful to gain insight into the nature of the genes involved 
in the intracellular life of bacteria.   
A previous study using microarrays to investigate the gene expression profiles of R6x 




to exponential phase, while cpsA was up-regulated during exponential phase compared to 
stationary phase [576].   
 
4.3 In Vitro Growth Phases 
We focused on the five distinct phases of bacterial growth in this study: early exponential phase 
(EEP), mid-exponential phase (MEP), late exponential phase (LEP), early stationary phase 
(ESP) and late stationary phase (LSP). The exponential phases describe the period of cell 
division. The exponential growth of bacteria requires there to be an abundant source of carbon, 
nitrogen, phosphate, and certain trace elements such as iron, in the growth medium, and 
involves bacterial growth and replication including multiple rounds of DNA synthesis, along 
with transcription and translation in order to synthesis the necessary macromolecules. This 
process is controlled by a number of gene regulatory processes. It is thought that both the 
accumulation of acetate and carbon starvation in the growth rich medium of LB broth leads to 
bacteria entering the stationary phase. [471]. The stationary phases begin when environmental 
conditions become unfavourable for growth of bacteria due to a reduction of nutrient 
availability and accumulation of toxic metabolites, eventually leading to decreased bacterial 
metabolic rate. During the late stationary phase, metabolic activity stops, causing the halting 
of replication and activation of resistance physiology [471].  
Previous studies have shown that specific virulence genes were expressed in response to a 
number of extra- and/or intracellular signals, and that overlapping regulatory networks 
modulating the expression of these virulence genes had evolved in bacteria to aid its adaptation 
to different environments and survival [472]. Most interestingly, virulence genes were shown 
to present growth-phase specific expression profiles in bacterial species such as Salmonella 




serotype 1. The reference strain of serotype 1 S. pneumoniae ST615 (NCTC7465), deposited 
in the National Collection of Type Cultures, London, United Kingdom, in 1948, was used to 
compare gene expression [257]. The five growth phases for ST306 and ST615 are clearly 
distinguishable in the growth curve presented in Figure 48. For ST306, the RNA was extracted 
when bacterial cultures reached the following OD500 values: 0.094 (EEP), 0.57 (MEP), 1.182 
(LEP), 1.379(ESP) and the late stationary phase (LEP) extracted 5 hours after ESP extraction. 
For ST615 the RNA was extracted when bacterial cultures reached the following OD500 
values: 0.083 (EEP), 0.067 (MEP), 1.167 (LEP), 1.266 (ESP) and the late stationary phase 
(LEP) were extracted 5 hours after ESP extraction. The generation time for ST306 and ST615 



























   


















      Figure 47. Growth curve of the serotype 1 ST306 (A) and ST615 (B) in BHI broth (OD500) 
 
In Figure 49 is presented the pairwise comparison of the expression of orthologous genes 
between ST615 and ST306. The genes down-regulated in ST615 compared to ST306 are shown 
in blue, while the up-regulated genes are shown in red. Genes that were not differentially 
expressed between ST615 and ST306 are shown in white.  
It is commonly accepted that a minimum sequencing depth of 5 to 10 million non-rRNA 
fragments is required to obtain representive bacterial transcriptome profiling [547]. The 
sequencing depth of the ST306 and ST615 samples was determined sufficient to generate 
optimal analysis of the transcriptomes, as the total number of read sequenced was higher than 
5 million. The percentage of uniquely mapped reads was higher than 78%, these were read  
and mapped to only one location in the genome. In this project, the transcriptome analysis was 






Table 3. Uniquely mapped reads are defined as "reads mapped to a single genomic location", and so do 









































ST615 EEP 26,677,691 24,612,526 551,317 1,513,848 92.3 2.1 5.7 
ST615 MEP 33,095,128 28,679,609 1,557,993 2,857,526 86.7 4.7 8.6 
ST615 LEP 31,063,468 25,268,535 1,594,668 4,200,265 81.3 5.1 13.5 
ST615 ESP 37,829,212 29,943,208 3,105,348 4,780,656 79.2 8.2 12.6 
ST615 LSP 30,376,684 27,760,276 1,079,506 1,536,902 91.4 3.6 5.1 









































































4.4 Gene Expression of ST615 and ST306 at Different Points of Growth 
The aim of this study is to examine the differentially expressed genes between two strains, 
ST615 and ST306, both of which belong to pneumococcal serotype 1, in the hope of explaining 
the differential properties described in Chapter 3. A pair-wise comparison of the expression of 
250 virulence genes with well-known functions was carrie out by normalising the expression 
of ST306 in each growth phase and compared with the expression of ST615 in the same growth 
point (Figure 48). The data was filtered by considering TPM (transcript per million) values 
greater than 10, and fold-change greater than 2. It has been suggested that genes would be 
expressed only when TPM values are greater than 10. A TPM value of 10 was used as a 
threshold to define gene expression in S. pneumoniae, and is a conservative estimate based on 
the analysis of Wagner et al 1994 [561].  













               Up-regulation                  Down-regulation                Not differentially expressed 
 
Figure 48. Pair-wise comparison of ST615 to ST306 gene expression at different time points (EEP: 
Early Exponential Phase, MEP: Mid Exponential Phase, LEP: Late Exponential Phase, ESP: Early 
Stationary Phase, LSP: Late Stationary Phase). The  250 virulence associated genes included in this 
analysis. TPM ˃ 10 and ˃ 2 fold-change. Down-regulated genes in ST615 when compared to ST306 
are shown in blue, up-regulated genes ST615 when compared to ST306 are shown in red, and not 












Orthologue genes were identified with BLASTP and the number of virulence factors were 
suggested to be 250 genes. As shown in Figure 49, the pair-wise comparison of the expression 
of 250 virulence genes between ST615 and ST306 showed similar levels of gene expression 
between the early and mid exponential phases, while the late exponential, early and late 
stationary phases had a different pattern of expression. 
 
Table 4. Number and percentage of 250 virulence genes differentially expressed in ST615 during five 
growth phases when compared to ST306. The percentage of differentially expressed genes is shown in 
parenthesis 
 
As shown in Table 5, between (41) 78% and (132) 88% of the 250 virulence genes were 
differentially expressed in ST615 when compared to ST306, with a higher proportion of those 
being down-regulated than up-regulated. 
4.5 Genes Classification Depened on their Functions During the Five Phases of Growth 
4.5.1 Selection of Functional Categories 
 
In this study, KEGG (Kyoto Encyclopedia of Gene and Genomes) was used. KEGG is a 
bioinformatic resource that links contemporary knowledge on molecular interaction networks 
such as a pathway or a complex. This resource is able to predict the cellular process and 
Growth 
phases 
No. of genes 
expressed (TPM 
>10) 
UP- Regulated genes 
% 
ST615 vs ST306 
Down Regulated genes % 
 ST615 vs ST306 




EEP 83 10 (12.0 %) 63 (75.9 %) 73 (87.9 %) 
MEP 52 16 (30.7 %) 25 (48.0 %) 41 (78.8 %) 
LEP 49 21 (42.8 %) 18 (36.7 %) 39 (79.5 %) 
ESP 81 30 (37.0 %) 34 (41.9 %) 64 (79.0 %) 




organism behaviour by classifying genes into different functional categories. The analysis of 
functional categories assists for studying cellular processes that are critical for the pathogens 
to survive  [549]. 
The biological functional category analysis of the two pneumococcal strains of serotype 1 was 
run by using information acquired from the KEGG database using DAVID Bioinformatics 
Resources 6.7 (https://david.ncifcrf.gov/). There was an exclusion of the hypothetical genes 
from the biological functional category analysis that resulted in the decrease the number of 
orthologue genes analysed to 250. A total of 6 biological functional categories were constructed 
by KEGG.  
The number of orthologous genes included in the biological functional categories obtained 
from the KEGG database is 250 genes, representing 12% of the whole genome used in the pair-
wise comparison of ST615 and ST306 (Figure 49). This focuses deeply on the difference 
between the two strains from the same serotype and compares them in the aspect of vital 
biological needs.  
In this study, six biological functional categories were analysed for broad investigation, 
dependent on the role in the cell activities and virulence. However, the TPM values of up-
regulated and down-regulated genes for all six biological functional categories for the five 
growth phases are shown in Appendix 2. 
The category of the biological functional genes are shown in the table below. The selection 



















Protein secretion blpU: pspA: cbpJ: cbpG: cbpF: blpK: blpY: prtA: spxB: lmb: ply: lytA: chpA: chpD: 
pspaA:spoJ 
DNA replication recA: cinA: dprA: hexB: radC: recR: recG: DivlVA 
RNA synthesis prsA: marR: serS: glyO: fmt: prmA: tgt 
Metabolism manA: lacR: glgC: eno: lacB: ldh: nagB: atpH: galK: malA 
                  
Table 5. Biological functional categories with genes list of orthologous genes between ST615  and 
ST306. 
 
The KEGG is used to analyse few number of genes that were mentioned in the table 6. 
However, the genes present in this table are not the only genes involved in these categories. 
There are more genes not identified by the KEGG database. Because of this issue, this study 
was focused only on the genes in the table. Figure 50 illustrates the percentage of the five points 
of growth phases of differentially expressed genes for each biological functional category. In 




























































































































































































4.6 Biological Functional Category 
   





                    Up-regulation                  Down-regulation                Not differentially expressed 
Figure 50. The percentage of pair-wise comparison of ST615 to ST306 between cell wall biosynthesis 
genes at different time points (EEP: Early Exponential Phase, MEP: Mid Exponential Phase, LEP: Late 
Exponential Phase, ESP: Early Stationary Phase, LSP: Late Stationary Phase). Down-regulated genes 
in ST615 when compared to ST306 are shown in blue, up-regulated genes ST615 when compared to 
ST306 are shown in red, and not differentially expressed genes between the two strains are shown in 
white. The total number of genes involved in the cell wall biosynthesis was 21 genes. 
 
 
The cell wall is important for stress-bearing and shape-maintaining in bacteria, and its integrity 
is of critical importance to cell viability. The cell wall consists of the cross-linked polymer 
peptidoglycan (PG). Many studies have explained the relationship between PG synthesis and 
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several enzymes involved in the synthesis of PG or other cell wall components or by looking 
at the incorporation of labeled PG precursors into the cell wall [551]. In Gram-positive bacteria, 
teichoic acids (TAs) are essential and can be divided, according to their anchors, into cell wall 
covalently attached TA (WTA) and membrane-anchored lipoteichoic acid (LTA) [551]. 
 As an important element in the biology of S. pneumoniae, the phosphorylcholine (P-Cho) 
moiety is unique to pneumococcal TAs, imparting anchors for choline-binding proteins 
(CBPs). The CBP family consists of several members, including LytA, -B, and -C (three 
autolysins); CbpA (an adhesin); and PspA (a protective antigen formerly named CbpC). In 
addition, specific binding of P-Cho to the receptor of platelet-activating factor (rPAF) has been 
found to contribute to pneumococcal adherence and invasion [551].  
Rod-shaped bacteria always divide through the same medial plane and have two modes of cell 
wall synthesis [551]: the first one is responsible for the elongation of the cell and the second 
one is responsible for the formation of the division septum. The two modes of synthesis seem 
to be catalyzed by different protein complexes. S. pneumoniae cells are not “true” cocci, as 
their shape is not completely round, but instead have the shape of a rugby ball and synthesize 
the cell wall not only at the septum but also at the so called “equatorial rings”. These differences 
in sites for cell wall synthesis and the mode of division reflect some of the diversity existing in 
bacteria - a basic aspect of bacterial cell biology. 
The recent bioinformatic study found evidence for 16 genes and other hypothetical genes, 
primarily clustered in the lic locus, that were involved in the biosynthesis of pneumococcal 
TAs and cell membrane [552]. Penicillin-binding proteins are encoded by four genes, pbp1a, 
pbp2a, pbp2x and pbp2b [552]. These genes have different functions - pbp1a and pbp2x are 




Moreover, there are some enzymes are essential for cell wall synthesis, like DD-
carboxypeptidase (dacA) which regulates cross-linking degree and coordinates of the division 
process, and monofunctional glycosyltransferases (Mgt) are able to catalyse only the formation 
of uncross-linked peptidoglycan [551].    
As shown in Figure 51, cell wall biosynthesis genes in ST615 were up-regulated compared to 
ST306 strain especially at late exponential phase. However, these genes in ST615 were down-
regulated compared to ST306 at early exponential phase.  
  
4.6.2 Transport & Binding Protein 
 
 
                        Up-regulation                  Down-regulation              Not differentially expressed 
 
Figure 51. The percentage of pair-wise comparison of ST615 to ST306 between transport & binding 
protein genes at different time points (EEP: Early Exponential Phase, MEP: Mid Exponential Phase, 
LEP: Late Exponential Phase, ESP: Early Stationary Phase, LSP: Late Stationary Phase). Down-
regulated genes in ST615 when compared to ST306 are shown in blue, up-regulated genes ST615 when 
compared to ST306 are shown in red, and not differentially expressed genes between the two strains 
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Few molecules are able to enter or leave cells, or cross organellar membranes, unaided by 
proteins. Even the transport of molecules, such as water and urea, which can diffuse across 
pure phospholipid bilayers, is often facilitated by transport proteins. All are integral 
transmembrane proteins and display a high degree of specificity for the substance transported. 
There are three major types of transport proteins. The first is uniporters that transport one 
molecule at a time down a concentration gradient - for example, moves glucose or amino acids 
across the plasma membrane. In contrast, the second and third are antiporters and symporters, 
which are responsible for the movement of one type of ion or molecule against its concentration 
gradient to the movement of a different ion or molecule down its concentration gradient [553]. 
In terms of transport proteins, polyamine transport in bacteria typically associates with the 
action of ABC (ATP-binding cassette) transporters or antiporters that are selective for specific 
molecules. The important role of polyamine is protecting the cell from physiological stress and 
modulating the activity of porins, transmembrane channels that allow the diffusion of 
hydrophilic compounds across the outer membrane. However, polyamine synthesis and the 
molecular function of these molecules in the pneumococcus has still unknown [554]. 
Moreover, psaB and psaC are involved in manganese ABC transporter, ATP-binding protein, 
while psaA is involved in manganese-binding adhesion lipoprotein. The main function of adcC 
is zinc ABC transpoter and ATP- binding protein. The genes are responsible for sugar and 
maltodextrin transporters are msmE and malD, respectively [543].    
In Figure 52, the transport and binding protein genes in ST615 strain were up-regulated 
compared to ST306 at early stationary phase. There were no differences in expression of 






4.6.3 Protein Secretion 
 
 
                        Up-regulation                  Down-regulation               Not differentially expressed 
 
Figure 52. The percentage of pair-wise comparison of ST615 to ST306 between protein secretion genes 
at different time points (EEP: Early Exponential Phase, MEP: Mid Exponential Phase, LEP: Late 
Exponential Phase, ESP: Early Stationary Phase, LSP: Late Stationary Phase). Down-regulated genes 
in ST615 when compared to ST306 are shown in blue, up-regulated genes ST615 when compared to 
ST306 are shown in red, and not differentially expressed genes between the two strains are shown in 
white. The total number of genes involved in the protein secretion was 16 genes.  
 
 
Protein secretion plays a key role in modulating the interactions of bacteria with their 
environments [555]. This is the main case when symbiotic bacteria (whether pathogenic, 
commensal or mutualistic) interact with larger host organisms. Large numbers of proteins are 
secreted by pathogens and other symbionts are able to enter inside host cells to adjust host 
physiology to promote colonization (toxins and effector proteins) [555].  
There are seven types of secretion systems used by bacteria that depend on bacteria category. 

















cell wall and the number of membrane surrounding the cell. The genomes of gram-positive 
species encode a family of specialized secretion systems generally called type VII section 
systems (T7SS). Recently, a study has identified genes for membrane proteins with abortive-
infectivity domains, designated spdABC (surface protein display) that are required for the 
trafficking of YSIRK/GS proteins into the cross wall compartment [556].  
With regard to secreted proteins, Autolysin (LytA) is an important protein to lyse the cell and 
release other virulence factors such as pneumlysin. Moreover, LytA mediates lysis to release 
proteins participated in immune evasion or cell wall components that may interfere with the 
host immune response [557]. Pneumolysin (Ply) is intracellular protein which exerts its impact 
when released in the environment. Ply causes death to wide range of cells and is responsible 
for immunomodulatory effects [248]. Sortase A (SrtA) is a membrane-anchored transpeptidase 
expressed by gram-positive bacteria. SrtA enzymes are responsible for the covalent attachment 
of specific proteins to the cell wall and are crucial for adherence and pathogenicity for 
pneumococcal [558].        
In Figure 53, protein secretion genes in ST306 strain were up-regulated at all growth phases 
particularly in mid exponential phase, while these genes in the ST615 strain were up-regulated 












4.6.4 DNA Replication 
  
 
                        Up-regulation                  Down-regulation               Not differentially expressed 
Figure 53. The percentage of pair-wise comparison of ST615 to ST306 between DNA replication genes 
at different time points (EEP: Early Exponential Phase, MEP: Mid Exponential Phase, LEP: Late 
Exponential Phase, ESP: Early Stationary Phase, LSP: Late Stationary Phase). Down-regulated genes 
in ST615 when compared to ST306 are shown in blue, up-regulated genes ST615 when compared to 
ST306 are shown in red, and not differentially expressed genes between the two strains are shown in 
white. The total number of genes involved in the DNA replication was 20 genes. 
 
 
The genetic information within the cells is stored in the double helix of DNA that is able to 
replicate to produce a new cell. The process of DNA replication is beginning by special initiator 
proteins that bind to double-stranded DNA and separate the two strands apart, breaking the 
hydrogen bonds between the bases. The replication origin (ori) contains two binding boxes for 
host-encoded proteins, IHF and DnaA, respectively, separated by an AT-rich region, followed 
by three repeats region DR-1, DR-2 and DR-3. Moreover, ori is a critical region due to its 

















There are several proteins required for DNA replication. These include DNA polymerase, 
single-strand DNA binding proteins, helicases, primase, topoisomerases, polymerases and 
others. 
Helicase cleaves the hydrogen bonds that linking the pairs together; DnaB is a principal 
helicase in DNA replication. Single-stranded DNA binding protein (SSB) binds to the single-
stranded of each DNA strand to prevent the strands from reassociating and to protect them from 
denaturation by nucleases. Primase is another enzyme that copies a DNA template strand by 
generating an RNA strand complementary to that DNA template. DNA polymerase I is 
involved in removing RNA primers in the processing of DNA after replication, whereas DNA 
polymerase III initiates synthesizing DNA from 5’ to 3’ direction, beginning at 3’ end of each 
RNA primer [477]. 
In Figure 54, DNA replication genes in ST615 strain were down-regulated compared to ST306 
strain. However, the expression of DNA replication genes in ST615 were up-regulated 

















                         Up-regulation                  Down-regulation               Not differentially expressed 
Figure 54. The percentage of pairwise comparison of ST615 to ST306 between RNA genes at different 
time points (EEP: Early Exponential Phase, MEP: Mid Exponential Phase, LEP: Late Exponential 
Phase, ESP: Early Stationary Phase, LSP: Late Stationary Phase). Down-regulated genes in ST615 
when compared to ST306 are shown in blue, up-regulated genes ST615 when compared to ST306 are 
shown in red, and not differentially expressed genes between the two strains are shown in white. The 




There are three major classes of RNA - mRNA, tRNA and rRNA - that are synthesised by a 
single DNA-dependent RNA polymerase in prokaryotic [552]. A small number of additional 
RNA molecules have been identified producing in the cells, known as small RNA (sRNA). 
Small RNA has several functions, including splicing, and is also required for the subcellular 
localization and extracellular transport proteins [560]. 
In order to synthesise RNA, there are three main steps: specific initiation at a promoter, 
elongation and termination at a specific site. RNA polymerase must locate and recognise the 

















of open complex). The polymerase has to stay tightly bound to the DNA in the ternary 
transcription complex to synthesise mRNA. This enzyme must recognise a termination signal 
to release the RNA and to start generating other new RNA [561].   
The genes involved in transcription and regulation are: ciaR DNA-binding response regulator, 
vncS sensor histidine kinase, prsA ribose-phosphate pyrophosphokinase, ATP-dependent RNA 
helicase, ABC transporter-ATP binding protein and marR transcriptional regulator. In addition, 
the translation genes are: all ribosomal proteins, serS seryl-tRNA synthetase, glyO glyl-tRNA 
synthetase, fmt methionyl-tRNA formyltransferase, prmA ribosomal protein methyltransferase 
and tgt tRNA- ribosyltransferase.  
In Figure 55, RNA genes in ST615 strain were up-regulated compared to ST306 strain at mid 
exponential phase and were down-regulated at early stationary phase. However, these genes in 
the ST615 strain were down-regulated compared to ST306 at early stationary phase and up-

















                        Up-regulation                  Down-regulation               Not differentially expressed 
Figure 55. The percentage of pairwise comparison of ST615 to ST306 between metabolic genes at 
different time points (EEP: Early Exponential Phase, MEP: Mid Exponential Phase, LEP: Late 
Exponential Phase, ESP: Early Stationary Phase, LSP: Late Stationary Phase). Down-regulated genes 
in ST615 when compared to ST306 are shown in blue, up-regulated genes ST615 when compared to 
ST306 are shown in red, and not differentially expressed genes between the two strains are shown in 
white. The total number of genes involved in the metabolism was 8 genes. 
 
Metabolism refers to all the biochemical reactions that occur in a cell. The study of bacterial 
metabolism concentrates on the chemical diversity of substrate oxidations and dissimilation 
reactions (reactions by which substrate molecules are broken down), which typically function 
in bacteria to generate energy [562].  
The bacterial metabolism studies also focus on the uptake and utilization of the inorganic or 
organic compounds required for growth and maintenance of a cellular steady state. These 
respective endergonic (energy-requiring) and exergonic (energy-yielding) reactions are then 

















self-replication of the cell. The microbial cells are capable to live, function, and replicate in an 
appropriate chemical milieu and the chemical changes rely on bacterial metabolism [562]. 
In terms of pneumococcal metabolism, the efficient utilisation of nutrients in order to 
generation of metabolic energy is crucial for these bacteria to survive in vivo. Many studies 
have shown central metabolic pathways in pneumococcal virulence. For instance, NADH 
oxidase, which reoxidizes NADH and decreases molecular oxygen to water, was observed to 
be required for the development of competence for genetic transformation and for virulence 
and surviving in mice. The other protein deeply studied that links pneumococcal central 
metabolism to virulence is the glycolytic enzyme α-enolase, which is responsible for binding 
to plasminogen [563]. 
The metabolic genes that were analysed were: manA mannose-6-phosphate isomerase, lacR 
lactose system repressor, glgC glucose-1-phosphate edenylyltransferase, eno enolase, lacB 
galactose-6-phosphate isomerase, ldh L-lactate dehydrogenase, nagB glucosamine-6-
phosphate isomerase, atpH ATP synthase F1, delta subunit, galK galactokinase, malA maltose 
metabolism. 
In Figure 56, this set of metabolic genes in the ST615 strain were up-regulated compared to 
ST306 strain at early exponential phase and the expression pattern was stable in late 
exponential and early stationary phase. Overall, metabolic genes in ST615 strain were up-
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Beta-N-acetylhexosaminidase - adherence 
 
 








4.7 Differential Expression of the Virulence Factors Genes Between ST615 and ST306 
The level of expression for each virulence factors at different points of growth phases is  
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Figure 56. Heat map of Virulence genes that are differentially expressed in ST615 
compared to ST306. TPM>10 and 2 fold-change. Red is >2 fold up-regulation, yellow 




                             
 
Figure 57. Venn diagram of pair-wise comparison of ST615 to ST306 of the 250 virulence genes that 
are different between mid and late exponential phases, and early and late stationary phases (A) 






The virulence genes would be the most interesting to show because they are expressed across 
all pneumococcal strains.  As observed in Table 8, the number of the down-regulated genes 
was higher than up-regulated genes in ST615 compared to ST306. Overall, the growth phases 
with a greater number of differentially expressed genes were in the early stationary phase and 
the late stationary phase. The gene expression for all virulence factors was analysed in detail.  
 
 EEP MEP LEP ESP LSP 
Number of Up-regulated genes 0 3 3 6 7 
      
Number of Down-regulated genes 4 3 5 7 10 
Number of differentially expressed genes 4               6                   8                 13                 17 
 
Table 7. Number of virulence genes that are up-regulated and down-regulated in ST615 when compared 




















































































Figure 58. Capsule genes are not differentially expressed between strains ST615 and ST306. Data are 




























































































































































































































































































































































































































































































































Figure 59. Differential expression of the choline binding proteins genes cbpA, cbpC, cbpD 
and pspA, the pneumococcal surface adhesion gene psaC , the surface exoglycosidases genes 
nanB, bgaA and strH, the autolysin and pneumolysin genes lytA and ply, the hyaluronidase 
genes hyl, the pneumococcal adherence and virulence factor A genes pavA, the sortase genes 
srtA and the competence genes comD in ST615 compared to ST306.  Data are shown as fold 




4.8 Capsule Genes: cps2A and cps2B 
There are more than 90 pneumococcal stains that are classified depending on the 
polysaccharide capsule. The pneumococcal capsule is one of the main pathogenic factors and 
all virulent strains are able to express the capsule. The cps2 is a series capsule gene in serotype 
1. There is a great similarity between all serotype in the genes cps2A to cps2J. The similarity 
between the strains of serotype 1 in these genes is around 89% [564]. 
As shown in Figure 59, the cps2A and cps2B genes were analysed in this study in order to 
observe any differences between ST615 and ST306. However, there was no difference in 
expression when ST615 was compared to ST306 in all points of growth phases because of  both 
ST615 and ST306 strains belong to serotype 1. 
4.9 Surface Protein 
4.9.1 Choline Binding Protein: cbpA, cbpC, cbpD and pspA 
The choline binding proteins are a family consisting of 15 surface proteins that are able to bind 
to choline residues of teichoic acid and lipoteichoic acid existing in the cell wall. The presence 
of choline binding proteins allows pneumococcal to interact with host cellular receptors [565] 
As shown in Figure 60, all choline-binding proteins were similar in expression for both strains. 
However, a slight difference was detected in the late stationary phase for the cbpA gene when 
ST615 compared to ST306.  
CbpA plays a critical role in complement activities by binding to factor H that prevents C3b 
deposition and leads to inhibit opsonising the bacteria [566]. CbpA has another role in 
immunity system by binding to polymeric immunoglobulin receptor, mostly involved in IgA 
secretion. Thus, cbpA is probably responsible for the translocation of pneumococcal through 




cbpA showed the same level of the expression during all growth phases except in the late 
stationary phase where the gene is down-regulated in ST615 compared to ST306. This 
similarity in the expression is because of using the same growth condition, media, PH and 
temperature. 
Although cbpC, cbpD and pspA were similar in the expression, all of these genes did not show 
any differences could be detected. In addition, these genes have been observed to be a key for 
adherence by their ability to adhere directly to nasopharyngeal carriage and virulence [566].  
 
4.9.2 Pneumococcal Surface Adhesion: psaC 
The pneumococcal surface adhesion psaC and psaB are members of the ABC transport family 
and are participated in adhesion that may associate with acquiring the nutrients through the 
ABC transporter system [568]. In this study, the expression of psaC in ST615 is down-
regulated, especially in the mid and late exponential phases, when compared to ST306. The 
low expression of psaC has a negative impact on pneumococcal growth and virulence.  
 
4.9.3 Surface Exoglycosidases: NanB, BgaA and StrH 
 
The nasopharynx is normally the first host niche that the pneumococcus faces during infection. 
The concentration of sugars, the major nutrient for the pneumococcus, is low in the 
nasopharynx. Therefore, pneumococcal requires an efficient mechanism to use the available 
sugars existing in the environment [569]. Pneumococcus possesses special proteins that are 
responsible for cleaving extracellular sugars and modifying the sugars to be more conveniently 




The expression of nanB in ST615 is down-regulated compared to ST306 in the early 
exponential phase and there was no expression during other phases. Moreover, bgaA down- 
regulated in ST615 compared to ST306 at early exponential phase. However, bgaA was up-
regulated in the late exponential phase, early and late stationary phases. The expression of bgaA 
reached a peak in the early stationary phase in ST615 as compared to ST306. For strH is down-
regulated in the early, late exponential and late stationary phase in ST615 compared to ST306.  
4.10 Autolysin and Pneumolysin: lytA and ply 
LytA is an amidase that is principle for cleaving the N-acetylmuramoyl-L-alanine bond of 
pneumococcal peptidoglycan, leading to the autolysis of pneumococcus [570] 
Ply is a major virulence factor that has been broadly studied. Pneumolysin is a cholesterol-
dependent cytolysin that is indirectly secreted from pneumococcus. The release of pneumolysin 
mostly occurs after the cell lysis by either autolysis or lysis caused by external components 
such as antibiotics that lyse the cell by forming pores on their membrane [571]. Moreover, ply 
contributes for pneumococcal survived and dissemination by inducing inflammation in the host 
system [572].  
As Figure 60 shown, the expression of lytA is down-regulated in all growth phases and 
especially at the late stationary phase in ST615 when compared to ST306. In the pneumolysin 
case, no differential expression was seen in the early, mid and late exponential phases but there 
was a down-regulation of ply gene in the early and late stationary phases in ST615 when 
compared to ST306. 
4.11 Hyaluronidase 
Hyaluronidase is a surface enzyme that dislocates hyaluronic acid, which is present in 
mammalian connective tissue and in the extracellular matrix [573]. The degradation occurs by 




therefore, a key virulence factor in the translocation of the pneumococcus between tissues 
[573].  
As shown in Figure 60, no differential expression was seen during the early, mid and late 
exponential phases of growth. The hyaluronidase hyl was down-regulated in ST615 when 
compared to ST306 in the late stationary phase and that was more obvious during the early 
stationary phase. 
4.12 Pneumococcal Adherence and Virulence Factor A: pavA 
PavA is a pneumococcal protein that binds to fibronectin and is responsible for adherence and 
virulence in the pneumococcus. That was proved after using PavA-deficient pneumococci were 
still able to bind to fibronectin by approximately 50% [169]. 
The pathogen-fibronectin interaction facilitates the attachment of the pneumococcus to host 
cells and it has been observed that the ability to adhere and cause invasive disease diminished 
in pavA mutants strains. 
As shown in Figure 60, the pavA gene was down-regulated in the late stationary phase and no 
expression was seen during all exponential phases and in the early stationary phase in ST615 
when compared to ST306. The deficiency of pavA gene in pneumococcus has increased the 
ability to be invasive. Moreover, the external host factors could indirectly affect the expression 
of the pavA gene. 
4.13 Sortase A 
Sortase A is highly conserved pneumococcal transpeptidase enzyme and is involved for 
connecting the pneumococcal pili and other specific proteins to the cell wall [574]. The impact 




 SrtA is responsible for pneumococcal adherence to human cells. However, no important 
impact of SrtA on pathogenicity of pneumococcal has been reported [575].   
As shown in Figure 60, sortase A was down-regulated in the mid, late exponential phases and 
in the late stationary phase. However, no differential expression was seen in the early 
exponential and stationary phases in ST615 when compared to ST306. 
4.14 Competence comD 
A previous study showed, the capability of pneumococcus to undergo genetic transformation 
was identified in this bacterium and was highly competent. Competence is a multicellular 
bacterial response which depends on a diffusible signal. This mechanism is known as quorum-
sensing and the mechanism was observed in gram positive and gram negative. Pneumococci 
produced a 17 amino acid peptide pheromone, namely competence-stimulating peptide, which 
is responsible, for quorum sensing. There are two important components for sensing the peptide 
and activation transcription of competence genes: the histidine kinase receptor (ComD) and its 
cognate response regulator (ComE) [576]. 
As Figure 60 shown, comD gene was up-regulated in all exponential phases, especially in the 
early exponential phase, which reached a peak. However, no differential expression was seen 
























ply   Was down-regulated in 
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TIGR4 
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The analysis of gene expression in vitro for the ST615 strain in comparison of ST306 strain 
showed that 41-132 genes of virulence genes were differentially expressed between the two 
strains. There was a different in level of the expression between the growth phases. However, 
the difference was between the exponential and stationary phases, while this difference was 
less obvious between the three subclasses of the exponential phases and the two subclasses of 
the stationary phases. 
This study showed the differential expression of several biological function categories in order 
to illustrate the possible differences in the cellular function, resulting in differences in virulence 
and the survival of the two strains used. 
The differential expressions of 16 critical pneumococcal virulence factors were analysed in the 
ST615 and the ST306 strains. The number of differentially-expressed genes varied between 
growth phases, ranging between 4 and 17 differentially expressed genes. The majority of 




However, the number of up-regulated and down-regulated genes was the same at mid 
exponential phase. 
The expression of genes involved in cell wall biosynthesis in ST615 strain was up-regulated 
compared to ST306 strain. Moreover, many genes involved in metabolism were up-regulated 
in ST615 when compared to ST306. The metabolism genes were up-regulated in ST615 as this 
bacterium grew faster and consumed a greater amount of nutrients in the media. In addition, 
many genes involved in transport and binding protein genes were up-regulated in ST615 as 
compared to ST306 at mid exponential phase, early and late stationary phases. Metabolism and 
transport and binding protein genes will directly contribute to growth and survival of the 
ST615.  
On the other hand, many genes involved in protein secretion were down-regulated in ST615  
compared to ST306 at all phases except late stationary phase. The environment plays indirect 
role in the expression levels of secreted protein genes, for instance, a broth or a tissue. Twenty 
genes involved DNA synthesis were down-regulated in ST615 when compared to ST306. 
Additionally, there was a difference in the expression levels of RNA synthesis at different 
growth phases in ST615 compared to ST306.  
This study analysed the differentially expressed genes in the ST615 and ST306 strains and 
observed that the expression of some genes involved in invasive disease - for instance, 
pneumolysin and hyaluronidase lyase – were down-regulated in ST615 when compared to 
ST306. In addition, some genes involved in adherence and colonization, for example, 
pneumococcal surface adhesins, pneumococcal adherence and enolases were also down-
regulated in ST615 when compared to ST306. In other words, ST306 showed highly expressed 





However, there was a similarity of expression between ST615 and ST306 in genes responsible 
for the expression of choline-binding proteins. Interestingly, the comD gene was up-regulated 
in ST615 when compared to ST306. In this study, the adherence and colonisation-related genes 
were down-regulated, whereas the genes involved in invasive in the pneumococcus were up-
regulated regardless of sequencing types. This could explain why that serotype 1 tends to cause 
invasive disease than nasopharyngeal carriage.  
 
However, there is a pattern of genes involved in nasopharyngeal colonisation and invasiveness 
that showed similarities in expression. Moreover, it is important to know that some of the 
proteins mentioned above are frequently involved in both carriage and invasive disease. There 
were few differences in virulence genes expression between ST615 and ST306 as both strains 




































































Streptococcus pneumoniae is a commensal bacterium commonly found in the human 
nasopharynx. It is a prominent cause of morbidity and mortality worldwide, responsible for a 
wide range of infections, from sinusitis and acute otitis media to meningitis, septicaemia and 
pneumonia, with the highest disease incidence reported in developing countries. Of the nearly 
100 different serotypes that were reported so far, serotype 1 ranks among the most prevalent 
pneumococcal serotypes causing invasive pneumococcal disease (IPD) worldwide.  
Serotype 1 (S1) pneumococci exhibit specific characteristics compared to other pneumococcal 
serotypes as it is often associated with outbreaks in closed communities and was found not to 
be associated with antimicrobial resistance [577]. The short duration and low bacterial density 
associated with serotype 1 nasopharyngeal colonisation may explain low antimicrobial 




Additionally, ST306 pneumolysin was documented for its ability to bind to erythrocytes; 
however, this pneumolysin variant was found not to be able to form pores on erythrocyte 
membrane [361]. Simultaneously, ST615 was a representive sequencing type for lineage C and 
was compared to ST306. This project was focused on the understanding of ST306 
pneumococcal variant in its ability to cause invasive disease despite in low haemolytic activity. 
In this study, we demonstrated that ST306 was able to colonise mouse nasopharyngeal niche 
for a longer period of time compared to ST615.  Our results found that the European ST306 
used in this project was unable to cause invasive disease in mice unless supplemented with 
purified PLY, in which case systemic dissemination to the lung and blood could occur.  
5.2 Pneumococci ST615 behave as an aggressive pathogen than ST306 in vitro 
To shed light on the mechanisms of pathogenicity specific to ST306 pneumococci, their 
properties were assessed in vitro: haemolytic activity, ability to adhere and invade epithelial 
cells, ability to evade phagocytosis and complement deposition.  
The haemolytic activity of the European ST306 and South American ST615 serotype 1 isolates 
were assayed to determine the levels of haemolytic activity in these sequence types in 
comparison to ST304 and ST128. Among the 16 isolates tested (Figure 16 A), both ST306 and 
ST615 were found to have a significantly lower haemolytic activity than serotype 2, D39 strain, 
used as the comparator strain. Interestingly, the haemolytic activity of all ST306 strains tested 
was the lowest, while the activity of ST615 was only slightly lower than that of D39.  These 
findings are in line with current literature, describing that Ply expressed by ST306 serotype 1 
isolates has a defective haemolytic activity [119]. The differential levels of haemolysis 
observed between D39 strain and serotype 1 (Figure 16 B) used in this study suggest that 
pneumolysin alone may have a significant impact on the reduced virulence of the ST306 




inducing an invasive disease [119]. However, these previous studies were focused on strains 
presenting fully-active pneumolysin or strains carrying pneumolysin mutations.  
The pneumococcus is known for its ability to adhere and invade epithelial and endothelial cells 
[56]. Several pneumococcal virulence factors have been reported to be involved in host cell 
adherence and invasion: CbpA (binds to glycoconjugates from human cells and is involved in 
translocation between tissues by binding to the IgA receptor), neuraminidases (cleaves terminal 
sugars from host surfaces revealing receptors for adherence), PavA (binds to fibronectin in the 
extracellular matrix), hyaluronate lyase (breaks down the extracellular matrix increasing tissue 
permeabilisation),  enolase (binds to human plasminogen), PsaA (acts as an adhesion) and pili 
(adheres to human cells). The deficient expression of any of these virulence factors has been 
shown to reduce the ability of the pneumococcus to adhere and decrease invasive properties 
[581, 582]. The ability to adhere promotes successful colonisation of the nasopharyngeal tissue 
and may be a precursor event to the onset of invasive disease. Here, we compared the adhesion 
properties of ST306, ST304 and ST615 serotype 1 isolates (an isolate from a pneumonia 
patient, an isolate form the nasopharynx of a healthy individual and an isolate from bacteremia 
patient, respectively) to those of the well-characterised serotype 2, D39 strain.   
Previous authors suggested that PLY-producing pneumococcal strains are able to activate the 
complement cascade, leading to depletion of complement in the host and reducing opsonic 
activity [535]. In Figure 20, different sequence types were subjected to opsonophagocytic 
killing assays using IVIg. Serotype 1 strains belonging to ST306 showed more killing at low 
dilution of IVIg anticapsular antibodies than other strains belonging to ST304 and ST615. 
Opsonophagocytic killing of pneumococcal isolate strains appears to be serotype dependent, 
with higher opsonophagocytic activity found for serotype 2 D39 compared to serotype 1 




hence increasing opsonic activity, the results did not appear to show an association between 
opsonic activity of serotype 1 sequence types and PLY content, invasion or adherence ability.  
Human nasopharyngeal epithelial cells and human broncho-alveolar epithelial cells were used 
to assess the ability of the serotype 1 isolates to adhere to tissue, in comparison to serotype 2 
and to examine the differences between the different serotype 1 isolates. Our results revealed 
a significantly lower ability of serotype 1 isolates to adhere to nasopharyngeal epithelial cells 
compared to D39. The CFU counts were lower in ST306 than D39 at 30 min post-infection. 
This suggests that the ST615 isolate may be more potent in host cells invasion and more prone 
to translocate to other tissues. Despite the reported [513] ability of D39 to invade human 
epithelial cells, the number of invading bacteria for this strain was very low compared to the 
number of adherent bacteria. The invasion ratios of serotype 1 ST615 was higher than D39. 
There were differences in percentages of adhesion between sequencing types of serotype-1, the 
ability of ST615 isolate to invade is probably a property to this strain and clearly associated 
with enhanced invasiveness, a potential key factor in its ability to translocate through lung 
tissues. In broncho-alveolar epithelial cells no adhesion or invasion was observed for any of 
the encapsulated isolates. In contrast to our results, previous studies have shown that the 
pneumococcus was capable to adhere to broncho-epithelial cells; this may be due to the 
different bacteria:cell ratio used in these published studies, a variable that has previously been 
show to influence the adhesion and invasion ratios in vitro [513, 583].   
An important virulence factor that has been shown to have an impact on the adherence 
properties of the pneumococcus is the capsule. The exposure of adhesins and other surface 
molecules is increased in the absence of capsule [7, 582]. In encapsulated isolates, the ability 
to modulate the thickness of capsule was described as an adaptation mechanism of the 




increased capsule allows evasion from the host immune system [163, 585, 7, 584]. The capsular 
composition also plays a prominent role due to the interaction of pneumococcal surface 
proteins and adhesins with host surfaces [586]. In addition, the capsular serotype affects the 
levels of C3 deposition on the bacterial surface which may in turn impair the ability of the 
immune system to phagocytose the bacteria [586]. It was shown that the biochemical structure 
of the different capsular types controls the accessibility and functionality of surface proteins; 
and as a result, a differential expression of surface proteins is probably in place to overcome 
these differences [587, 588].The capsule thickness would impair phagocytosis and the number 
of complement deposition were assessed in all isolates of serotype 1 and compared to the 
serotype 2 strain D39. A previous study showed that carriage isolates reduce the expression of 
their capsule in order to increase their ability to adhere to host surfaces [419]. The variation of 
capsule thickness is not a permanent adaptation to specific serotype, it is reasonable that the 
differences in capsule thickness are only temporary and not reproducible in vitro. OPKA 
experiment was performed in order to study the role of capsule as well. During an 
opsonophagocytic killing assay where the bacteria were opsonised using intra-venous IgG, it 
was shown that the serotype 2 D39 strain was more susceptible to phagocytosis by HL-60 
neutrophils than the serotype 1 strains. Moreover, there was also difference between the two 
serotype 1 isolates used in the OPKA experiments; European and South American isolates. The 
capsule thickness of the ST306 did not differ from serotype 1 ST615 isolates or serotype 2 
strain. 
The levels of C3 deposition were determined to clarify the mechanisms through which the 
serotype 1 isolates were more resistant to phagocytosis by HL-60-derived neutrophils than the 
serotype 2 strain. The C3 deposition on the surface of the different isolates showed that ST306 
and ST615 had a lower complement-binding ability compared to the serotype 2 strain. There 




structure of the type 1 capsule might play a determining factor in the binding of complement 
proteins to the bacterial surface. The capsule of most pneumococcal serotypes has a neutral or 
a negative charge, whereas the serotype 1 capsule was described to hold both negative and 
positive charges [589]. The zwitterionic nature of serotype 1 capsule, which displays both 
negative and positive charges, suggests that the positive charges may inhibit the deposition of 
the complement protein C3b on the surface of the bacteria leading to reduced phagocytosis, 
immune evasion and therefore increased virulence.  Moreover, previous authors reported that 
the presence of an amino group (NH3+) on the capsule of serotype 1 could explain a reduction 
in complement deposition [590,591]. Altogether, these observations might explain the 
differences described in our investigations.     
To conclude, in vitro characterisation of serotype 1 isolates suggest that pneumococci serotype 
1 are less prone to surface binding by complement proteins leading to impaired phagocytosis 
by the host, thereby rendering this serotype more resistant to host immune defense, which may 
thus explain its increased virulence properties. More particularly, it was also observed that the 
South American ST615 isolate was the only encapsulated isolate able to invade nasopharyngeal 
epithelial cells, and complement deposition was very low. This observation suggests that this 
particular isolate might express yet-to-identify virulence determinants permitting ST615 to 
translocate into deeper tissues.   
5.3 Pneumococci ST615 are more virulent than ST306 in mouse models of 
pneumococcal pneumonia 
In view of the results obtained in vitro, we further investigated the invasive properties of ST306 





The virulence of ST306 and ST615 isolates were compared using a well-established in vivo 
model of invasive pneumonia in mice [120]. Upon infection with serotype 2 D39, MF1 infected 
mice started showing disease symptoms as early as 24h post-infection and became moribund 
by 48h post-infection with only up to 10-20% surviving the infection [120]. A significant 
difference was observed between ST306 and ST615 with a mouse survival rate of 10-20% for 
ST615 and 100% for ST306. However, the disease progression – as measured by the onset of 
clinical symptoms - in ST615 and ST306 serotype 1-infected mice was considerably faster than 
that in mice infected with the D39 strain; approximately 80-100% of the mice (Figure 25) 
succumbed to the infection between 24h and 48h post-infection [120].   
Overall, our results showed that the South American ST615 isolate was significantly more 
virulent than the European ST306. A time-course analysis was performed in order to monitor 
the infection kinetics and dissemination into peripheral blood. There were significant 
differences in the bacterial densities of the tissues analysed in mice infected with the ST615 
compared to those infected with ST306.  
The exact mechanisms underlying the breach of the nasopharyngeal epithelium and subsequent 
dissemination to the lungs or blood remain unclear [581]. Our results showed that serotype 1 
ST615 tended to disseminate into blood very early (Figure 30). On the other hand, ST306 was 
not able to translocate into blood at any of the experimental time points, while the bacterial 
density in the lungs of mice were very similar between both sequence types. These observations 
may be correlated with the invasion patterns observed in vitro upon infection of nasopharyngeal 
epithelial cells, whereby the ST615 isolate was the only isolate detected intracellularly. For this 
reason, it could be helpful to investigate genetic differences, for example, possible single 




well as possible differences in the mRNA expression of critical virulence factors in vitro as 
well as in vivo.  
We also sought to determine whether increasing the bacterial load in the inoculum was 
permissive to disseminate ST306 into peripheral blood from lung or nasopharynx. Hence mice 
were infected with a one-log excess dose compared to our standard model, at 107 CFU/mouse, 
but the mice failed to show any detectable levels in whole blood samples. This observation 
indicates that even upon administration of high dose, ST306 is not capable of invading the 
blood systemic circulation to cause bacteremia.   
In view of the differential properties observed between ST306 and ST615, we expected to see 
significant differences in the host immune response generated against these 2 sequence types, 
however, our results failed to detect any significant disparities. These results warrant further 
investigations, for example, the focus could be placed on earlier markers i.e., earlier 
experimental time points, and on the analysis of immune cell populations in other tissues such 
as the spleen or blood.   
In a pulse experiment, LPS-free recombinant pneumolysin was co-administered with serotype 
1 ST306. We made the surprising findings that the presence of haemolitically active 
pneumlysin significantly promoted the translocation of pneumococci into peripheral blood as 
early as 12 hour post-infection. This was accompanied by signs of disease starting to show at 
approximately 6 hour post-infection. Most interestingly, all symptoms resolved by 72 hours.   
 In mice infected by serotype 2, D39 strain, an increase in the number of T regulatory cells was 
described during invasive disease [530]. In our investigations, results showed that serotype 1 




suggesting that the activation of Treg may be a necessary mechanism to control local 
inflammatory responses and systemic spread of pneumococci  [530].  
In summary, intra-serotype virulence differences were observed, with ST615 isolate found to 
be significantly more invasive than ST306 isolate. This was translated in vitro by the invasion 
properties of ST615 in Detroit 562 nasopharyngeal cells (Figure 18) and the highest incidence 
of clincal symptoms and death in mice (Figure 25). Mice infected with pneumococci ST615 
pneumococci failed to combat or clear the infection and ultimately succumbed. The nature of 
the immune inflammatory response generated against ST615 failed to be characterised (Figure 
44, 45), however current literature suggests that innate cells such as neutrophils and 
macrophages are actively involved in the very early stages of infection.  
In our hands, low haemolytic ST306 showed the inability to translocate from lungs or 
nasopharynx to the blood, and mice infected with ST306 did not exhibit any visual sign of 
disease symptoms, and all mice exposed to ST306 ultimately survived. In line with previous 
studies, our results suggest that the haemolytic activity of pneumolysin is critical to the 
dissemination of pneumococci to blood, likely due to its tissue damaging and inflammatory 
properties [251].   This observation, however, does not rule out that other virulence factors 
maye also be involved, and this was explored through our transcriptomics analysis.  
5.4 Serotype 1 during nasopharyngeal carriage  
Current literature has documented pneumococci serotype 1 as a rarely detected capsular type 
in nasopharyngeal swabs [592, 577]. This raises the question as to whether nasopharyngeal 
carriage is a pre-requisite for invasive disease. A clearer understanding of serotype 1 
pathogenesis woud help design preventive strategies to reduce the burden of disease caused by 




The two sequence types ST306 and ST615 were assessed in a well-characterised in vivo model 
of long-term nasopharyngeal carriage in mice to understand their pattern of colonisation and 
identify possible differences. The serotype 2 strain D39 was documented for its ability to 
colonise the nasopharynx of mice at a stable and constant density for a period of at least 28 
days [593]. Here our results showed that serotype 1 ST615 was able to establish colonisation 
for a period of up to 14 days (Figure 21). Interestingly, ST306-infected mice showed a decline 
in bacterial density at day 7 in the nasopharync, rose on day 14 and gradually decreased with 
pneumococci still present, though at lower density, on day 28. The bacterial nasopharyngeal 
density between ST306 and ST615 were variable during the observation period ascertaining 
our previous observations that the 2 strains present very distinct phenotypes and/or protein 
expression patterns. Overall, and in line with current reports, serotype 1 is able to establish 
nasopharyngeal colonisation, but for a shorter period of time and at lower bacterial density 
compared to D39. On the other hand, we showed that colonisaton of mice with a haemolitically-
deficient ST306 was able to remain longer than those mice inoculated with a haemolitically- 
sufficient ST615.   Our results are in contradiction with previous finding reporting that a low 
haemolitically- active pneumolysin promoted clearance of colonisation [97,98].   
 
 Host immune responses during nasopharyngeal carriage have been investigated in previous 
studies, describing the production of immunomodulatory cytokines such as IL-10 and TGF-β1, 
as well as the recruitment of T regulatory cells, as contributing towards the long-term 
persistence of pneumococcal carriage [468]. This implies that in the absence of immune-
regulatory responses, pneumococcal carriage may fail to establish, potentially due to an overt 
pro-inflammatory response. In this project, results showed that serotype 1 failed to induce 




was enhanced in the nasopharyngeal homogenates of mice infected with ST306 compared to 
mice infected with ST615, particularly at day 7 post-infection (Figure 47).  In our models, 
serotype 1 failed to induce any detectable production of immune-modulatory cytokines or T 
regulatory cells. Previous reports have shown that serotype 1 purified capsule was able to 
trigger ctivation of CD4+ T cells upon intraperitoneal injection accompanied by the induction 
of IL-10 and TGF-β, leading to immune tolerance [594, 595]. This differing result can be 
interpreted by the different experimental protocols used. Many studies suggesting induction of 
T regulatory cells and the production of IL-10 and TGF-β1 cytokines were performed using 
injected purified capsule [547]. Although capsular serotypes have emerged as important 
mediators of host immunity to pneumococci, the interaction of the capsule with bacterial 
surface proteins anchored to the cell wall can amend the host immune response [587, 586].   
5.5 Co-administration of ST306 and ST615 serotype 1 in mouse model of 
nasopharyngeal colonisation    
Co-colonisation with multiple pneumococcal serotypes was described as a contributing factor 
in the progression into invasive disease, as well as horizontal gene transfer and host-to-host 
transmission [599, 600]. Previous studies have examined the effect of inter-species 
nasopharyngeal co-colonisation on the density, duration and serotype distribution of 
pneumococcal carriage in mice [596, 582, 597, 598].  
In the first few years of life, the prevalence of pneumococcal carriage increases and reaches a 
peak at approximately 50% to >70% in hosts aged 2–3 years, and then decrease until stabilising 
at an incidence of 5–10% in hosts aged over 10 years in developed countries, while the 
incidence reported in developing countries can be as high as 25–60%. The estimation of the 
median duration of carriage is approximately 31 days in adults and 60.5 days in children, with 
variable length of carriage based on type of capsule and previous immunologic exposure, as 




invasive disease in young adults (9-15 yr) which is the age group with lower pneumococcal 
carriage rates. This may be due to the fact that there is no competition occurring in the 
nasopharynx of young adults hence leading to better colonising ability and better chances of 
spreading and causing invasive disease [538].  
Co-colonisation is believed to promote acquisition of new serotypes, rather than leading 
to clearance [602]. In our study, the co-administration of ST306 and ST615 failed to show any 
change in the carriage patterns of each individual sequence type (Figure 21 compared to Figure 
24). The co-administration of strains belonged to serotype 1 had no impact on the density of 
either strain ST306 and ST615. In other words, there was no evident sign of competitive 
interaction between the two sequence types.   
There is generally a high incidence of pneumococcal carriage in infants and in the elderly, 
however in the particular case of serotype 1, the incidence of invasive pneumococcal disease 
caused by serotype 1 is higher in infants [577] suggesting that serotype 1 is more efficient at 
establishing nasopharyngeal carriage in individuals that have had very little exposure to the 
pneumococcus or that have a less mature immune system [577, 90, 603].  Hence, it would be 
of interest to carry a co-colonization experiment using neonate mouse models for example.   
 
5.6 Pneumococci ST306 and ST615 differentially expressed genes during in vitro growth  
Sequencing is a revolutionary approach that has significantly facilitated the analysis and 
identification of genes that are pivotal for the virulence or metabolism of bacteria [604]. We 
previously discussed that, using in vivo mouse models, ST306 of serotype 1 is less virulent 
than ST615, and is also less efficient at establishing nasopharyngeal carriage. Differential gene 
expression analysis between these two strains was performed using pure culture samples 




on the differential gene expression of specific virulence factors in serotype 1 compared to 
serotype 2; however, our study is the first to carry out such an in depth analysis. The focus was 
placed on the expression of 250 pivotal pneumococcal virulence factors and 6 groups of 
biological functions.    
Of the 250 virulence genes, between 78% and 88% of the orthologous genes were differentially 
expressed between the two strains, with a general down-regulation of biological functions 
related to bacterial activity such as the metabolisms (lacB, malA, nagB, glgC, manA, lacR and 
ldh) protein secretion and DNA replication. It has previsouly been reported that faster growing 
pneumococci are better colonisers; thus, the down-regulation of mechanisms involved in 
growth may explain the poor ability of serotype 1 to colonise the nasopharynx [605].   
One key finding was the higher expression of genes involved in cell wall biosynthesis (bacA, 
fibA, lytB, licC, licB, pck, pgdA, penA, dltD, dltA, pgm and cbf1) found in ST615, compared to 
ST306.   Therefore, genes involved in metabolism (lacB, malA, nagB, glgC, manA, lacR and 
ldh) showed up-regulation in ST615 vs. ST306 during all growth phases except during the EEP. 
Moreover, transport and binding protein genes 
(rafF,rafG,amiA,amiC,amiD,amiE,amiF,aliA,aliB,potA,potC and potD) showed up-regulated 
in ST615 compared to ST306.   
Analysis was carried out on the differential expression of 16 virulence factors and showed that 
virulence factors associated with carriage (i.e. choline binding proteins, pneumococcal surface 
adhesins, pneumococcal adherence and enolases) and invasive potential (pneumolysin and 
hyaluronidase lyate) are down-regulated in ST615 compared to ST306. In contrast, some 
factors, such as β-galactosidase and competence system, were shown to be up-regulated in 




5.7 Summary  
In this project, we provided evidence that serotype 1 ST615 was a highly invasive sequence 
type capable to colonise the nasopharyngeal niche but for a shorter period of time and at a 
lower density than ST306.  
The differential gene expression observed between ST615 and ST306 was mainly reflected in 
virulence factors involved in nasopharyngeal carriage and invasive properties. These 
observations suggest that it was reported that pneumococcal transmission is also possible 
during invasive episodes [606]. In this project, we sought to elucidate mechanisms inherent to 
serotype 1 that may explain their highly invasive nature in contrast with their poor colonising 
abilities. Pervious studies have demonstrated that pneumonic spread was more virulent than 
carriage spread [606]. However, the mechanisms leading to the increased virulence remain 
unknown. A possibility is the increased expression of important virulence factors during 
pneumonia; it is legitimate to postulate that, when pneumococci are transmitted via coughing 
or upon contact with the sputum, pneumococci are highly virulent and are thus more prone to 
becoming invasive. This may explain why serotype 1 is a major cause of disease outbreaks and 
is frequently isolated from communities where a recent outbreak has occurred [592].   
In addition, it was observed that isolates from same sequencing type were similar to each other 
during adherence in vitro and during nasopharyngeal carriage in vivo. The results obtained in 
vitro seem to corroborate with our in vivo observations. Transcriptomics analysis suggests that 
the ability of serotype 1 to cause nasopharyngeal carriage might be attributed to the expression 
of virulence factors such as pneumolysin (ply), neuraminidases, hyaluronidase or the 
pneumococcal adherence and virulence factor (pavA) rather than the capsule.   
In summary, not only the capsule of serotype 1 is likely to affect on its ability to carry long 




in order to survive and cause invasive diseases, with the progression into pneumonia acting as 
an alternative method of transmission for this serotype.  
Additionally, another potential reason behind the low virulence properties of ST306 resides in 
the loss of the variable region of pneumococcal pathogenicity island 1 (vPPI1). According to a 
recently published study, ST3018 strain encoding (vPPI1) was able to survive and proliferate 
in the lungs and then invade the pleural cavity and blood [609]. A number of the genes present 
within vPPI1 of a ST3018 virulent strain exhibit sequence similarity to metabolic pathway 
genes and could have a secondary effect on the expression of other virulence factors. Therefore, 
total levels of choline-binding protein A (CbpA), neuraminidase A (NanA), and pneumolysin 
(Ply) were compared between the ST3018 virulent strain and its ΔPPI1 mutant strain by 
quantitative Western blot analysis. However, the findings revealed that no significant 
differences between the ST3018 virulent and its ΔPPI1 strains in the relative expression levels 
of CbpA, NanA, and Ply were detected [609]. 
5.8 Future work 
In this project, there was no detectable difference in the host immune responses between 
serotype 1 ST306 and ST615. Hence, the immunological mechanisms resulting in the 
differential colonization and invasive properties of ST306 and ST615 remain to be determined, 
for example, using different mouse strains. 
The purpose of the co-colonisation experiment was to determine whether the two strains could 
complement each other or instead compete with each other. The findings showed that 
nasopharyngeal co-colonisation had no impact on strains from the same serotype. More 
investigation is required to study the interaction between carriage and invasive serotypes, for 
example, several serotypes could be investigated in a co-colonisation experiment to further 




The analysis of differentially expressed genes in ST615 compared to ST306 showed that there 
were several differences in the biological functions and virulence factors expression in vitro. It 
would be useful to investigate the differential genes expression of ST615 and ST306 in vivo. 
There is a need to develop a robust method for the extraction of good quality and yield of RNA 
from tissue in order to obtain confident RNAseq analysis. It would be of interest to perform 
the analysis of gene expression of serotype 1 in vivo at different points of infection and using 
bacteria collected from different tissue niches e.g., nasopharynx, lung, blood and brain. Finally, 
the results obtained in this study maybe be used as a ground to study the gene expression of 
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